

# CANCER 52

England & Wales · Charity number 1174569

## Details

---

Status	Registered
Legal form	Charitable company
Company number	<a href="#">07994413</a>
Registered	2017-09-08
Register	<a href="#">View on the Charity Commission register</a>

## Contact

---

Address	Cancer52 124-128 City Road London EC1V 2NX
Phone	0203 355 1989
Email	<a href="mailto:info@cancer52.org.uk">info@cancer52.org.uk</a>
Website	<a href="http://www.cancer52.org.uk">www.cancer52.org.uk</a>

## Activities

---

**Objects:** TO PROMOTE AND PROTECT THE HEALTH OF SUFFERERS OF RARE AND LESS COMMON CANCERS FOR THE PUBLIC BENEFIT BY:(A) ADVANCING AND PROMOTING THE UNDERSTANDING, AWARENESS, RESEARCH AND LEARNING ABOUT RARE AND LESS COMMON CANCERS;(B) ACTING AS A COLLECTIVE VOICE AND ADVOCATING FOR THE NEEDS OF INDIVIDUALS AFFECTED BY A RARE OR LESS COMMON CANCER IN ORDER TO IMPROVE THE OUTCOMES OF DIAGNOSIS, TREATMENT AND LONG-TERM SUPPORT; AND(C) SUPPORTING, REPRESENTING AND EMPOWERING NOT-FOR-PROFIT ORGANISATIONS WORKING IN THE FIELD OF RARE AND LESS COMMON CANCER.

**Activities:** To promote and protect the health and sufferers of rare and less common cancers for the public benefit by : (a) Promoting understanding, awareness and research about rare and less common cancers (b) acting as a collective voice and advocating needs of individuals affected by a rare or less common cancers (c) supporting not-for-profit organisations in field of rare and less common cancers

## Classification

- **How:** Provides Advocacy/advice/information, Acts As An Umbrella Or Resource Body
- **What:** General Charitable Purposes, The Advancement Of Health Or Saving Of Lives, Other Charitable Purposes
- **Who:** Other Charities Or Voluntary Bodies, Other Defined Groups

## Geography

- Northern Ireland
- Scotland
- Throughout England And Wales

## Finances

Period end	Income	Expenditure	Assets	Employees
2025-03-31	£363,420	£348,601	-	-
2024-03-31	£230,779	£268,701	-	-
2023-03-31	£176,598	£198,052	-	-
2022-03-31	£144,709	£151,150	-	-
2021-03-31	£175,695	£126,028	-	-

## Trustees

Name	Role	Appointed
<b>Anne MacDowell</b>	Chair	2023-10-12
Amanda Boughey		2025-02-26
Anna Evans		2021-06-08
Clare Clifton		2025-02-26
Dr Max Brodermann		2021-06-08
Michael Draeger		2021-06-08
Nic Puntis		2019-03-20
Sophie Davies		2021-06-08
Willemke Dagmar Droogsma		2025-02-26
Yasmin Sheikh		2025-02-26

**CANCER 52**

England & Wales - Charity number 1174569

---

# Accounts

---

# Annual Review & Financial Statements

1 Apr 2024 – 31 Mar 2025

**Cancer52** is registered as a charity in England and Wales, **Charity No. 1174569** and as a company limited by guarantee in England and Wales, **Company No. 07994413**

# Contents

<b>LET'S MAKE SOME NOISE</b>	<b>3</b>	<b>FUNDING</b>	<b>20</b>
Foreword	3	The National Lottery Community Fund	20
Welcome to our Annual Review 2024–2025	4	The value of support	21
		Voluntary member donations	21
		Support from industry	21
<b>STRENGTH IN UNITY: OUR PRINCIPLES</b>	<b>5</b>		
Our core principles	5	<b>FUTURE PLANS</b>	<b>22</b>
<b>UNITING WITH ONE VOICE: WHO WE ARE</b>	<b>6</b>	<b>STRUCTURE AND CONSTITUTION</b>	<b>23</b>
The Cancer52 team	6	Structure and governance	23
Our charity members	6	Purpose	23
		Public benefit	23
<b>MAKING THE CANCER52 VOICE HEARD</b>	<b>7</b>	Board and management operations and structure	24
Informing, advising and supporting our members	7		
<b>PARTNERSHIP: REPRESENTATION AND ADVOCACY IN POLICY</b>	<b>11</b>	<b>MONEY TALKS: FINANCIAL REVIEW</b>	<b>25</b>
<b>PARTNERSHIP: COLLABORATION ON BEHALF OF PATIENTS</b>	<b>15</b>	<b>INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF CANCER52</b>	<b>26</b>
Informing our stakeholders	18	Section A	28
		Section B	29
		Section C	30
<b>MAKING THE VOICE OF PEOPLE WITH RARE AND LESS COMMON CANCERS HEARD: OUR HEADLINE ACHIEVEMENTS FOR 2024–2025</b>	<b>19</b>	<b>INDEPENDENT EXAMINER'S REPORT ON THE ACCOUNTS</b>	<b>26</b>
Partnership	19		
Policy	19	<b>ADMINISTRATIVE DETAILS</b>	<b>40</b>
People	19		
		<b>LIST OF CHARITY MEMBERS 2024–2025</b>	<b>41</b>

# Let's make some noise:



Trustees Annual Report and Directors Report  
for the year ended 31st March 2025

## Foreword

**It has been a year of transition and growth for Cancer52. In October we welcomed our new CEO, Chris Walden, who has seamlessly stepped into the role, bringing clarity, and a deep commitment to our mission. His ability to connect not only with members, but with policymakers and stakeholders has ensured that Cancer52's voice not only continues to be heard but is increasingly influential. Under his leadership, our organisation has been widely consulted in the development of the National Cancer Plan for England**

I would like to extend heartfelt thanks to Jane Lyons MBE, our former CEO, and Sasha Daly, who served as Interim CEO, for their dedication and leadership. Their achievements, alongside the skills and dedication of the wider team, laid the foundation for a smooth and successful transition.

I'd also like to congratulate Jane on her recent MBE, in recognition of everything she accomplished during her tenure, to bring the profile of rare and less common cancers to the fore.

I am deeply grateful to our trustees, whose expertise and support continue to guide **Cancer52** with wisdom and integrity. Special thanks go to those involved in the CEO recruitment process, who undertook the challenging task of selecting Chris from a very strong field of candidates. We said goodbye to two long-standing trustees, Rebecca Porta, CEO of *The Urology Foundation* and Helen Morement, CEO of *AMMF – The Cholangiocarcinoma Charity*, whose many years of service have been invaluable. At the same time, we are thrilled to welcome new trustees who bring a rich diversity of skills and experience. Chosen from a large pool of applicants, they enhance the strength and expertise of our governance.

Finally, I want to acknowledge the fantastic expertise and dedication of our member charities. Their collaboration with Chris and the team ensures that the needs of people with rare and less common cancers remain front and centre of everything we do.



Anne MacDowell,  
Chair of the Board

*Anne MacDowell*



Chris Walden, CEO

## Welcome to our Annual Review 2024–2025

**It's a pleasure to welcome you to our first Annual Review since I had the absolute honour of succeeding the incredible Jane Lyons. Jane developed and grew Cancer52 over the past 10 years and was recently awarded a well-deserved MBE. I am thrilled to build on what she has already created. I'm also grateful to Sasha Daly, who stepped into the role of Interim CEO following Jane's departure and led the organisation with skill and dedication during a critical period of transition.**

In 2024–2025, thanks to funding from our members, the National Lottery Community Fund and other partners, we've made significant strides in shaping policy to better support those affected by rare and less common cancers. We're now poised to make even greater progress, with exciting opportunities emerging for our member charities, especially around the much-anticipated National Cancer Plan for England.

We are proud of the collective work we've undertaken this year to ensure the patient voice is heard at the highest levels of policy making. Our commitment to improving equality in cancer care remains central to everything we do.

**Cancer52** members' work inspires us every day to champion those with rare and less common cancers. Our members' dedication, expertise and passion drive dynamic and collaborative action, and we are deeply grateful for their commitment to **Cancer52's** shared aims.

*Chris Walden*



# Strength in unity: our principles

**Cancer52** is a national organisation, created in 2007 and registered as a charity in England and Wales in September 2017.

We are the unifying body for charitable and not-for-profit organisations working in the field of rare and less common cancers. We represent over 100, predominantly small, patient-support and research-focused cancer charities and organisations.

**Cancer52** gets its name from when rare and less common cancers accounted for 52% of all cancer deaths in the UK, when only 47% of cancers diagnosed in England are of this type.<sup>1</sup> In 2020, this shifted to 47% of diagnoses and 55% of cancer deaths.<sup>2</sup>

Our member charities and organisations are united in seeking a better future for everyone affected by rare and less common cancers. We provide a collective voice to champion earlier diagnosis, better treatment, better representation, funding and support for people with all cancers other than the four most common cancers (breast, lung, bowel, and prostate). **Cancer52** ensures the voices of people with rare and less common cancers do not go unheard.



## Our core principles

### Our aim

**Cancer52's primary aim is to promote improved diagnosis, treatment and support for those affected by rare and less common cancers.**

### Our mission

**Cancer52's mission is to provide a strong, unified voice for rare and less common cancer organisations by representing, informing, sharing and involving our members in achieving our vision.**

### Our vision

**Cancer52's vision is to end inequalities in diagnosis, treatment and patient outcomes experienced by those with rare and less common cancers compared with the four most common cancers.**

### Our values

Everything **Cancer52** does is underpinned by the aim to be:

ambitious | outcome-focused |  
collaborative | evidence-based | influential  
and to behave with honesty and integrity.

# Uniting with one voice: who we are

**Cancer52 aims to better represent people with rare and less common cancers at a senior policy and decision-making level. Sourcing and bringing together the knowledge and expertise of our many members makes this possible.**

## The Cancer52 team

Jane Lyons stepped down as CEO of Cancer52 in July 2024 to be succeeded by our interim CEO Sasha Daly, until Chris Walden took up post in October 2024.

### **Chris Walden, CEO:**

Has responsibility for the overall running of the charity. Chris was supported by an excellent team of part-time contractual staff, who each provide expertise in their area:

### **Ainsley Taylor, Operations Consultant:**

Responsible for overseeing all operational aspects of the charity. Supporting the CEO in managing financial reporting, fundraising, policy and governance work, operational tasks and administration duties, including overseeing membership administration and the co-ordination of membership donations, recruitment and supporting the Board of Trustees.

### **Sasha Daly, Policy Lead:**

Working with members and external stakeholders to direct the policy work of Cancer52.

### **Jen Harrison, Health Inequalities Lead:**

Driving health inequalities work and other policy-related activities.

### **Stephanie Judycki, Communications Executive:**

Leading on internal and external communications including member e-bulletins, Cancer52 website and social media.

### **Ambika Chadda, Executive Assistant:**

Providing administrative support to the team and co-ordinating our membership, meetings and events administration.

Our Board of Trustees is listed on **page 40**.

### **Jason Dennis, of J & H Accounting Services Limited:**

Coordinated our financial agreements and obligations.

Thank you to the team for their hard work and dedication.

## Our charity members

**Cancer52's** members are united in their determination to improve treatment and outcomes for their individual patient groups.

Most **Cancer52** member organisations are small, with 74% taking in an annual income of less than £1 million, 62% of the total membership have an income less than £500,000 and 33% an income of less than £100,000. Almost all of our members offer patient support and more than two-thirds invest in research.<sup>3</sup>

The full list of **Cancer52's** members at time of going to press can be seen on **page 29**.

**Cancer52's** active membership continues to grow. During the 2024-25 financial year, we happily welcomed newly registered charities, The Ella Dawson Foundation and The Sophie Fitzpatrick Charitable Foundation.

We hugely value and appreciate our members' ongoing dedication and commitment to **Cancer52**.



# Making the Cancer52 voice heard

**Cancer52 works tirelessly to support people with rare and less common cancers and to ensure a strong presence in this community.**

- We are represented at the highest level on boards and taskforces.
- We value close teamwork and collaboration.
- We use a range of skills and methods, within a flexible structure, to help members support patients.

## Informing, advising and supporting our members

### Meeting with our members

Virtual meetings continue to play an important part in our work as they allow our member charities and organisations from across the country to voice their concerns, connect with each other, easily share information and hear from relevant thought leaders in the field. We also recognise the huge value in meeting face-to-face. In 2024 we hosted two in-person London events, in June and November, each attended by over 100 people. In March 2025 we also hosted a smaller in-person event in Manchester.



**482**

**individuals attended  
All Member Meetings.**



**Over 100**

**people attended each in-person  
event in June and November 2024**



**202**

**people attended  
our CEO meetings.**

### Sharing

We want everyone with rare and less common cancers to have the chance to be effectively supported so that they are able to make informed choices. We consistently encourage our members to exchange knowledge so that even those working with limited resources have access to a continuing flow of useful information.

People with cancer benefit most when charities collaborate to make the most of available resources and not duplicate efforts. We know that a collaborative voice is a stronger voice.

### Regular members' e-bulletin

Throughout this financial year, our weekly e-bulletin updated our members on:

- Developments in Government and NHS policy pertinent to cancer
- Cancer52 responses to official consultations
- Charity member or national organisation meetings
- Information for patients
- Opportunities to get involved with projects that support people with rare and less common cancers
- Patient surveys
- Shared learning or awareness-raising projects
- Member job opportunities
- Training courses
- NHS and other cancer charity webinars
- Funding opportunities

The average open rate for our e-bulletin maintained a high of 65% in 2024–2025. This rate is well over double the market open rate average (27%) for newsletter emails,<sup>4</sup> making clear that our members consider our bulletins as a useful and efficient way of keeping up to date.

### Cancer52 All Member Meetings

Fortnightly virtual meetings continued throughout the financial year. They offered crucial networking opportunities and the chance to help participants learn from interesting and thought-provoking speakers. Meetings were well attended and warmly welcomed.

### CEO Calls

Monthly virtual meetings provide member CEOs direct access to their peers. Started during the COVID-19 pandemic, these meetings have continued to offer incredibly valuable opportunities to raise problems, talk through ideas, share best practice and offer peer support.

*'Cancer 52 provides a very powerful voice in the space, bringing people together really effectively.'*

Dr Michele Afif, The Brain Tumour Charity

*'Thank you also for everything Cancer52 is doing. Your efforts in bringing organisations together in this way are truly invaluable.'*

Dr Jen Kelly, The Grace Kelly Childhood Cancer Trust

Our All Member Meetings are great relationship builders and boost the profile of organisations that represent people diagnosed with rare and less common cancers.

*'We are delighted to be part of this brilliant group of charities under the Cancer52 umbrella, and look forward to our continued involvement.'*

Ines Thiru, The Ruth Strauss Foundation

## Big Cancer52 Conversation

Cancer52 has held two **Big Cancer52 Conversation** London events, in June and November 2024, and one in Manchester in March 2025. Our **Big Cancer52 Conversation** series brings together our member charities alongside senior leaders from industry, health and research, to share learning and spark collaboration to improve outcomes for rare and less common cancers.

Our event on 19th June 2024 in Canary Wharf, London, was supported by the Cancer Platform, and enabled a range of valuable discussions around health inequalities. The event took a 'marketplace' format, and member charities Young Lives vs Cancer, OUTpatients and Ovacom hosted a marketplace stall exploring the theme of health inequalities. The conversation continued on other marketplace stalls, including those focused on improving access to data, improving outcomes for children and young people with cancer and improving access to clinical trials.

Our second event on 13th November 2024 in London focused specifically on health inequalities. Event attendees heard from keynote speakers and panellists including

Professor Bola Owolabi, Director of NHS England's Healthcare Inequalities Improvement Programme, Professor Frank Chinegwundoh MBE, Chair of Cancer Black Care, Ian Vousden, Director at Kent & Medway Cancer Alliance and Yvonne Adebola, Executive Group Member at use MY data and expert by experience. They also learnt about good practice in tackling health inequalities from several **Cancer52** members.

**Cancer52** also hosted a **Big Cancer52 Conversation** in Manchester on 26th March 2025, our first major event outside of London. The event explored place-based approaches to tackling health inequalities faced by people with rare and less common cancers, and was opened by Ali Jones, Director of Cancer Commissioning and Early Diagnosis at Greater Manchester Cancer Alliance. The event hosted presentations from 10GM, who deliver the Greater Manchester Cancer and Inequalities Network, as well as from our members including North West Cancer Research, Oracle Head and Neck Cancer UK, Myeloma UK, and Yorkshire Cancer Research. Our **Big Cancer52 Conversation** in Manchester received very positive feedback, which helped forge connections with new stakeholders in the area.



Our Big Cancer52 Conversation events initiated the following key workstreams:

**Charities and industry working better together**, focused on helping our member charities to develop best practice on engagement with industry to benefit patients. This has included exploring opportunities to draw on ABPI's support to develop tools and resources for members.

**Improving access to clinical trials**, focused on addressing barriers faced by people affected by rare and less common cancers. This theme was explored in the Cancer52 patient survey.

**Proxy staging measures for blood and brain cancers**, focused on ensuring that data is inclusive of all cancers, including those that cannot be staged or are difficult to stage. This includes work that informed the subsequent Cancer52 report, Improving Diagnosis (see page 13).

**Health inequalities**, focused on sharing and developing best practice and working together to address inequalities in diagnosis, treatment, care and outcomes for people living with rare and less common cancers.

From January 2025 these Working Groups evolved and adapted to **Health Inequalities, Access to Treatments, Data and Research (including genomics and clinical trials)**.



# Partnership: Representation and advocacy in policy

Cancer52 represents its members at the highest policy and decision-making levels, acting as a conduit to organisations that need to hear the voices of those with rare and less common cancers. As a strong and determined alliance, we amplify calls for improvements in cancer services, including those supported by our member charities.

Central to Cancer52's policy work is the Policy and Public Affairs Steering Group (PPASG), which meets frequently to exchange information and help formulate Cancer52's

policy asks and responses to calls for evidence.

During 2024–2025, the group was chaired by Rachel Downing, Head of Policy and Campaigns at Target Ovarian Cancer from Summer 2024. She took over after Chris Walden, previously Deputy Director of Policy, Campaigns and Engagement at Blood Cancer UK, stepped down as Chair. Our policy lead, Sasha Daly, manages relationships with the Chair and members of the group, agrees agendas, and facilitates the functioning, outputs and reporting.

## A Manifesto for Rare and Less Common Cancers Launch Event



**During 2024–2025, Cancer52 officially launched The Other Half, a manifesto aimed at transforming outcomes for people with rare and less common cancers with an event in Parliament on 16 April.<sup>5</sup>**

The date coincided with the second reading of the Tobacco and Vapes Bill which gave a high profile to issues around cancer on the day. In total, 26 member charities attended with 11 patient representatives. All constituency MPs for the patient representatives were invited to join the reception and four attended in person, meeting their patient representatives and our Cancer52 team. Of the other constituency MPs who could not attend, many had contact and follow up with the related charity member organisation. Other MPs from the Health and Social Care Select Committee and those invited by Cancer52 Board members attended too.

**Cancer52** also took the manifesto to the Liberal Democrat, Labour, and Conservative Party Conferences, building strong relationships with influential figures including Clive Jones MP and members of the Labour Government Ministerial team. These efforts contributed to the Government's announcement of a new National Cancer Plan for England in Autumn 2024.



### **National Strategies on Health and Cancer**

The year 2024–2025 proved to be a time of rapid political and policy change but **Cancer52** and its membership remained agile and responsive and continued to lobby for national and local leadership on rare and less common cancers. This included regular engagement with the NHS Cancer Programme, the NHS National Cancer Board and DHSC, as well as responses to consultations on the **Darzi Review**, **10 Year Health Plan** and request for a **National Cancer Plan**.<sup>6</sup>

## National Cancer Plan

Cancer52 prepared a **briefing** for a **Westminster Hall Debate** on the **'Potential merits of a cancer strategy for England'** (nominated by **Clive Jones MP**) that took place on **31st October 2024**.<sup>7</sup> In the briefing Cancer52 outlined its support for a cancer strategy to provide the direction and focus to bring the required system improvements in cancer services. This focus is especially important for rare and less common cancers; without the direction and focus a strategy brings to the system, improvements in cancer services will not be delivered and rare and less common cancers will be disproportionately affected. The debate was successful and a National Cancer Plan was announced and is scheduled for release late 2025. The consultation for the National Cancer Plan opened on 4th February 2025 and ran until 29th April 2025.

The Call for Evidence, Shaping the National Cancer Plan specifically mentioned rare and less common cancers:<sup>8</sup>

### Improving outcomes for rarer cancers

Finally, the National Cancer Plan will seek to improve outcomes for those diagnosed with rarer and less common cancers and for cancer in children and young people. It will foster opportunities for UK researchers to collaborate on international cancer research. This is particularly important for areas where affected populations are small, such as with rare cancers.

**Cancer52** worked with its members to build a response to the consultation.

## Raising the voice of rare and less common cancer patients

To underpin its policy work with robust evidence, in summer 2024, **Cancer52** conducted a major patient survey, capturing the experiences of 1,371 individuals. In partnership with IQVIA, insights were analysed and findings published in the ***State of the Nation report on Rare and Less Common Cancers. Learnings from patients and partners***, launched on World Cancer Day, 4th February 2025.<sup>9</sup> The anonymised findings were also shared with member charities to support their own advocacy and service development.

**Cancer52** responded to a number of consultations from DHSC on GP Incentive Schemes and DHSC Statistical Outputs; from NICE on People and Communities Strategy, Methods and Process for including technology appraisal recommendations in guidelines, and Topic Prioritisation; and from the ABPI on the PMCPA code of conduct.

**Cancer52** also supported campaigns, and shared with members, work on sick pay for people living with cancer and the Tobacco and Vapes Bill.

### Improving Diagnosis Report

**Cancer52** worked with its members, biotech company GRAIL, and consultancy Incisive Health to take a deep dive led by patients, carers and clinicians to gain insights around what matters most in early diagnosis.

The resulting report ***Improving diagnosis: Patient and clinician perspectives on increasing early diagnosis in rare and less common cancers*** offers a constructive contribution on how to measure early diagnosis, including for non-stageable cancers such as blood and brain, that have previously been outside of NHS targets.<sup>10</sup> These policy recommendations for the next National Cancer Plan for England suggest how to measure early diagnosis at an early and actionable point where interventions will be most effective and best improve outcomes and quality of life.

## Roundtable in Westminster

Cancer52 held a roundtable event in Westminster, hosted by Clive Jones MP, on 24th February. MPs across several parties joined 12 of our member charities, and three patients spoke powerfully about their cancer journey.



*Patients, member charities, and MPs at the Parliamentary roundtable event.*

## Rare Cancers Bill

Cancer52, alongside our member charities, supported the **Rare Cancers Bill**, a Private Members Bill initiated by Dr Scott Arthur MP.<sup>11</sup> The Bill received cross-party support when it was debated on 14th March 2025. This legislation has the potential to improve survival for rare cancers by encouraging a greater focus and drive in research in these areas. The law would:

- 1 Ensure a named governmental lead has responsibility to support research and innovation for these cancers.
- 2 Ensure patients can get better access and information about relevant research and clinical trials.
- 3 Place a duty on the Government to review, and potentially strengthen, Orphan Drug Regulations. (Medicines that pharmaceutical companies may be unwilling to invest in if it is for diseases that only affect a very small number of people).

*Cancer52, alongside members and Dr Scott Arthur MP outside House of Commons.*



# Partnership: Collaboration on behalf of patients

## Working collaboratively across the NHS

### WORKING WITH THE NHS CANCER PROGRAMME

#### NHSE National Cancer Board

Alongside Cancer Research UK and Macmillan Cancer Support, **Cancer52** has a place on the NHS England (NHSE) National Cancer Board. Together we provide strategic leadership across the healthcare sector in delivering the cancer ambitions inside the **NHS Long Term Plan**.<sup>12</sup>

During 2024–2025, **Cancer52** participated in several NHSE boards and groups, where its influence was used to oversee, advise on and implement changes for those affected by cancer, including:

- Cancer Campaigns and Oversight Group
- Early Detection and Screening Task and Finish Group
- The Cancer Patient Experience Survey Advisory Group
- NHSE Quarterly Cancer Charity Forum (chair)
- Cancer Data and Analytics Advisory Group (CDAAG)

#### Working collaboratively to improve health inequalities in cancer

Over the past financial year, **Cancer52's** commitment to tackling health inequalities affecting people with rare and less common cancers has deepened. **Cancer52** actively engaged members through a comprehensive survey to map existing resources and relationships with key stakeholders, including cancer alliances and Integrated Care Boards (ICBs).

Collaborating with NHS England's Core20PLUS5 Community Connectors programme marked a significant milestone. In February 2025, **Cancer52** participated in a national learning event and contributed to the development of resources hosted on the Future NHS Collaboration Platform, enhancing knowledge-sharing across the sector.

A major highlight was the publication of *A Fair Chance: reducing health inequalities for people with rare and less common cancers*, a report exploring the health inequalities faced by those with rare and less common cancers. This report brought together insights from patients, charities, and stakeholders, offering a unified call to action. The report was disseminated widely, reaching the Department of Health and Social Care (DHSC), NHS England, cancer alliances and ICBs.<sup>13</sup>

Three flagship Big **Cancer52** Conversation events brought together a diverse group of stakeholders, including representatives from charities, healthcare and industry to drive collaborative action addressing inequalities outlined in the A Fair Chance report.

**Cancer52** also launched a new initiative in partnership with NHS England and the Charities Aid Foundation, aimed at uniting the charity sector around the issue of health inequalities. Our contribution to cross-charity commissioned research, led by the University of Oxford, further advanced efforts to improve the data landscape. **Cancer52** also strengthened ties with academic institutions such as King's College London and the London School of Hygiene and Tropical Medicine.

Throughout the year, work was shared with a broad range of stakeholders, including corporate supporters, voluntary sector partners and NHS England's data and campaigns teams. Health inequalities were a key focus in the patient survey, ensuring that lived experiences continue to inform our approach.

**Cancer52** contributed to initiatives led by National Voices and engaged with health inequalities work spearheaded by several of our corporate supporters. Notably, **Cancer52** influenced the Association of the British Pharmaceutical Industry (ABPI) to expand the scope of their professional exam to include health inequalities, marking a step forward in embedding equity into industry standards.

### Working collaboratively across the wider cancer community

Strategic partnerships were a key feature of 2024–2025. **Cancer52** secured funded partnerships with **IQVIA** and **GRAIL** to support data analysis and explore early diagnosis in rare and less common cancers. To maximise impact for people living with cancer, **Cancer52** also collaborated with the following organisations, and charities outside its direct membership:

### Charities Medicines Access Coalition

**Cancer52** is a member of the Charities Medicines Access Coalition (CMAC), which works to find long-term solutions to the challenges that can delay or prevent patient access to new and innovative medicines. This coalition has established relationships with decision-makers including NHS England, the National Institute for Health and Care Excellence (NICE) and the Association of the British Pharmaceutical Industry (ABPI). **Cancer52** engaged with NHSE, the ABPI, Blood Cancer Alliance and pharmaceutical companies on the NHS Commercial Framework consultation.

### Genomics England

Genomics England have collaborated with **Cancer52** throughout 2024 and 2025, attending a Big **Cancer52** Conversation and All Member Meeting, and hosting a roundtable event attended by 16 member charities to discuss genomics and rare and less common cancers.



*Genomics England Roundtable*

A survey of **Cancer52** members and the patients they represent, conducted prior to the roundtable, demonstrated a low level of awareness of whole genomics sequencing (WGS) and potential benefits for patients with rare and less common cancers. The roundtable raised the pressing need for collaboration between organisations, patient involvement and awareness in genomics research and testing, particularly for rare and less common cancers. Other topics discussed on the day included leveraging genomic advances and identifying key challenges and using WGS data to maximise the impact of genomics.

## NICE VCSE Forum Steering Group

**Cancer52** sits on NICE Voluntary and Community Sector (VCSE) Forum's to help engage its members in NICE updates. The NICE VCSE forum ensures that the people affected by NICE's work can be heard in the decision making process.

## The Cancer Data Collaborative

**Cancer52** collaborated with Cancer Research UK and Macmillan Cancer Support in data sharing. Data collaboratives are an emerging form of collaboration in which data held by an entity can be leveraged in partnership with another entity (from the public sector, civil society and/or academia) for public good.

## One Cancer Voice

One Cancer Voice (OCV) consists of cancer charities working together on fundamental policy asks, such as a governmental cancer plan. This alliance was increasingly active following the General Election and subsequent calls for evidence for health and cancer policies. **Cancer52** played a key role on the OCV steering group to shape the agenda and calls to action as well as to engage our members in OCV's public facing activities.

## Fair Market Value for patients' and charities' time and expertise

**Cancer52** finalised and launched guidance on Fair Market Value working in partnership with the Charities Research Involvement Group, Health Research Charities Ireland (HRCI), the National Rheumatoid Arthritis Society (NRAS) and the Patient Information Forum (PIF). This guidance makes five key recommendations to bring consistency to reimbursement for cross-sector partnership work.<sup>14</sup>

These recommendations have already been endorsed by Asthma + Lung UK, Breakthrough Cancer Research, Cleft Lip and Palate Association (CLAPA), Debra Ireland, Irish Heart Foundation, Irish Lung Fibrosis Association, Maynooth University and the National Institute for Health and Care Research (NIHR).

## Signposting across patient information

**Cancer52** has led work that helps patients and their loved ones to access patient information and patient support relevant to their cancer type. **Cancer52** has worked with Macmillan Cancer Support to initiate new links with their online patient information to signpost to smaller charities focused on rare and less common cancers.



*One Cancer Voice Summit*

## Healthcare charities

National Voices is a wide-ranging coalition of healthcare charities that helps **Cancer52** engage in topics particularly relevant to people with rare and less common cancers.

## ABPI Patient Advisory Council

**Cancer52's** CEO sat on the Association of the British Pharmaceutical Industry (ABPI) Patient Advisory Council while **Cancer52** also took part in the Patient Organisation Forum briefings - alongside other larger, well-known charities and contributed to the steering group responsible for planning meetings and organising speakers. **Cancer52** also continued to partner with the ABPI on an Anti-Microbial Resistance campaign specific to people living with rare and less common cancers called Together for Antibiotics.<sup>15,16</sup>

## Travel insurance for cancer patients

**Cancer52** has been supporting member charity, Planets, in their work to improve travel insurance options for people whose cancer diagnosis means they often face prohibitive costs that do not necessarily reflect the risk. **Cancer52** collaborated with Verisk, a company that provides health risk data (including for rare and less common cancers) for up to 90% of the UK Insurance industry, on reviewing risk assessments for individual rare and less common cancers.

## Keeping our stakeholders informed

As an organisation, and also as our members' representative, **Cancer52** is in ongoing communication with members of other charities, NHS professionals and others with influence in the rare and less common cancer field.

### Website

The **Cancer52** website links to all member organisations, plus the sponsors and groups **Cancer52** collaborates with, offering a useful portal for sharing information between members, patients and the general public. It includes a webpage listing all rare and less common cancers with links to relevant patient support and research organisations. **Cancer52** posted reports on its activities during the year and featured a news stream of prominent issues. A password protected webpage for members was introduced with a range of helpful links and information. Website users can access reports together with informative videos, contact and donation opportunities.

### Social media

This year, LinkedIn has emerged as **Cancer52's** primary social channel, followed by X (formally Twitter) and Facebook. **Cancer52** has increased its following, especially on LinkedIn, reaching nearly 1,000 followers. **Cancer52** uses social media to communicate with members and the wider public; to raise awareness of the work of the organisation, distribute new information and react to events that impact the rare and less common cancer community.

# Making the voice of people with rare and less common cancers heard: our headline achievements for 2024–2025

## Partnership

### Informing, sharing with, and empowering our members

**Cancer52** membership and engagement levels increased in 2024–2025, confirming that continuing to invest and expand our Big **Cancer52** Conversation events successfully facilitates partnerships. **Cancer52** also forged new and productive partnerships, enabling us to strengthen research and data on the impact of rare and less common cancers. We are grateful for our member's significant positive engagement and feedback.

## Policy

### Responding collectively to the changing political cancer priorities

**Cancer52** achieved significant policy and advocacy successes in 2024–2025, driving national attention to rare and less common cancers. By engaging with key political figures and contributing to consultations on national health strategies, **Cancer52** formed part of the sector influencing the Government to announce its new National Cancer Plan. **Cancer52's** impactful briefings, responses and collaborative reports provided robust evidence to shape policy, ensuring the voices of those affected by rare cancers were heard at the highest levels of policy.

## People

### Advocating for those affected by rare and less common cancers through collaboration

**Cancer52** created several opportunities for patients and policymakers to engage, including the manifesto launch, and roundtable in Parliament. **Cancer52** conducted a comprehensive patient survey, the findings of which underpinned several reports and policy asks. Furthermore, patient interview findings shaped the Improving Diagnosis Report and key recommendations. **Cancer52** has hosted several in-person events to enable members to collaborate to tackle health inequalities and create greater equity in cancer care.





# Funding



## The National Lottery Community Fund

During the financial year 2023–2024, Cancer52 successfully secured substantial three-year funding from The National Lottery Community Fund (TNLCF), the largest community funder in the UK. In 2024–2025 Cancer52 received its second year of funding which was used on staffing resources to work on the three key target outcomes:

**Outcome 1:**  
Policy advances for rare and less common cancer

**Outcome 2:**  
Addressing patient health inequalities

**Outcome 3:**  
Increasing member engagement

Cancer52's work means the impact of this funding has, and will continue to benefit people affected by rare and less common cancers, the wider rare and less common cancer community, Cancer52 itself and charity members.

From TNLCF, Cancer52 also received a grant uplift on the original fund, to accommodate the additional expenses incurred from the recruitment of a new CEO when Jane Lyons MBE retired from the organisation in July 2024. These additional funds were invaluable in recruiting a CEO of the highest

## The value of support

**Cancer52** also continued to receive funding via donations from members, individual donations and support from pharmaceutical companies. These funds are vital in order to help the rare and less common cancer community via our ongoing delivery of core work and relevant projects.

**Cancer52** greatly appreciates the valuable time, expertise and energy generously donated by its members.

**Cancer52** is incredibly grateful to every donor and supporter for their financial support which helps propel us towards achieving our objectives. The financial benefaction of charity members represents a very significant contribution in terms of the number and variety of organisations that support **Cancer52**.

## Voluntary member donations

A considerable amount of **Cancer52**'s financial support comes from member charities who make a voluntary donation aligned to their income.

We maintained the strong income from member charities this financial year. **Cancer52** asked members with an annual income over £100,000 to pay a donation where possible but, as always, were considerate of those smaller charities encountering the rising cost of living. Membership donations, which are based on charity income level, increased by almost 4% in 2024/25.

## Individual donations

Donations are welcome and gratefully received from any individuals or organisations who recognise the value of **Cancer52**'s contribution in supporting people with rare and less common cancers.

During the financial year 2024-25, **Cancer52** received over £9,000 from a variety of platforms and individuals. Of particular note, thanks go to the families and friends of Mike Martin, who

ran the Hastings Half Marathon in his memory, as well as the family and friends of Anthony Cox who raised a significant amount to support the work of **Cancer52**.

## Support from industry

In 2024–2025 we received support from Abbvie, Astra Zeneca, Daiichi Sankyo, GSK, Incyte, Johnson & Johnson, Merck, Novartis, Pfizer, Roche and Takeda, who all benefited from membership to **Cancer52**'s Corporate Supporter Programme. Gilead and MSD also benefitted from membership to the programme although these income figures will be shown in the 2025-2026 financial report.

In addition to membership to the Corporate Supporter Programme, AstraZeneca and Gilead kindly sponsored our Big **Cancer52** Conversation event in November 2024, and AstraZeneca supported the March 2025 event. Roche also supported **Cancer52** by providing a ticket to the Labour Party Conference in 2024.

**Cancer52** has a clearly written policy to guide its work with the pharmaceutical industry and follows industry guidelines.<sup>17</sup> Some 36.5% of our funding comes from pharmaceutical companies and comprises support for specific projects as well as unrestricted support.

**Cancer52** believes all its industry partners recognise the value of working with an umbrella organisation that channels one voice for rare and less common cancers.



# Future plans

Cancer52 is proud to provide a strong, unified voice to promote improved diagnosis, treatment and support for those affected by rare and less common cancers so that we see an end to inequalities in diagnosis, treatment and patient outcomes experienced by those with these challenging diseases.

**As part of its three-year strategy, Cancer52 has made progress in its plans to:**

Be a well-resourced organisation making the voice of rare and less common cancers heard through securing TNLCF funding over three years

Retain its market leadership position

Build its thought leadership and collective policy steer to shape national cancer and health policy

Work collaboratively with members and the wider rare and less common cancer community

Carry forward aims, mission and values

Place reducing inequalities at the heart of everything it does and making this a key workstream of the **Big Cancer52 Conversation**.

**In the next year, Cancer52 will build upon these successes to evolve and pivot to a new strategy, scheduled for development and implementation from summer 2025.**

# Structure and Constitution



## Structure and Governance


**Cancer52** is incorporated as a charitable company limited by guarantee and is a registered charity in England and Wales. It is governed by its Memorandum and Articles of Association, and its work, management, finances and strategy are overseen by a Board of trustees, who are also the company directors. The trustees who held office during the financial year and at the date of the report are set out on page 40.

Under the Articles of Association, a minimum of three trustees and a maximum of twelve trustees {directors} can be in office. New directors may only be appointed where the notice and approval requirements set out in the Articles of Association have been satisfied.

The Board has agreed that trustees are appointed for an initial 3-year term of office followed by the opportunity for renewals for a further three years per term. In most cases, trustees will serve for a maximum of nine years, but the term may go beyond this period if both parties agree it is beneficial to the organisation, with review and approval by the Board at the end of each term of tenure. Trustees do not receive remuneration for their duties.

## Public benefit

**Cancer52** encourages and facilitates interaction and collaboration between members and other stakeholders. This support in turn aids members' provision of information and support to people diagnosed with, treated for or living with a rare or less common cancer. Outcomes for people with rare or less common cancers also improve when we drive change and enhancements in the cancer system.



## Purpose

The charity's purposes are set out in its Memorandum and Articles of Association as follows:

To promote and protect the health of people with rare and less common cancers by:

1. Advancing and promoting understanding, awareness, research and learning about rare and less common cancers;
2. Acting as a collective voice and advocating for the needs of individuals affected by a rare or less common cancer in order to improve diagnosis, treatment and long-term support outcomes
3. Supporting, representing and empowering not-for-profit organisations working in the field of rare and less common cancers.

As part of the business planning processes, **Cancer52's** aims and objectives are reviewed each year. This includes looking at how those groups of people we were set up to help have benefited and what has been achieved in previous years. The Charity Commission's general guidance on public benefit was referred to when reviewing **Cancer52's** aims and objectives and also in the planning work for the future.

## Board and management operations and structure

### Board of Trustees

The Board of Trustees meets at least four times a year to review **Cancer52's** work, finances and services, and to agree strategic goals for the charity. In-person board meetings resumed in 2024-25 with a virtual option, and meetings invited the Chief Executive and the Operations Consultant, and others as appropriate.

The Finance Committee also meet separately with the Chief Executive, Operations Consultant, and **Cancer52's** accountant on a quarterly basis to monitor and scrutinise the financial strategy and operations and make any necessary recommendations to the full Board of Trustees.

### Recruitment and appointment of new Trustees

Moving into the role of CEO, Chris Walden stepped down from the Board of Trustees in August 2024. The Board also said goodbye to Rebecca Porta, a Board member for over seven years, who stepped down in September 2024.

Four new trustees were appointed to the Board in February 2025. **Cancer52** welcomed Amanda Boughey, Clare Clifton, Dagmar Droogsma and Yasmin Sheikh to bring their vast experience and expertise.

### Related parties

Related parties are considered to be the trustees and those connected with the trustees, including their close families, business and other charity interests. There have been no transactions with related parties, other than the reimbursement of reasonable travel expenses for the purposes of attendance at board meetings and other relevant organisational activities.

## Risk assessment and management

The Board of Trustees and the Chief Executive maintain a risk register and assess risk on an annual basis. The trustees are satisfied that major risks to the organisation have been accurately identified and that appropriate systems and procedures for managing those risks are in place.

### Safeguarding

**Cancer52** has a strong commitment to protecting and promoting the health, wellbeing and safety of all engaged in its work. While not a patient representative charity, **Cancer52** still adheres to good safeguarding practice. The Safeguarding Policy is reviewed each year and is accessible on the Governance section of **Cancer52's** website. Each year, all staff and volunteers are required to participate in a full-day safeguarding training course, provided by an external organisation to ensure everyone is up to date with the latest safeguarding requirements.

**Cancer52** has sought to strengthen its risk management training this year and all employees are required to take General Data Protection Regulation (GDPR) training.

### Annual review

The Annual Review 2024–2025 was completed and disseminated, with thanks to the Board nominees Nic Puntis and Clare Clifton.

# Money talks: financial review 2024–2025

## Financial statement

As shown in the statement of financial activities on the following pages, in the year 2024–2025

- Reserves brought forward from 2023–2024 were £50,913.
- Income for the financial year was £363,420.
- Expenditure for the current financial year was £348,601, resulting in a surplus of £14,819.
- Reserves of £65,732 were available at the end of the 2024–2025 financial year.

### Reserves policy

The Board of Trustees' strategy on reserves is to maintain sufficient funds to cover the operational running costs in the event of a major setback. This means that we aim to hold between five and seven months' unrestricted annual expenditure in reserve.

At the end of the 2024–2025 financial year, **Cancer52's** reserves stood at £65,732 which covers five months running expenses not covered directly by the National Lottery and any other restricted income.

The Company has taken advantage of the small companies' exemption in preparing this report. The trustees declare that they have approved the trustees' report (including directors' report) above.

#### Signed on behalf of the charity's trustees/directors

Signature \_\_\_\_\_

Anne MacDowell

*Trustee / Director*

Date \_\_\_\_\_

Signature \_\_\_\_\_

Nic Puntis

*Trustee / Director*

Date \_\_\_\_\_



**Section A Independent Examiner's Report**

**Report to the trustees/directors/ members of**

Cancer 52

**On accounts for the year ended**

31<sup>st</sup> March 2025

**Charity no.:**

1174569

**Company no.:**

07994413

**Set out on pages**

**28**

To

**40**

**Responsibilities and basis of report**

I report to the charity trustees on my examination of the accounts of the Company for the year ended **31<sup>st</sup> March 2025**.

As the charity's trustees of the Company (who are also the directors of the company for the purposes of company law), you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ("the 2006 Act").

Having satisfied myself that the accounts of the Company are not required to be audited for this year under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ("the 2011 Act"). In carrying out my examination, I have followed the Directions given by the Charity Commission (under section 145(5)(b) of the 2011 Act.

**Independent examiner's statement**

I have completed my examination. I confirm that no material matters have come to my attention (other than that disclosed below \*) which gives me cause to believe that:

- accounting records were not kept in accordance with section 386 of the Companies Act 2006; or
- the accounts do not accord with such records; or
- the accounts do not comply with relevant accounting requirements under section 396 of the Companies Act 2006 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
- the accounts have not been prepared in accordance with the Charities SORP (FRS102).

**Name:** Jason Dennis

**Relevant professional qualification(s) or body (if any):** AAT - Association of Accounting Technicians  
ATT – Association of Taxation Technicians

**Address:** 31 Clover Way, Paddock Wood, Tonbridge, Kent TN12 6BQ

**Section B Disclosure**

Only complete if the examiner needs to highlight material matters of concern (see CC32, Independent examination of charity accounts: directions and guidance for examiners).

**Give here brief details of any items that the examiner wishes to disclose.**

[Empty box for disclosure details]

# Section A

## Statement of financial activities

(including summary income and expenditure account)

Recommended categories by activity	Guidance Note	Unrestricted	Restricted	Endowment	Total funds	Prior year
		funds	income funds	funds	funds	funds
		£	£	£	£	£
		F01	F02	F03	F04	F05
<b>Income (Note 3)</b>						
<b>Income and endowments from:</b>						
Donations and legacies	S01	191,378	172,042	-	363,420	230,779
<b>Total</b>	S07	191,378	172,042	-	363,420	230,779
<b>Expenditure (Notes 4)</b>						
<b>Expenditure on:</b>						
Raising funds	S08	4,284	-	-	4,284	20,493
Charitable activities	S09	129,488	208,829	-	338,317	242,208
Other	S11	6,000	-	-	6,000	6,000
<b>Total</b>	S12	139,772	208,829	-	348,601	268,701
<b>Net income/(expenditure) before tax for the reporting period</b>						
	S13	51,606	(36,787)	-	14,819	(37,922)
Tax payable	S14	-	-	-	-	-
<b>Net income/(expenditure) after tax before investment gains/(losses)</b>						
	S15	51,606	(36,787)	-	14,819	(37,922)
Net gains/(losses) on investments	S16	-	-	-	-	-
<b>Net income/(expenditure) Extraordinary items</b>						
	S17	51,606	(36,787)	-	14,819	(37,922)
<b>Transfers between funds</b>						
	S18	-	-	-	-	-
<b>Other recognised gains/(losses):</b>						
Gains and losses on revaluation of fixed assets for the charity's own use	S19	(36,000)	36,000	-	-	-
Other gains/(losses)	S20	-	-	-	-	-
	S21	-	-	-	-	-
<b>Net movement in funds</b>						
	S22	15,606	(787)	-	14,819	(37,922)
<b>Reconciliation of funds:</b>						
Total funds brought forward	S23	50,017	896	-	50,913	88,835
<b>Total funds carried forward</b>	S24	65,623	109	-	65,732	50,913

# Section B

## Balance sheet (as at 31st March 2025)

	Guidance Note	Unrestricted funds £	Restricted income funds £	Endowment funds £	Total this year £	Total last year £
<b>Current assets</b>						
Debtors (Note 8)	B07	3,230	-	-	3,230	-
Cash at bank and in hand (Note 10)	B09	124,626	109	-	124,735	111,651
<b>Total current assets</b>	B10	127,856	109	-	127,965	111,651
<b>Creditors and deferred income : amounts falling due within one year (Note 9)</b>						
	B11	62,233	-	-	62,233	60,738
<b>Net current assets/(liabilities)</b>	B12	65,623	109	-	65,732	50,913
<b>Total assets less current liabilities</b>	B13	65,623	109	-	65,732	50,913
<b>Total net assets or liabilities</b>	B16	65,623	109	-	65,732	50,913
<b>Funds of the Charity</b>						
Endowment funds	B17	-	-	-	-	-
Restricted income funds (Note 12)	B18	-	109	-	109	896
Unrestricted funds	B19	65,623	-	-	65,623	50,017
Revaluation reserve	B20	-	-	-	-	-
Fair value reserve	B21	-	-	-	-	-
<b>Total funds</b>	B22	65,623	109	-	65,732	50,913

The company was entitled to exemption from audit under s477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to small companies subject to the small companies regime and in accordance with FRS102 SORP.

Signed by one or two trustee/directors on behalf of all the trustees/directors

Name	Signature	Date of approval dd/mm/yyyy
Anne MacDowell		
Nic Puntis		

Signature of Chair authenticating accounts being sent to Companies House

Name	Signature	Date of approval dd/mm/yyyy
Anne MacDowell		

# Section C

## Notes to the accounts

### NOTE 1: Basis of preparation

#### Note 1 Basis of preparation

***This section should be completed by all charities.***

#### 1.1 Basis of accounting

These accounts have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant note(s) to these accounts.

The accounts have been prepared in accordance with:

- and with\* 

✓
---

 the Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued on 16 July 2014
- and with\* 

✓
---

 the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102)
- and with the Charities Act 2011.

The charity constitutes a public benefit entity as defined by FRS 102.\*

✓
---

\* -Tick as appropriate

#### 1.2 Going concern

***If there are material uncertainties related to events or conditions that cast significant doubt on the charity's ability to continue as a going concern, please provide the following details or state "Not applicable", if appropriate:***

An explanation as to those factors that support the conclusion that the charity is a going concern;

<b><i>Not applicable</i></b>
------------------------------

Disclosure of any uncertainties that make the going concern assumption doubtful;

<b><i>Not applicable</i></b>
------------------------------

Where accounts are not prepared on a going concern basis, please disclose this fact together with the basis on which the trustees prepared the accounts and the reason why the charity is not regarded as a going concern.

<b><i>Not applicable</i></b>
------------------------------

**1.3 Change of accounting policy**

The accounts present a true and fair view and no changes have been made to the accounting policies adopted in note { 1.1 }.

Yes*	<input checked="" type="checkbox"/>	* -Tick as appropriate
No*	<input type="checkbox"/>	

**Please disclose:**

<i>(i) the nature of the change in accounting policy;</i>	<i>Not applicable</i>
<i>(ii) the reasons why applying the new accounting policy provides more reliable and more relevant information; and</i>	<i>Not applicable</i>
<i>(iii) the amount of the adjustment for each line affected in the current period, each prior period presented and the aggregate amount of the adjustment relating to periods before those presented, 3.44 FRS102 SORP.</i>	<i>Not applicable</i>

**1.4 Changes to accounting estimates**

No changes to accounting estimates have occurred in the reporting period (3.46 FRS102 SORP).

Yes*	<input checked="" type="checkbox"/>	* -Tick as appropriate
No*	<input type="checkbox"/>	

**Please disclose:**

<i>(i) the nature of any changes;</i>	<i>Not applicable</i>
<i>(ii) the effect of the change on income and expense or assets and liabilities for the current period; and</i>	<i>Not applicable</i>
<i>(iii) where practicable, the effect of the change in one or more future periods.</i>	<i>Not applicable</i>

**1.5 Material prior year errors**

No material prior year error have been identified in the reporting period (3.47 FRS102 SORP).

Yes*	<input checked="" type="checkbox"/>	* -Tick as appropriate
No*	<input type="checkbox"/>	

**Please disclose:**

<i>(i) the nature of the prior period error;</i>	<i>Not applicable</i>
<i>(ii) for each prior period presented in the accounts, the amount of the correction for each account line item affected; and</i>	<i>Not applicable</i>
<i>(iii) the amount of the correction at the beginning of the earliest prior period presented in the accounts.</i>	<i>Not applicable</i>

## NOTE 2: Accounting policies

### 2.1 INCOME

<b>Recognition of income</b>	<p>These are included in the Statement of Financial Activities (SoFA) when:</p> <ul style="list-style-type: none"> <li>the charity becomes entitled to the resources;</li> <li>it is more likely than not that the trustees will receive the resources;</li> <li>the monetary value can be measured with sufficient reliability.</li> </ul>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">✓</td> <td></td> <td></td> </tr> </tbody> </table>	Yes*	No*	N/a*	✓		
Yes*	No*	N/a*						
✓								
<b>Offsetting</b>	<p>There has been no offsetting of assets and liabilities, or income and expenses, unless required or permitted by the FRS 102 SORP or FRS 102.</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">✓</td> <td></td> <td></td> </tr> </tbody> </table>	Yes*	No*	N/a*	✓		
Yes*	No*	N/a*						
✓								
<b>Grants and donations</b>	<p>Grants and donations are only included in the SoFA when the general income recognition criteria are met (5.10 to 5.12 FRS102 SORP).</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">✓</td> <td></td> <td></td> </tr> </tbody> </table>	Yes*	No*	N/a*	✓		
Yes*	No*	N/a*						
✓								
	<p>In the case of performance related grants, income must only be recognised to the extent that the charity has provided the specified goods or services as entitlement to the grant only occurs when the performance related conditions are met (5.16 FRS 102 SORP).</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> <td style="text-align: center;">✓</td> </tr> </tbody> </table>	Yes*	No*	N/a*			✓
Yes*	No*	N/a*						
		✓						
<b>Legacies</b>	<p>Legacies are included in the SOFA when receipt is probable, that is, when there has been grant of probate, the executors have established that there are sufficient assets in the estate and any conditions attached to the legacy are either within the control of the charity or have been met.</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">✓</td> <td></td> <td></td> </tr> </tbody> </table>	Yes*	No*	N/a*	✓		
Yes*	No*	N/a*						
✓								
<b>Government grants</b>	<p>The charity has received government grants in the reporting period</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">✓</td> <td></td> <td></td> </tr> </tbody> </table>	Yes*	No*	N/a*	✓		
Yes*	No*	N/a*						
✓								
<b>Tax reclaims on donations and gifts</b>	<p>Gift Aid receivable is included in income when there is a valid declaration from the donor. Any Gift Aid amount recovered on a donation is considered to be part of that gift and is treated as an addition to the same fund as the initial donation unless the donor or the terms of the appeal have specified otherwise.</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">✓</td> <td></td> <td></td> </tr> </tbody> </table>	Yes*	No*	N/a*	✓		
Yes*	No*	N/a*						
✓								
<b>Contractual income and performance related grants</b>	<p>This is only included in the SoFA once the charity has provided the related goods or services or met the performance related conditions.</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> <td style="text-align: center;">✓</td> </tr> </tbody> </table>	Yes*	No*	N/a*			✓
Yes*	No*	N/a*						
		✓						
<b>Donated goods</b>	<p>Donated goods are measured at fair value (the amount for which the asset could be exchanged) unless impractical to do so.</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> <td style="text-align: center;">✓</td> </tr> </tbody> </table>	Yes*	No*	N/a*			✓
Yes*	No*	N/a*						
		✓						
	<p>The cost of any stock of goods donated for distribution to beneficiaries is deemed to be the fair value of those gifts at the time of their receipt and they are recognised on receipt. In the reporting period in which the stocks are distributed, they are recognised as an expense at the carrying amount of the stocks at distribution.</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> <td style="text-align: center;">✓</td> </tr> </tbody> </table>	Yes*	No*	N/a*			✓
Yes*	No*	N/a*						
		✓						
	<p>Donated goods for resale are measured at fair value on initial recognition, which is the expected proceeds from sale less the expected costs of sale, and recognised in 'Income from other trading activities' with the corresponding stock recognised in the balance sheet. On its sale the value of stock is charged against 'Income from other trading activities' and the proceeds from sale are also recognised as 'Income from other trading activities'.</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> <td style="text-align: center;">✓</td> </tr> </tbody> </table>	Yes*	No*	N/a*			✓
Yes*	No*	N/a*						
		✓						
	<p>Goods donated for on-going use by the charity are recognised as tangible fixed assets and included in the SoFA as incoming resources when receivable.</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> <td style="text-align: center;">✓</td> </tr> </tbody> </table>	Yes*	No*	N/a*			✓
Yes*	No*	N/a*						
		✓						
	<p>Gifts in kind for use by the charity are included in the SoFA as income from donations when receivable.</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">✓</td> <td></td> <td></td> </tr> </tbody> </table>	Yes*	No*	N/a*	✓		
Yes*	No*	N/a*						
✓								
<b>Donated services and facilities</b>	<p>Donated services and facilities are included in the SOFA when received at the value of the gift to the charity provided the value of the gift can be measured reliably.</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> <td style="text-align: center;">✓</td> </tr> </tbody> </table>	Yes*	No*	N/a*			✓
Yes*	No*	N/a*						
		✓						
	<p>Donated services and facilities that are consumed immediately are recognised as income with an equivalent amount recognised as an expense under the appropriate heading in the SOFA.</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> <td style="text-align: center;">✓</td> </tr> </tbody> </table>	Yes*	No*	N/a*			✓
Yes*	No*	N/a*						
		✓						

**Support costs**                      The charity has incurred expenditure on support costs.                      Yes\*    No\*    N/a\*  

	✓	
--	---	--

**Volunteer help**                      The value of any voluntary help received is not included in the accounts but is described in the trustees' annual report.                      Yes\*    No\*    N/a\*  

✓		
---	--	--

**2.2 EXPENDITURE AND LIABILITIES**

**Liability recognition**                      Liabilities are recognised where it is more likely than not that there is a legal or constructive obligation committing the charity to pay out resources and the amount of the obligation can be measured with reasonable certainty.                      Yes\*    No\*    N/a\*  

✓	✓	✓
---	---	---

**Governance and support costs**                      Support costs have been allocated between governance costs and other support. Governance costs comprise all costs involving public accountability of the charity and its compliance with regulation and good practice.                      Yes\*    No\*    N/a\*  

		✓
--	--	---

Support costs include central functions and have been allocated to activity cost categories on a basis consistent with the use of resources, eg allocating property costs by floor areas, or per capita, staff costs by the time spent and other costs by their usage.                      Yes\*    No\*    N/a\*  

		✓
--	--	---

**Grants with performance conditions**                      Where the charity gives a grant with conditions for its payment being a specific level of service or output to be provided, such grants are only recognised in the SoFA once the recipient of the grant has provided the specified service or output.                      Yes\*    No\*    N/a\*  

		✓
--	--	---

**Grants payable without performance conditions**                      Where there are no conditions attaching to the grant that enables the donor charity to realistically avoid the commitment, a liability for the full funding obligation must be recognised.                      Yes\*    No\*    N/a\*  

		✓
--	--	---

**Redundancy cost**                      The charity made no redundancy payments during the reporting period.                      Yes\*    No\*    N/a\*  

✓		
---	--	--

**Deferred income**                      No material item of deferred income has been included in the accounts.                      Yes\*    No\*    N/a\*  

	✓	
--	---	--

**Creditors**                      The charity has creditors which are measured at settlement amounts less any trade discounts                      Yes\*    No\*    N/a\*  

		✓
--	--	---

**Provisions for liabilities**                      A liability is measured on recognition at its historical cost and then subsequently measured at the best estimate of the amount required to settle the obligation at the reporting date                      Yes\*    No\*    N/a\*  

		✓
--	--	---

**Basic financial instruments**                      The charity accounts for basic financial instruments on initial recognition as per paragraph 10.7 FRS102 SORP. Subsequent measurement is as per paragraphs 11.17 to 11.19, FRS102 SORP.                      Yes\*    No\*    N/a\*  

		✓
--	--	---

## 2.3 ASSETS

**Tangible fixed assets for use by charity** These are capitalised if they can be used for more than one year, and cost at least

£2,500		
Yes*	No*	N/a*
		✓

They are valued at cost.

The depreciation rates and methods used are disclosed in note 14.

**Intangible fixed assets** The charity has intangible fixed assets, that is, non-monetary assets that do not have physical substance but are identifiable and are controlled by the charity through custody or legal rights. The amortisation rates and methods used are disclosed in note 15.

Yes*	No*	N/a*
		✓

They are valued at cost.

Yes*	No*	N/a*
		✓

**Heritage assets** The charity has heritage assets, that is, non-monetary assets with historic, artistic, scientific, technological, geophysical or environmental qualities that are held and maintained principally for their contribution to knowledge and culture. The depreciation rates and methods used as disclosed in note 16.

Yes*	No*	N/a*
		✓

They are valued at cost.

Yes*	No*	N/a*
		✓

**Investments** Fixed asset investments in quoted shares, traded bonds and similar investments are valued at initially at cost and subsequently at fair value (their market value) at the year end. The same treatment is applied to unlisted investments unless fair value cannot be measured reliably in which case it is measured at cost less impairment.

Yes*	No*	N/a*
		✓

Investments held for resale or pending their sale and cash and cash equivalents with a maturity date of less than 1 year are treated as current asset investments

Yes*	No*	N/a*
		✓

**Stocks and work in progress** Stocks held for sale as part of non-charitable trade are measured at the lower or cost or net realisable value.

Yes*	No*	N/a*
		✓

Goods or services provided as part of a charitable activity are measured at net realisable value based on the service potential provided by items of stock.

Yes*	No*	N/a*
		✓

Work in progress is valued at cost less any foreseeable loss that is likely to occur on the contract.

Yes*	No*	N/a*
		✓

**Debtors** Debtors (including trade debtors and loans receivable) are measured on initial recognition at settlement amount after any trade discounts or amount advanced by the charity. Subsequently, they are measured at the cash or other consideration expected to be received.

Yes*	No*	N/a*
✓		

**Current asset investments** The charity has investments which it holds for resale or pending their sale and cash and cash equivalents with a maturity date less than one year. These include cash on deposit and cash equivalents with a maturity of less than one year held for investment purposes rather than to meet short-term cash commitments as they fall due.

Yes*	No*	N/a*
✓		

They are valued at fair value except where they qualify as basic financial instruments.

Yes*	No*	N/a*
✓		

**POLICIES ADOPTED ADDITIONAL TO OR DIFFERENT FROM THOSE ABOVE**

--	--

## NOTE 3: Income

Analysis of income		Unrestricted funds	income funds	Endowment funds	Total funds £	Prior year £
<b>Donations</b>	Donations and gifts	134,928	10,000	-	144,928	146,179
	General grants provided by government - TNLCF (National Lottery Community Fund)	-	162,042	-	162,042	36,943
	Membership subscriptions and sponsorships which are in substance donations	56,450	-	-	56,450	47,657
	<b>Total</b>	<b>191,378</b>	<b>172,042</b>	<b>-</b>	<b>363,420</b>	<b>230,779</b>
<b>TOTAL INCOME</b>		<b>191,378</b>	<b>172,042</b>	<b>-</b>	<b>363,420</b>	<b>230,779</b>

## NOTE 4: Analysis of receipts of government grants

	Description	This year £
Government grant 1	The National Lottery Community Fund - Funding for Core expenditure	162,042
	<b>Total</b>	<b>162,042</b>

## NOTE 5: Expenditure

Analysis	This year				Last year			
	Unrestricted funds	Restricted income funds	Endowment funds	Total funds	Unrestricted funds	Restricted income funds	Endowment funds	Total funds
<b>Expenditure on raising funds</b>				£				£
Fundraising consultant services	4,284	-	-	4,284	20,493	-	-	20,493
<b>Total expenditure on raising funds</b>	<b>4,284</b>	<b>-</b>	<b>-</b>	<b>4,284</b>	<b>20,493</b>	<b>-</b>	<b>-</b>	<b>20,493</b>
<b>Expenditure on charitable activities:</b>								
All Member Meetings, Steering Group Meetings, Room Hire, Venue Costs, Conference expenses	3,453	-	-	3,453	4,716	-	-	4,716
Manifesto	106	-	-	106	-	-	-	-
Branding Design	1,688	-	-	1,688	-	-	-	-
Merchandise	-	-	-	-	121	-	-	121
Recovery Costs Project	2,400	-	-	2,400	-	-	-	-
Cancer Awareness Project	2,399	-	-	2,399	-	-	-	-
Inequalities report	-	-	-	-	11,565	-	-	11,565
TNLCF - National Lottery funded expenditure	-	198,829	-	198,829	-	36,047	-	36,047
NCRI Project	-	-	-	-	401	-	-	401
Big Cancer Conversation 52 Events	7,507	10,000	-	17,507	17,089	-	-	17,089
Pfizer Project Support	-	-	-	-	186	-	-	186
Impact Reporting and Annual Review	1,566	-	-	1,566	1,805	-	-	1,805
Telephone	320	-	-	320	302	-	-	302
Registered Office Change	-	-	-	-	119	-	-	119
Contract Review	300	-	-	300	-	-	-	-
IT and Computer running expenses and Website mtce	2,089	-	-	2,089	1,380	-	-	1,380
Policy consultants - Policy Support and Report	17,419	-	-	17,419	33,441	-	-	33,441
Policy Workshop	6,000	-	-	6,000	15,000	-	-	15,000
Subscriptions	2,376	-	-	2,376	2,632	-	-	2,632
Operations Management Services	35,500	-	-	35,500	33,146	-	-	33,146
Other Administration Support Services	21,204	-	-	21,204	14,348	-	-	14,348
Insurance	741	-	-	741	574	-	-	574
Parliamentary Event	1,858	-	-	1,858	2,261	-	-	2,261
Salaries and Ers NI and Pensions (Non-TNLCF Funded)	-	-	-	-	47,518	-	-	47,518
Training	2,786	-	-	2,786	866	-	-	866
Communications and PR Services	14,577	-	-	14,577	15,767	-	-	15,767
Bank and credit fees	216	-	-	216	216	-	-	216
Trustees/Directors Travel	257	-	-	257	608	-	-	608
Other Travel and Contractor Expenses	4,502	-	-	4,502	563	-	-	563
Trustee Recruitment costs and expenses	224	-	-	224	491	-	-	491
Other Recruitment costs	-	-	-	-	1,046	-	-	1,046
<b>Total expenditure on charitable activities</b>	<b>129,488</b>	<b>208,829</b>	<b>-</b>	<b>338,317</b>	<b>206,161</b>	<b>36,047</b>	<b>-</b>	<b>242,208</b>
<b>Other</b>								
Independent Examiner	6,000	-	-	6,000	6,000	-	-	6,000
<b>Total other expenditure</b>	<b>6,000</b>	<b>-</b>	<b>-</b>	<b>6,000</b>	<b>6,000</b>	<b>-</b>	<b>-</b>	<b>6,000</b>
<b>TOTAL EXPENDITURE</b>	<b>139,772</b>	<b>208,829</b>	<b>-</b>	<b>348,601</b>	<b>232,654</b>	<b>36,047</b>	<b>-</b>	<b>268,701</b>

## NOTE 6: Details of certain types of expenditure

### Note 6.1 Fees for examination of the accounts

Please provide details of the amount paid for any statutory external scrutiny of accounts and other services provided by your independent examiner. If nothing was paid please enter '0' in the appropriate box(es).

Independent examiner's fees

This year £	Last year £
6,000	6,000

## NOTE 7: Paid Employees

### 7.1 Staff Costs

	This year £	Last year £
Salaries and wages	48,840	60,000
Social security costs	694	2,029
Pension costs (defined contribution scheme)	2,442	3,000
Other employee benefits	-	-
<b>Total staff costs</b>	<b>51,976</b>	<b>65,029</b>

Please note £48,840 Salaries and Wages ; £694 Social security costs and £2442 Pension costs were funded by the The National Lottery Community Fund and are included in the TNLCF - National Lottery Funded Expenditure line in Note 4 instead of Salaries, Employers NI and Pensions.

Please give details of the number of employees whose total employee benefits (excluding employer pension costs) fell within each band of £10,000 from £60,000 upwards. If there are no such transactions, please enter 'true' in the box provided.

No employees received employee benefits (excluding employer pension costs) for the reporting period of more than £60,000

**TRUE**

Band	Number of employees	
	This year	Last year
£60,000 to £69,999	-	1

Please provide the total amount paid to key management

This year £	Last year £
48,840	60,000

### 6.2 Average head count in the year

The parts of the charity in which the employees work

	This year Number	Last year Number
Fundraising	-	-
Charitable Activities	-	-
Governance	1	1
Other	-	-
<b>Total</b>	<b>1</b>	<b>1</b>

## NOTE 8: Debtors and prepayments

Please complete this note if the charity has any debtors or prepayments.

### 8.1 Analysis of debtors

	This year £	Last year £
Prepayments and Deferred expenditure deferred	3,230	-
<b>Total</b>	<b>3,230</b>	<b>-</b>

## NOTE 9: Creditors, deferred income and accruals

### 9.1 Analysis of creditors, deferred income and accruals

	Amounts falling due within one year		Amounts falling due after more than one year	
	This year £	Last year £	This year £	Last year £
Accruals	21,612	23,425	-	-
Deferred income	40,189	36,943	-	-
Other creditors	432	370	-	-
<b>Total</b>	<b>62,233</b>	<b>60,738</b>	<b>-</b>	<b>-</b>

## NOTE 10: Cash at bank and in hand

Cash at bank and on hand  
Total

This year £	Last year £
124,735	111,651
<b>124,735</b>	<b>111,651</b>

## NOTE 11: Fair value of assets and liabilities

10.1 Please provide details of the charity's exposure to credit risk (the risk of incurring a loss due to a debtor not paying what is owed), liquidity risk (the risk of not being able to meet short term financial demands) and market risk (the risk that the value of an investment will fall due to changes in the market) arising from financial instruments to which the charity is exposed at the end of the reporting period and explain how the charity manages those risks.

This year	Last year
Credit risk is low due to income being in the form of donations. Cash is the only investment so market risk is low on investment values falling. Liquidity risk is low as costs are managed in relation to income received.	Credit risk is low due to income being in the form of donations. Cash is the only investment so market risk is low on investment values falling. Liquidity risk is low as costs are managed in relation to income received.

10.2 Please give details of the amount of change in the fair value of basic financial instruments (debtors, creditors, investments (see section 11, FRS 102 SORP)) measured at fair value through the SoFA that is attributable to changes in credit risk.

Not applicable	Not applicable
----------------	----------------

## NOTE 12: Charity funds

### 12.1 Details of material funds held and movements during the CURRENT reporting period

Please give details of the movements of material individual funds in the reporting period together with a balancing figure for 'Other funds' (which should include revaluation reserve and fair value reserve, if applicable). The 'Total funds' figure below should reconcile to 'Total funds' in the balance sheet.

\* Key: PE - permanent endowment funds; EE - expendable endowment funds; R - restricted income funds, including special trusts, of the charity; and U - unrestricted funds

Fund names	Type PE, EE R or UR *	Purpose and Restrictions	Fund balances brought forward £	Income £	Expenditure £	Transfers £	Gains and losses £	Fund balances carried forward £
General Fund	UR	General all purpose no restrictions	50,017	191,378	(139,772)	(36,000)	-	65,623
Restricted Fund	R	TNLCF - National Lottery Community Fund. Funding for Core Expenditure	896	162,042	(198,829)	36,000	-	109
Restricted Fund	R	Restricted for Big Cancer Conversation Events	-	10,000	(10,000)	-	-	-
<b>Total Funds as per balance sheet</b>			<b>50,913</b>	<b>363,420</b>	<b>(348,601)</b>	<b>-</b>	<b>-</b>	<b>65,732</b>

Fund balances carried forward include assets and liabilities denominated in a foreign currency

Yes\*  No\*

If yes, please state the basis on which the assets and/or liabilities have been translated into sterling (or the currency in which the accounts are drawn up).

### 12.2 Details of material funds held and movements during the PREVIOUS reporting period

Please give details of the movements of material individual funds in the reporting period together with a balancing figure for 'Other funds' (which should include revaluation reserve and fair value reserve, if applicable). The 'Total funds' figure below should reconcile to 'Total funds' in the balance sheet.

\* Key: PE - permanent endowment funds; EE - expendable endowment funds; R - restricted income funds, including special trusts, of the charity; and U - unrestricted funds

Fund names	Type PE, EE R or UR *	Purpose and Restrictions	Fund balances brought forward £	Income £	Expenditure £	Transfers £	Gains and losses £	Fund balances carried forward £
General Fund	UR	General all purpose no restrictions	76,252	193,836	(232,654)	12,583	-	50,017
Restricted Fund	R	TNLCF - National Lottery Community Fund. Funding for Core Expenditure	-	36,943	(36,047)	-	-	896
Restricted Fund	R	Restricted for Showcase Project	12,583	-	-	(12,583)	-	-
<b>Total Funds as per balance sheet</b>			<b>88,835</b>	<b>230,779</b>	<b>(268,701)</b>	<b>-</b>	<b>-</b>	<b>50,913</b>

Fund balances carried forward include assets and liabilities denominated in a foreign currency

Yes\*  No\*

## NOTE 13: Transactions with trustees and relates parties

### Note 13 Transactions with trustees and related parties

If the charity has any transactions with related parties (other than the trustee expenses explained in guidance notes) details of such transactions should be provided in this note. If there are no transactions to report, please enter "True" in the box or "False" if there are transactions to report.

#### 13.1 Trustee remuneration and benefits

This year

None of the trustees have been paid any remuneration or received any other benefits from an employment with their charity or a related entity (True or False)

TRUE

#### 13.2 Trustees' expenses

If the charity has paid trustees expenses for fulfilling their duties, details of such transactions should be provided in this note. If there are no transactions to report, please enter "True" in the box below. If there are transactions to report, please enter "False".

No trustee expenses have been incurred (True or False)

TRUE

Type of expenses reimbursed	This year	Last year
	£	£
Travel	257	608
<b>TOTAL</b>	<b>257</b>	<b>608</b>

Please provide the number of trustees reimbursed for expenses or who had expenses paid by the charity

2

1

#### 13.3 Transaction(s) with related parties

Please give details of any transaction undertaken by (or on behalf of) the charity in which a related party has a material interest, including where funds have been held as agent for related parties. If there are no such transactions, please enter 'true' in the box provided.

This year

There have been no related party transactions in the reporting period (True or False)

TRUE

Last year

There have been no related party transactions in the reporting period (True or False)

TRUE

# Administrative details

## TRUSTEES

Anne MacDowell  
Helen Morement  
Nic Puntis  
Anna Evans  
Dr Max Brodermann  
Michael Draeger  
Sophie Davies  
Amanda Boughey (From 26th February 2025)  
Clare Clifton (From 26th February 2025)  
Dagmar Droogsma (From 26th February 2025)  
Yasmin Sheikh (From 26th February 2025)  
Rebecca Porta (Until 25th September 2025)

Chair

## EXECUTIVE OFFICERS

Baroness Delyth Morgan  
Chris Walden  
Anne MacDowell

President  
Chief Executive  
Company Secretary

## REGISTERED OFFICE

Cancer52, 124 City Road, London,  
EC1V 2NX

## WEBSITE

[www.cancer52.org.uk](http://www.cancer52.org.uk)

## BANKERS

Co-operative Bank

# References

- <sup>1</sup> National Cancer Registration and Analysis Service (NCRAS) by Public Health England figures. May 2019.
- <sup>2</sup> Cancer Statistics for the UK. Cancer Research UK. Available: <https://www.cancerresearchuk.org/health-professional/cancer-statistics-for-the-uk#heading-Zero>.
- <sup>3</sup> Internal membership research. Cancer52. August 2025.
- <sup>4</sup> 2024 Email marketing statistics compilation including open rates, clickthrough rates and click-to-open rates. Smart Insights. Available: <https://www.smartinsights.com/email-marketing/email-communications-strategy/statistics-sources-for-email-marketing/#q4>
- <sup>5</sup> The Other Half. A manifesto to transform outcomes for people with rare and less common cancers. Cancer52. Available: [https://e2236186-a9de-45db-b8f6-3f2d6db40cb4.usrfiles.com/ugd/e22361\\_754a20aff7d14b7bab33be31fdb06b3b.pdf](https://e2236186-a9de-45db-b8f6-3f2d6db40cb4.usrfiles.com/ugd/e22361_754a20aff7d14b7bab33be31fdb06b3b.pdf)
- <sup>6</sup> Response to 10 Year Health Plan Consultation. Cancer52. December 2024. Available: [https://e2236186-a9de-45db-b8f6-3f2d6db40cb4.usrfiles.com/ugd/e22361\\_46ec1b110dc9448ca43d87598b6176b2.pdf](https://e2236186-a9de-45db-b8f6-3f2d6db40cb4.usrfiles.com/ugd/e22361_46ec1b110dc9448ca43d87598b6176b2.pdf)
- <sup>7</sup> Briefing on Westminster Hall Debate on 'Potential merits of a cancer strategy for England.' Cancer52. October 2024. Available: [https://e2236186-a9de-45db-b8f6-3f2d6db40cb4.usrfiles.com/ugd/e22361\\_5b964fd137d041c1b64a9a15c63f1b07.pdf](https://e2236186-a9de-45db-b8f6-3f2d6db40cb4.usrfiles.com/ugd/e22361_5b964fd137d041c1b64a9a15c63f1b07.pdf)
- <sup>8</sup> Shaping the National Plan: Call for Evidence. Dept. of Health and Social Care. April 2025. Available: <https://www.gov.uk/government/calls-for-evidence/shaping-the-national-cancer-plan/shaping-the-national-cancer-plan>
- <sup>9</sup> State of the Nation report on Rare and Less Common Cancers. Learnings from patients and partners. Cancer52. February 2025. Available: [e22361\\_9bcebf3bb6724611b7dd4ac8fa465164.pdf](https://e22361_9bcebf3bb6724611b7dd4ac8fa465164.pdf)
- <sup>10</sup> Improving diagnosis: Patient and clinician perspectives on increasing early diagnosis in rare and less common cancers. Cancer52. March 2025. Available: [e22361\\_3894b4ec9952401d8e080e7ae78ee91f.pdf](https://e22361_3894b4ec9952401d8e080e7ae78ee91f.pdf)
- <sup>11</sup> Rare Cancers Bill. UK Government. Available: <https://bills.parliament.uk/bills/3779/news>
- <sup>12</sup> NHS Long Term Plan. August 2019. Available: [ARCHIVED CONTENT] NHS Long Term Plan » The NHS Long Term Plan
- <sup>13</sup> A Fair Chance: reducing health inequalities for people with rare and less common cancers. Cancer52. November 2024. Available: [e22361\\_bcd514c019456c898f5403672d66ad.pdf](https://e22361_bcd514c019456c898f5403672d66ad.pdf)
- <sup>14</sup> Fair Market Value for Charities in Partnership Work. Cancer52, Charities Research Involvement Group, HRCI - Health Research Charities Ireland, the National Rheumatoid Arthritis Society (NRAS) and the Patient Information Forum (PIF). September 2024. Available: [https://e2236186-a9de-45db-b8f6-3f2d6db40cb4.usrfiles.com/ugd/e22361\\_259ec3eb912d4c35a2dbe31664816248.pdf](https://e2236186-a9de-45db-b8f6-3f2d6db40cb4.usrfiles.com/ugd/e22361_259ec3eb912d4c35a2dbe31664816248.pdf)
- <sup>15</sup> Together for Antibiotics. ABPI. Available: [https://www.togetherforantibiotics.org.uk/resources/?3b293f58a0d649e6a204d1476bc6a631\\_cat=Cancer52&3b293f58a0d649e6a204d1476bc6a631\\_page=1](https://www.togetherforantibiotics.org.uk/resources/?3b293f58a0d649e6a204d1476bc6a631_cat=Cancer52&3b293f58a0d649e6a204d1476bc6a631_page=1)
- <sup>16</sup> ABPI AMR: Resources (togetherforantibiotics.org.uk). ABPI. Available: <https://www.togetherforantibiotics.org.uk/>
- <sup>17</sup> Cancer52 Policy on Working with the Pharmaceutical & Healthcare Industry. Cancer52. April 2024. Available: [https://www.cancer52.org.uk/\\_files/ugd/e22361\\_b5e75296a92547b9b9ebde37b998a762.pdf](https://www.cancer52.org.uk/_files/ugd/e22361_b5e75296a92547b9b9ebde37b998a762.pdf)

# List of charity members 2024/25

ACLT (African Caribbean Leukaemia Trust)  
[www.aclt.org](http://www.aclt.org)

Action Against Heartburn  
[www.actionagaintheartburn.org.uk](http://www.actionagaintheartburn.org.uk)

Action Bladder Cancer UK  
[www.actionbladdercanceruk.org](http://www.actionbladdercanceruk.org)

Action Kidney Cancer  
[www.actionkidneycancer.org](http://www.actionkidneycancer.org)

Action on Womb Cancer  
[www.actiononwombcancer.org.uk](http://www.actiononwombcancer.org.uk)

Alike  
[www.alike.org.uk](http://www.alike.org.uk)

ALK Positive UK  
[www.alkpositive.org.uk](http://www.alkpositive.org.uk)

AMMF – The Cholangiocarcinoma Charity  
[www.ammf.org.uk](http://www.ammf.org.uk)

Anthony Nolan  
[www.anthonynolan.org](http://www.anthonynolan.org)

Association for Multiple Endocrine Neoplasia Disorders (AMEND)  
[www.amend.org.uk](http://www.amend.org.uk)

Baggy Trousers UK  
[www.baggytrousersuk.org](http://www.baggytrousersuk.org)

Balls to Cancer  
[www.ballstocancer.co.uk](http://www.ballstocancer.co.uk)

Blood Cancer UK  
[www.bloodcancer.org.uk](http://www.bloodcancer.org.uk)

Bone Cancer Research Trust  
[www.bcrct.org.uk](http://www.bcrct.org.uk)

Bowel Research UK  
[www.bowelresearchuk.org](http://www.bowelresearchuk.org)

Brain Tumour Research  
[www.braintumourresearch.org](http://www.braintumourresearch.org)

Brain Tumour Research Campaign  
[www.btrc-charity.org](http://www.btrc-charity.org)

Brainstrust  
[www.brainstrust.org.uk](http://www.brainstrust.org.uk)

British Lymphology Society (BLS)  
[www.thebls.com](http://www.thebls.com)

British Thyroid Foundation (BTF-thyroid)  
[www.btf-thyroid.org](http://www.btf-thyroid.org)

Butterfly Thyroid Cancer Trust (BTCT)  
[www.butterfly.org.uk](http://www.butterfly.org.uk)

Cancer Laryngectomy Trust  
[www.cancerlt.org](http://www.cancerlt.org)

Cancer of Unknown Primary (CUP) Foundation - Jo's friends  
[www.cupfoundjo.org](http://www.cupfoundjo.org)

Cancer Support UK  
[www.cancersupportuk.org](http://www.cancersupportuk.org)

Childhood Eye Cancer Trust (CHECT)  
[www.chect.org.uk](http://www.chect.org.uk)

Children's Cancer and Leukaemia Group (CCLG)  
[www.cclg.org.uk](http://www.cclg.org.uk)

Chordoma UK  
[www.chordoma-uk.org](http://www.chordoma-uk.org)

Chris Lucas Trust  
[www.chrislucastrust.com](http://www.chrislucastrust.com)

Chronic Myeloid Leukaemia (CML) Support Group UK  
[www.cmlsupport.org.uk](http://www.cmlsupport.org.uk)

CLL Support Association  
[www.cllsupport.org.uk](http://www.cllsupport.org.uk)

Debbie Fund  
[www.debbiefund.org](http://www.debbiefund.org)

EHE Rare Cancer Charity (UK)  
[www.ehercc.org.uk](http://www.ehercc.org.uk)

Ellen MacArthur Cancer Trust  
[www.ellenmacarthurcancertrust.org](http://www.ellenmacarthurcancertrust.org)

Fight Bladder Cancer  
[www.fightbladdercancer.co.uk](http://www.fightbladdercancer.co.uk)

GIST Cancer UK  
[www.gistcancer.org.uk](http://www.gistcancer.org.uk)

Grace Kelly Childhood Cancer Trust  
[www.gkcct.org](http://www.gkcct.org)

GUTS Charity  
[www.gutscharity.org.uk](http://www.gutscharity.org.uk)

Heartburn Cancer UK  
[www.heartburncanceruk.org](http://www.heartburncanceruk.org)

HLRCC Foundation  
[www.hlrccinfo.org](http://www.hlrccinfo.org)

ICPV Independent Cancer Patients' Voice  
[www.icpv.org.uk](http://www.icpv.org.uk)

International Brain Tumour Alliance (IBTA)  
[www.theibta.org](http://www.theibta.org)

It's In The Bag Cancer Support Ltd  
[www.itsinthebag.org.uk](http://www.itsinthebag.org.uk)

It's on the Ball  
[www.itsontheball.org](http://www.itsontheball.org)

Kidney Cancer UK  
[www.kcuk.org.uk](http://www.kcuk.org.uk)

Leukaemia CARE  
[www.leukaemiacare.org.uk](http://www.leukaemiacare.org.uk)

Leukaemia UK  
[www.leukaemiauk.org.uk](http://www.leukaemiauk.org.uk)

London Asbestos Support Awareness Group  
[www.lasag.org.uk](http://www.lasag.org.uk)

Lymphoedema Support Network  
[www.lymphoedema.org](http://www.lymphoedema.org)

Lymphoma Action  
[www.lymphoma-action.org.uk](http://www.lymphoma-action.org.uk)

Maggie's Cancer Caring Centres -  
Maggie's Centres  
[www.maggiescentres.org](http://www.maggiescentres.org)

MDS (Myelodysplastic Syndromes) UK  
Patient Support Group  
[www.mdspatientsupport.org.uk](http://www.mdspatientsupport.org.uk)

Melanoma Focus  
[www.melanomafocus.com](http://www.melanomafocus.com)

Melanoma UK  
[www.melanomauk.org.uk](http://www.melanomauk.org.uk)

Mesothelioma UK  
[www.mesothelioma.uk.com](http://www.mesothelioma.uk.com)

Mind Over Cancer  
[www.mindovercancer.org.uk](http://www.mindovercancer.org.uk)

MPN Voice  
[www.mpnvoice.org.uk](http://www.mpnvoice.org.uk)

Mummy's Star  
[www.mummysstar.org](http://www.mummysstar.org)

Myeloma UK  
[www.myeloma.org.uk](http://www.myeloma.org.uk)

Neuroblastoma UK  
[www.neuroblastoma.org.uk](http://www.neuroblastoma.org.uk)

Neuroendocrine Cancer UK (NCUK)  
[www.neuroendocrinecancer.org.uk](http://www.neuroendocrinecancer.org.uk)

North West Cancer Research  
[www.nwcr.org](http://www.nwcr.org)

OcuMel UK  
[www.ocumeluk.org](http://www.ocumeluk.org)

Odyssey  
[www.odyssey.org.uk](http://www.odyssey.org.uk)

Oracle Cancer Trust  
[www.oraclecancertrust.org](http://www.oraclecancertrust.org)

Orchid Cancer Appeal  
[www.orchid-cancer.org.uk](http://www.orchid-cancer.org.uk)

OUTpatients  
[www.outpatients.org.uk](http://www.outpatients.org.uk)

Ovacome, The Ovarian Cancer Support Network  
[www.ovacome.org.uk](http://www.ovacome.org.uk)

Ovarian Cancer Action  
[www.ovarian.org.uk](http://www.ovarian.org.uk)

Pancreatic Cancer Action  
[www.pancreaticcanceraction.org](http://www.pancreaticcanceraction.org)

Pancreatic Cancer UK (PCUK)  
[www.pancreaticcancer.org.uk](http://www.pancreaticcancer.org.uk)

Peaches Womb cancer Trust  
[www.peachestrust.org](http://www.peachestrust.org)

Pelvic Radiation Disease Association PRDA  
[www.prda.org.uk](http://www.prda.org.uk)

Penny Brohn UK  
[www.pennybrohn.org.uk](http://www.pennybrohn.org.uk)

PLANETS  
[www.planetscharity.org](http://www.planetscharity.org)

Pseudomyxoma Survivor  
[www.pseudomyxomasurvivor.org](http://www.pseudomyxomasurvivor.org)

Ruth Strauss Foundation  
[www.ruthstraussfoundation.com](http://www.ruthstraussfoundation.com)

Salivary Gland Cancer UK  
[www.salivaryglandcancer.uk](http://www.salivaryglandcancer.uk)

Sarcoma UK  
[www.sarcoma.org.uk](http://www.sarcoma.org.uk)

Shine Cancer Support  
[www.shinecancersupport.org](http://www.shinecancersupport.org)

Solving Kids' Cancer  
[www.solvingkidscancer.org.uk](http://www.solvingkidscancer.org.uk)

Swallows Head & Neck Cancer Charity  
[www.theswallows.org.uk](http://www.theswallows.org.uk)

Target Ovarian Cancer  
[www.targetovariancancer.org.uk](http://www.targetovariancancer.org.uk)

Team Margot Foundation  
[www.teammargot.com](http://www.teammargot.com)

Teenage Cancer Trust (TCT)  
[www.teenagecancertrust.org](http://www.teenagecancertrust.org)

The Bottom Line  
[www.bottomlinecharity.com](http://www.bottomlinecharity.com)

The Brain Tumour Charity  
[www.thebraintumourcharity.org](http://www.thebraintumourcharity.org)

The Charley Ashton Foundation

The Ella Dawson Foundation  
[www.elladawsonfoundation.org.uk](http://www.elladawsonfoundation.org.uk)

The Eve Appeal  
[www.eveappeal.org.uk](http://www.eveappeal.org.uk)

The Leanne Pero Foundation  
[www.theleanneperofoundation.com](http://www.theleanneperofoundation.com)

The Myrovlytis Trust  
[www.myrovlytistrust.org](http://www.myrovlytistrust.org)

The Northern Ireland Rare Disease Partnership  
[www.nirdp.org.uk](http://www.nirdp.org.uk)

The Robin Cancer Trust  
[www.therobincancertrust.org](http://www.therobincancertrust.org)

The Sophie Fitzpatrick Charitable Foundation  
[sophiefitzpatrickcharitablefoundationforrarecancers.com](http://sophiefitzpatrickcharitablefoundationforrarecancers.com)

The Urology Foundation  
[www.theurologyfoundation.org](http://www.theurologyfoundation.org)

ThymicUK  
[www.thymicuk.org](http://www.thymicuk.org)

Thyroid Cancer Support Group Wales  
[www.thyroidsupportwales.co.uk](http://www.thyroidsupportwales.co.uk)

Tom Bowdidge Youth Cancer Foundation  
[www.tombowdidgefoundation.org](http://www.tombowdidgefoundation.org)

Trekstock  
[www.trekstock.com](http://www.trekstock.com)

UCARE  
[www.ucare-cancer.org.uk](http://www.ucare-cancer.org.uk)

UK Masto  
[www.ukmasto.org](http://www.ukmasto.org)

Urostomy Association  
[www.urostomyassociation.org.uk](http://www.urostomyassociation.org.uk)

VHL UK/Ireland  
[www.vhl-uk-ireland.org](http://www.vhl-uk-ireland.org)

Wellbeing of Women  
[www.wellbeingofwomen.org.uk](http://www.wellbeingofwomen.org.uk)

WMUK  
[www.wmuk.org.uk](http://www.wmuk.org.uk)

Womb Cancer Info  
[www.wombcancerinfo.wixsite.com/home](http://www.wombcancerinfo.wixsite.com/home)

Womb Cancer Support UK  
[www.wombcancersupportuk.weebly.com](http://www.wombcancersupportuk.weebly.com)

Worldwide Cancer Research  
[www.worldwidecancerresearch.org](http://www.worldwidecancerresearch.org)

Yorkshire Cancer Community  
[www.yorkshirecancercommunity.co.uk](http://www.yorkshirecancercommunity.co.uk)

Young Lives Vs. Cancer  
[www.younglivesvscancer.org.uk](http://www.younglivesvscancer.org.uk)

Young Tongues  
[www.youngtonguesglobal.com](http://www.youngtonguesglobal.com)



**Cancer52** is registered as a charity in England and Wales, **Charity No. 1174569** and as a company limited by guarantee in England and Wales, **Company No. 07994413**

If we **work together**  
we can make as much noise as the big four



**CANCER 52**

England & Wales - Charity number 1174569

---

# Accounts

---

# cancer52

the common voice for  
rare & less common cancers

Cancer52 is registered as  
a charity in England and Wales,  
Charity No. 1174569 and as a  
company limited by guarantee  
in England and Wales,  
Company No. 07994413

## Annual Review

& Financial Statements

1 Apr 2023 – 31 Mar 2024

[cancer52.org.uk](https://cancer52.org.uk)

# Contents

<b>LET'S MAKE SOME NOISE</b>	<b>3</b>	<b>FUNDING</b>	<b>19</b>
Foreword	3	The National Lottery Community Fund	19
Welcome to our Annual Review 2023–2024	4	The value of support	20
		Voluntary member donations	20
<b>STRENGTH IN UNITY: OUR PRINCIPLES</b>	<b>5</b>	Support from industry	20
Our core principles	5		
		<b>FUTURE PLANS</b>	<b>21</b>
<b>UNITING WITH ONE VOICE: WHO WE ARE</b>	<b>6</b>		
The Cancer52 team	6	<b>THE ACOUSTICS: STRUCTURE AND CONSTITUTION</b>	<b>22</b>
Our charity members	6	Structure and governance	22
		Purpose	22
<b>PARTNERSHIP: REPRESENTATION AND ADVOCACY IN POLICY</b>	<b>7</b>	Public benefit	22
		Board and management operations and structure	23
<b>MAKING THE CANCER52 VOICE HEARD</b>	<b>8</b>		
Informing, advising and supporting our members	8	<b>MONEY TALKS: FINANCIAL REVIEW</b>	<b>25</b>
<b>PARTNERSHIP: COLLABORATION ON BEHALF OF PATIENTS</b>	<b>14</b>	<b>INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF CANCER52</b>	<b>26</b>
Informing our stakeholders	14	Section A	28
		Section B	29
<b>MAKING THE VOICE OF PEOPLE WITH RARE AND LESS COMMON CANCERS HEARD: OUR HEADLINE ACHIEVEMENTS FOR 2023–2024</b>	<b>18</b>	Section C	30
Partnership	18	<b>INDEPENDENT EXAMINER'S REPORT ON THE ACCOUNTS</b>	<b>26</b>
Policy	18		
Patients	18	<b>ADMINISTRATIVE DETAILS</b>	<b>40</b>
		<b>LIST OF CHARITY MEMBERS 2023–2024</b>	<b>41</b>

# Let's make some noise:



Trustees Annual Report and Directors Report  
for the year ended 31st March 2023

## Foreword

Rare and less common cancers\* may sound as though they represent a small proportion of the cancer burden, yet these cancers account for 47% of all cancer diagnoses and a staggering 55% of cancer deaths in the UK each year. The large numbers and the disparity in outcomes highlight the urgent need for increased focus and funding.

**Cancer52** is dedicated to the mission of providing a strong, unified voice for rare and less common cancer organisations. This financial year, we were grateful to have been awarded a substantial grant from The National Lottery Community Fund. This funding presents an exciting opportunity for **Cancer52** to have secure three-year funding to deliver on our ambitions to improve health inequalities, change policy and support our members.

Progress towards **Cancer52's** aim to improve diagnosis, treatment and outcomes for patients with rare and less common cancers has been led by our CEO, Jane Lyons, and a small but dedicated and very capable team. They work with the incredible support of dedicated member organisations and our wider collaborators. Together, as a strong and determined alliance, we amplify the call for improvements in cancer services, ensuring that the needs of those with rare and less common cancers are not overlooked. I would like to thank Jane, the entire team and all our partners for their dedication, hard work, and ambition. Together, we will continue to make a difference to all those diagnosed with rare and less common cancers.

*Anne MacDowell*

\*defined as all cancers except breast, bowel, lung and prostate



Anne MacDowell,  
Chair of the Board

## Welcome to our Annual Review 2023–2024

I'm proud to introduce our Annual Review for the financial year 2023-2024. It was a seismic year – with the development and delivery of the Big Cancer52 Conversation concept; a landscape changing award from The National Lottery Community Fund and the resultant introduction of new team members to build on our work, particularly in the fields of policy and health inequalities.

The Big Cancer52 Conversations are face to face events where Cancer52 through its unique collaborating and convening power, brings together charities, industry, key decision makers and external stakeholders to work together on initiatives that help deliver a better deal for people with rare and less common cancers. Feedback from the events clearly demonstrates that these conversations are the first of their kind and that they are pushing positive agendas faster and further.

The grant from The National Lottery Community Fund helped us set clear outcomes for policy and health inequalities work. Our policy work moved at speed and with influence in the latter half of 2023 and the first quarter of 2024, working with cancer policy thought leaders and member charities to carry out a wide-ranging review of our policy priorities and then craft and deliver a well-received Manifesto, ready to be launched at a Parliamentary event. The Manifesto remains a driving force of policy challenges for us with the new government.

My thanks to interim chair Rebecca Porta for her support in the earlier part of the year, and to Anne MacDowell who joined the charity as Chair in the Autumn of 2023. Finally though, my thanks as ever to the Cancer52 team, and to all the fantastic 115 member charities and their teams. We are truly stronger working together.

*Jane Lyons*



Jane Lyons, CEO



# Strength in unity: our principles

**Cancer52** is a national organisation, created in 2007 and registered as a charity in England and Wales in September 2017.

We are the unifying body for charitable and not-for-profit organisations working in the field of rare and less common cancers. We represent, currently 115, predominantly small, patient-support and research-focused cancer charities and organisations.

**Cancer52** gets its name from when rare and less common cancers accounted for 52% of all cancer deaths in the UK, when only 47% of cancers diagnosed in England are of this type.<sup>1</sup> In 2020, this shifted to 47% of diagnoses and 55% of cancer deaths.<sup>2</sup>

Our member charities and organisations are united in seeking a better future for everyone affected by rare and less common cancers. We provide a collective voice to champion earlier diagnosis, better treatment, better representation, funding and support for people with cancers other than the four most common cancers (breast, lung, bowel and prostate). **Cancer52** ensures the voices of people with rare and less common cancers do not go unheard.



## Our core principles

### Our aim

**Cancer52's primary aim is to promote improved diagnosis, treatment and support for those affected by rare and less common cancers.**

### Our vision

**Cancer52's vision is to end inequalities in diagnosis, treatment and patient outcomes experienced by those with rare and less common cancers compared with the four most common cancers.**

### Our mission

**Cancer52's mission is to provide a strong, unified voice for rare and less common cancer organisations by representing, informing, sharing and involving our members in achieving our vision.**

### Our values

Everything **Cancer52** does is underpinned by the aim to be:  
ambitious | outcome-focused | collaborative | evidence-based | influential and to behave with honesty and integrity.

# Uniting with one voice: who we are

**Cancer52 aims to better represent people with rare and less common cancers at a senior policy and decision-making level. Sourcing and bringing together the knowledge and expertise of our many members makes this possible.**

## The Cancer52 team

During the year ending 31 March 2024, the CEO of **Cancer52** was:

- **Jane Lyons** who was responsible for the overall running of the charity.

Jane was supported by an excellent team of part-time contractual staff, who each provide expertise in their area:

- **Ainsley Taylor, Operations Consultant:** Responsible for overseeing all operational aspects of the organisation. Supporting the CEO in managing financial reporting, fundraising, policy and governance work, operational tasks, and administration duties, including the co-ordination of membership donations, recruitment and supporting the Board of Trustees.
- **Sasha Daly, Policy Lead:** Working with members and external stakeholders to direct the policy work of **Cancer52**.
- **Jen Harrison, Health Inequalities Lead:** Driving health inequalities work and other policy-related activities.
- **Stephanie Judycki, Communications Executive:** Leading on internal and external communications including member e-bulletins, **Cancer52** website and social media.
- **Ambika Chadda, Executive Assistant:** Providing administrative support to the team, and co-ordinating our membership, meetings and events administration.

As well as the immediate team of contractors, **Cancer52** also enlist specialists in the area of accounting and fundraising as required during the financial year:

Jason Dennis coordinated our financial agreements and obligations.

Lesley Hynes coordinated our fundraising.

Our Board of Trustees is listed on page 27.

Thanks to you all for your hard work and dedication.

## Our charity members

**Cancer52's** members are united in their determination to improve treatment and outcomes for their individual patient groups.

The majority of **Cancer52's** member organisations are small - 65% have an annual income of less than £1 million – with 57% of those having an income less than £500,000, and 25% an income of less than £100,000. Almost all of our members offer patient support and over two-thirds invest in research.<sup>3</sup>

The full list of **Cancer52's** members at time of going to press can be seen on page 29.

**Cancer52's** active membership continues to grow. During the 2023-24 financial year, we happily welcomed **Odyssey, The Ruth Strauss Foundation, Swallows Head & Neck Cancer Charity, The Bottom Line, The Leanne Pero Foundation, Worldwide Cancer Research, and Young Tongues.**

We hugely value and appreciate our members' ongoing dedication and commitment to **Cancer52**.

# Partnership: Representation and advocacy in policy

**Cancer52** represents its members at the highest policy and decision-making levels, acting as a conduit to organisations that need to hear the patient voices of those with rare and less common cancers. As a strong and determined alliance, we amplify the call for improvements in cancer services, including those supported by our member charities.

Central to **Cancer52**'s policy work is the Policy and Public Affairs Steering Group (PPASG), which met frequently to exchange information and help formulate **Cancer52**'s policy asks. The group informed responses to several NICE consultations, Major Conditions Strategy response and Health and Social Care Select Committee inquiry. During 2023-2024, the group was chaired by Chris Walden, **Cancer52** Trustee, and Charlotte Crowley, Policy and Evidence Manager at Leukaemia Care. Bradley Price, previously Policy and Public Affairs Manager of Sarcoma UK acted as vice chair until 2023, when Rachel Downing, Head of Policy and Campaigns at Target Ovarian Cancer took on the role. Our incoming policy lead, Sasha Daly, manages the relationships with the Chair and Vice-Chair and members of the Group as well as agrees agendas and facilitates the functioning, outputs and reporting.

## House of Commons Health and Social Care Select Committee

**Cancer52** submitted a response to the inquiry into Future Cancer, focusing on innovations. Jane Lyons, CEO, was pleased to also provide oral evidence to the committee on 21st June 2023. The full session is available on Parliamentlive.tv.<sup>5</sup> See full session.



## National Strategies on Health and Cancer

The year 2023 proved to be a time of rapid political and policy change but **Cancer52** and its membership remained agile and responsive. The Department of Health and Social Care (DHSC) announced that instead of the 10-Year Cancer Plan a Major Conditions Strategy would launch covering six major conditions, including cancer.<sup>6,7</sup> **Cancer52**'s pan member response that included insights from over 250 patients for the 10-Year Cancer Plan consultation was submitted as evidence for the

new strategy.<sup>8</sup> Furthermore a response to the Major Conditions Strategy was submitted by **Cancer52**.<sup>9</sup>

**Cancer52** also met with then Cancer Minister Helen Whately MP and participated in Major Conditions Strategy roundtables to ensure that rare and less common cancers remain a priority. Helen Whately MP also attended an All Member Meeting, spoke to members and took questions.

# Making the Cancer52 voice heard

**Cancer52 works tirelessly to support people with rare and less common cancers and to ensure a strong presence in this community.**

- We are represented at the highest level on boards and taskforces.
- We value close teamwork and collaboration.
- We use a range of skills and methods within a flexible structure to help members support patients.

## Informing, advising and supporting our members

### Meeting with our members

Virtual meetings continue to play an important part in our work as they allow our member charities and organisations from across the country to voice their concerns, connect, quickly and easily share information and hear from thought leaders in the field of rare and less common cancers. We also recognise the huge value in meeting face-to-face and hosted two large, in-person events in London in June and November 2023, each attended by circa 100 people.



# 587

**individuals attended all Member Meetings, an increase of 28% on the previous year**



# 100

**people attended each in-person event in June and November 2023**



# 181

**people attended our eight CEO meetings.**

### Sharing

We want everyone with rare and less common cancers to have the chance to be best supported and make informed choices. We consistently encourage our members to exchange knowledge so that even those supported by charities with limited resources have access to a continuing flow of useful information. People with cancer are best supported when charities collaborate to make the most of the resources available and not duplicate efforts. We know that a collaborative voice is a stronger voice.

### Regular members' e-bulletin

Throughout this financial year, our weekly e-bulletin updated our members on:

- Developments in Government and NHS policy pertinent to cancer
- Responses Cancer52 have made to official consultations
- Relevant meetings of member charities or national organisations
- Information for patients
- Opportunities to get involved with projects that support people with rare and less common cancers
- Patient surveys
- Projects where members wanted to share learning or to raise awareness
- Member and NHS Cancer Programme job opportunities
- Training courses
- NHS and other cancer charity webinars

The average open rate for our e-bulletin increased slightly from an already high average of 59% to 60% in March 2024. This is over double the market open rate average (27%) for newsletter emails.<sup>4</sup> It is clear that our members prize our bulletins as a useful and efficient way of informing their patients of critical events and developments.

### Cancer52 All Member Meetings

Fortnightly virtual meetings continued throughout the financial year. They offered crucial networking opportunities and the chance to help patients by learning from interesting and thought-provoking speakers. Meetings were well attended and warmly welcomed.

*'You are doing such great work for us smaller charities representing rare and less common cancers, and we really enjoy belonging to a larger group where we can get our voices heard by government and policy makers - thank you!'*

Sharon Deveson Kell, Action Kidney Cancer

### CEO Calls

Monthly virtual meetings provide member CEOs direct access to their peers. Started during the COVID-19 pandemic, these meetings have continued to offer incredibly valuable opportunities to raise problems, talk through ideas, share best practice and offer peer support.

*'Thank you for arranging this morning's meeting. As seems to be the norm with Cancer52, it was relevant and absorbing, giving me much food for thought.'*

Dr Michele Afif, The Brain Tumour Charity

The meetings are great relationship builders and boost the profile of people with rare and less common cancers.

*'A great Cancer52 is a great rare and less common cancer community'*

Fiona Hazell, Leukaemia UK

## Big Cancer52 Conversation

On 14th June 2023, Cancer52 held the first in-person Big Cancer52 Conversation event in Canary Wharf, London. The Big Cancer52 Conversation helped to foster cross-sector collaborations with the aim of improving outcomes for those affected with rare and less common cancers.

Key speakers were David Fitzgerald, Director – Policy and Strategy, NHS Cancer Programme, NHSE; Richard Torbett, Chief Executive of the ABPI; and Tony Colville, MD of the Cancer Awareness Trust. Several member CEOs, Rebecca Porta (The Urology Foundation and Trustee), Nic Puntis (GIST Cancer UK and Trustee) and Liz Darlison (Mesothelioma UK), Brad Gudger (Alike), and Victoria Clare (Ovacome) all took part as chairs or panellists. Alongside Dr Max Brodermann (Haematology Registrar and Trustee). The event was a huge success and received enormously positive feedback. Three new workstreams were created from the event, and the existing health inequalities workstream bolstered.

Following on from this success, the second Big Cancer52 Conversation was held on 15th November 2023. The Autumn Gathering provided an opportunity to regroup people following our inaugural Big Cancer52 Conversation, review shared progress, welcome newcomers to the conversation and transform conversation into action. Two member charities – Bottom Line and Solving Kids' Cancer – who attended our inaugural Big Cancer52 Conversation in June, returned to share their success stories of how the first event helped them to progress their work in rare and less common cancers.

CEO, Jane Lyons, hosted a conversation with a panel of representatives from key stakeholder organisations, including: David Fitzgerald, Director of Policy and Strategy for the NHS Cancer Programme, NHS England; Brian Duggan, Strategic Partnership Policy Director, ABPI; Dr Max Brodermann, Haematology Registrar and Cancer52 Trustee. In line with our planning for 2024, and to keep the momentum with Big Cancer52 Conversation, a further meeting was planned for June 2024. We are grateful for the support of The Cancer Awareness Trust and Canary Wharf Group, which enabled us to hold these events.



The key workstreams arising from the **Big Cancer52 Conversation** are:

**Charities and industry working better together**, focused on helping our member charities to develop best practice on engagement with industry to benefit patients. This has included exploring opportunities to draw on ABPI's support to develop tools and resources for members.

**Improving access to clinical trials**, focused on addressing barriers faced by people affected by rare and less common cancers. This theme will be explored in the **Cancer52** patient survey, and we have also engaged with clinical trials services such as RareCan to explore opportunities for collaboration.

**Proxy staging measures for blood and brain cancers**, focused on ensuring that data is inclusive of all cancers, including those that cannot be staged or are difficult to stage. This includes work to identify a proxy measure, in lieu of staging data, to take to policymakers.

**Health inequalities**, focused on sharing and developing best practice and working together to address inequalities in diagnosis, treatment, care and outcomes for people living with rare and less common cancers. We conducted a health inequalities survey with members, which will form the basis of our work in 2024.

## Cancer52 Member Working Groups

These four key workstreams are now working groups and join other **Cancer52** working groups that help members who face similar challenges in supporting people with cancer. This year, working groups examined cancer-related menopause, irritable bowel syndrome (IBS) by way of misdiagnosis and the NHS website cancer pages.



## Identifying Cancer52's policy priorities with members

Throughout September and October **Cancer52** undertook its own consultation with members to clarify the most important policy issues to the community and develop **Cancer52's** policy strategy. This work was led by our CEO and policy lead working with a policy think tank with long standing expertise in cancer and health. Work included an audit of **Cancer52's** policy position over

the last 10 years, a survey of members and a half-day workshop of **Cancer52** members and Board members in order to develop **Cancer52's** policy and public affairs strategy. From this, **Cancer52** developed a well received strategy with input from the Policy Public Affairs Steering Group (PPASG), agreeing a work plan for 2024.




# A Manifesto for Rare and Less Common Cancers

**At the start of 2024, and with Lottery funding in place, our policy lead took on the work to develop a manifesto to engage key stakeholders and increase the voice of Cancer52 and its members, leading into the General Election expected later in the year.<sup>10</sup> This work involved more member engagement to identify the priorities, a workshop with the Policy and Public Affairs Steering Group to refine the priorities, a review of other relevant charity manifestos and identification of key collaborative partners. Cancer Research UK provided statistical input to the priority areas which provided a new evidence base on rare and less common cancers. A launch event was then planned to engage members, their patient representative, key stakeholders and politicians.**

**In the manifesto 'The Other Half. A manifesto to transform outcomes for people with rare and less common cancers', Cancer52 outlined three key priorities.**

**Priority 1**

Reduce the number of deaths from rare and less common cancers by 15% by 2040, saving 80,000 lives\*, and address health inequalities that contribute to poorer outcomes




**Incidence**

Mortality and survival rate improvements have been lower, while incidence rate increases have been higher in rare and less common cancers compared to the four common cancers.

**Priority 2**

Increase early diagnosis of rare and less common cancers which will improve patient experience, quality of life and help save more lives

The rare and less common cancer types with highest proportion of patients diagnosed at stage 3 and 4 include\*:



\*Cancer Research UK data, see Cancer52 Manifesto for full details: <https://bit.ly/442jycS>

**Priority 3**

A new national mission on rare and less common cancers with patient involvement at its core

# Partnership: Collaboration on behalf of patients

## Working collaboratively across the NHS

### WORKING WITH THE NHS CANCER PROGRAMME

#### NHSE National Cancer Board

Alongside Cancer Research UK and Macmillan Cancer Support, **Cancer52** has a place on the NHSE National Cancer Board. Together we provide strategic leadership across the healthcare sector in delivering the cancer ambitions inside the NHS Long Term Plan.<sup>11</sup>

During 2023–2024, **Cancer52** participated in several NHS England (NHSE) boards and groups, where its influence was used to oversee, advise on and implement changes for those affected by cancer:

- Cancer Campaigns and Oversight Group
- Cancer Campaigns Community of Practice
- Early Detection and Screening Task and Finish Group
- The Cancer Patient Experience Survey Advisory Group
- The Cancer Patient Experience Survey Reporting Sub Group
- NHSE Quarterly Cancer Charity Forum
- Cancer Data and Analytics Advisory Group (CDAAG)

#### Working collaboratively to improve health inequalities in cancer

**Cancer52** has continued to develop its health inequalities agenda, including creating an overarching delivery plan with an active Health Inequalities Working Group and wider **Cancer52** membership. A health inequalities members' survey was also conducted to inform ongoing work.

**Cancer52's** profile in health inequalities is continuing to grow. This year National Voices asked **Cancer52** to collaborate in leading a coalition of health and social care charities in England. **Cancer52** has also supported its members to develop, share and champion their own work on health inequalities, like Team Margot's work into diversity among organ donors and OUTpatients' work to address anti-trans hostility. Alongside this, **Cancer52** is supporting members from blood and brain cancer charities to ensure that early diagnosis measures are inclusive of all cancers.

**Cancer52** has also received funding from The National Lottery Community Fund (TNLCF) for work with Cancer Alliances to deliver best practice/knowledge-sharing events in London and Manchester in November 2024. The **Cancer52** workplan includes publication of a two-year progress update to **Cancer52's** health inequalities report, and a health inequalities toolkit and resource library for **Cancer52** members. Alongside this, we are working to build relationships with other policy and system partners; including the Office for Health Improvement and Disparities (OHID) and health inequalities leads at Macmillan, Cancer Research UK and other voluntary, community, and social enterprise (VCSE) organisations.

## Working collaboratively across the wider cancer community

To maximise impact for people living with cancer, **Cancer52** collaborates with relevant organisations and multiple charities outside its direct membership.

### Charities Medicines Access Coalition

**Cancer52** is a member of the Charities Medicines Access Coalition (CMAC), which works to find long-term solutions to the challenges that can delay or prevent patient access to new and innovative medicines. This coalition has established relationships with decision-makers including NHS England, the National Institute for Health and Care Excellence (NICE) and the Association of the British Pharmaceutical Industry (ABPI). **Cancer52** led responses to NICE strategy consultations during 2023 and into 2024 on working with people and communities and responded to the ABPI consultation on its code of practice. **Cancer52** also worked with CMAC to raise issues on behalf of its member charities. Finally, **Cancer52** engaged with and consulted on the agreement between the DHSC, NHSE and the ABPI on the voluntary scheme for branded medicines pricing, access and growth.

### NICE VCSE Forum Steering Group

**Cancer52** sits on NICE Voluntary and Community Sector (VCSE) Forum's steering group to help oversee the forum's work and engage its members. The NICE VCSE Forum has an important role in ensuring the people affected by NICE's work can be heard in the decision making process.

### The Cancer Data Collaborative

**Cancer52** collaborated with Cancer Research UK and Macmillan in data sharing. Data collaboratives are an emerging form of collaboration in which data held by an entity can be leveraged in partnership with another entity (from the public sector, civil society and/or academia) for public good.

### Improving the data landscape on cancer inequalities

**Cancer52** engaged with Cross-Charity Commissioned Research alongside Breast Cancer Now, Prostate Cancer UK, Bowel Cancer UK, Macmillan and Cancer Research UK and carried out by the Big Data Institute at Oxford University. The key questions for this research are:

What is the evidence available related to inequalities in cancer incidence, care and outcome across the UK?

What data is available, or potentially available, to investigate cancer inequalities and inequities across the UK, what are the strengths and weaknesses of these data, and what barriers exist to their use?

### Fair Market Value for patients' and charities' time and expertise

**Cancer52** worked with the Patient Information Forum (PIF) and the National Rheumatoid Arthritis Society (NRAS) to conduct a survey with charities.<sup>12</sup> This work developed into a project to produce guidance for charities on charging fair rates when working in partnership with industry, research bodies and public bodies. See survey findings.

### Signposting across patient information

**Cancer52** has led work that helps patients and their loved ones to access patient information and patient support that is relevant to their cancer type. **Cancer52** has worked with both the NHS and Macmillan Cancer Support to initiate new links with their online patient information to signpost to smaller charities focused on rare and less common cancers.

## One Cancer Voice

One Cancer Voice (OCV) consists of 50 charities working together on fundamental policy asks, such as a governmental cancer plan. This alliance was increasingly active leading up to the expected general election in 2024 and **Cancer52** played a key role on the OCV steering group to shape the agenda and calls to action as well as engage our members in OCV's public facing activities.

## Children and young people with cancer

Many of our member charities support children and young people with cancer and these charities have together formed the Children and Young People's Cancer Coalition. **Cancer52** sits on the steering group and supports the work of charities in this field.

## Healthcare charities

National Voices is a wide-ranging coalition of healthcare charities that helps **Cancer52** engage in topics particularly relevant to people with rare and less common cancers.

## Rare cancers

The Specialised Healthcare Alliance campaigns on behalf of those with rare and complex conditions. **Cancer52** is a member and attends briefings on wider topics affecting people with rare cancers.

## HPV Coalition

Human papillomavirus (HPV) is the name of a common virus which is linked to several rare and less common cancers. **Cancer52** is part of the HPV coalition, an expert advisory group that comes together to inform and advance the UK's journey towards the elimination of HPV-related cancers.

## ABPI Patient Advisory Council

**Cancer52's** CEO sat on the Association of the British Pharmaceutical Industry (ABPI) Patient Advisory Council and **Cancer52** joined the Patient Organisation Forum briefings, alongside other larger, well-known charities, and sat on the steering group that plans the meetings and organises speakers. In 2023 **Cancer52** worked with the ABPI on a further Anti-Microbial Resistance campaign specific to people living with rare and less common cancers called Together for Antibiotics.<sup>13,14</sup>

## Travel insurance for cancer patients

**Cancer52** has been supporting member charity, Planets, in their work to improve travel insurance options for people who have had a cancer diagnosis, and often face prohibitive costs that do not necessarily reflect the risk. One part of the work is collaborating with Verisk, a company that provides the health risk data (including for rare and less common cancers) for up to 90% of the UK Insurance industry, on reviewing risk assessments for individual rare and less common cancers.

## Informing our stakeholders

As an organisation, and also as our members' representative, **Cancer52** is in ongoing communication with members of other charities, NHS professionals and administrators and anyone else who has influence in the rare and less common cancer field.

### Website

The **Cancer52** website links to all member organisations, plus the sponsors and groups **Cancer52** collaborates with, offering a useful portal for sharing information between members, patients and the general public. It includes a webpage listing all rare and less common cancers with links to relevant patient support and research organisations. **Cancer52** posted reports on its activities during the year and featured a news stream of prominent issues.

Website users can access reports together with informative videos, contact and donation opportunities.

### Social media

**Cancer52** has been especially active this year on LinkedIn, X (formally Twitter) and Facebook. The organisation has created a substantial increase in followers, including an increase of more than 40% on LinkedIn within one financial year. **Cancer52** uses social media to communicate with members and the wider public, to raise awareness of the organisation, and to distribute new information and react to events that impact the rare and less common cancer community.



Cancer52 CEO, Jane Lyons, participated in a podcast on innovation in cancer care alongside Pfizer UK Oncology Lead, Stefan Podesta and Dr Ellie Cannon.

# Making the voice of people with rare and less common cancers heard: our headline achievements for 2023–2024

## Partnership

### Informing, sharing with, and empowering our members

**Cancer52** membership and engagement levels have increased in 2023-2024. We are grateful for the significant positive feedback from our members. This confirms that efforts invested in establishing the Big **Cancer52** Conversation events have been successful in facilitating partnership.

## Policy

### Responding collectively to the changing political cancer priorities

**Cancer52** continues to work alongside the NHSE Cancer Programme to improve outcomes for those with rare and less common cancers and to meet the early diagnosis target of diagnosing 75% of all cancers at stage I and II by 2028. **Cancer52**'s previous collaborative work with its members and patients will now be used to input to the Government's Major Conditions Strategy. **Cancer52** also secured funding especially to expand policy work and has developed a manifesto and initiated in-person policy events.

## Patients

### Advocating for those affected by rare and less common cancers through collaboration

**Cancer52** continues to take patient voice and experiences to influencers and policy decision makers. Highlights include feeding the patient voice into the Major Conditions Strategy where **Cancer52** provided oral evidence at the Health and Social Care Committee on Future Cancer. **Cancer52** is proud of its work with our members in health inequalities striving to ensure an equitable experience of cancer care.



# Funding

## The National Lottery Community Fund



In 2023–2024, Cancer52 successfully secured substantial three-year funding from The National Lottery Community Fund (TNLCF), the largest community funder in the UK. Cancer52 was delighted to receive this funding as recognition of its achievements alongside its members for the rare and less common cancer community. The funding will provide, over three years, scope to increase staffing resources to further grow capacity and sustainability, and has three key target outcomes:

### Outcome 1:

Policy advances for rare and less common cancer

### Outcome 2:

Addressing patient health inequalities

### Outcome 3:

Increasing member engagement

Expanding Cancer52's work means the impact of this funding will benefit Cancer52 itself, charity members, people with rare and less common cancers, and the wider rare and less common cancer community.

Cancer52 also continued to receive funding via donations from members, individual donations, and support from pharmaceutical companies. These funds are vital to the ongoing delivery of core work and relevant projects that are of benefit to the rare and less common cancer community.

## The value of support

The valuable time, expertise and energy generously donated by members is hugely appreciated.

**Cancer52** is incredibly grateful to every donor and supporter for their financial support which helps propel us towards achieving our objectives. This includes financial support from charity members.

## Voluntary member donations

A significant amount of **Cancer52**'s financial support comes from member charities who make a voluntary donation aligned to their income.

In this financial year, membership donations totalled a record £47,800 from 49 member charities. **Cancer52** asked members with an annual income over £100,000 to pay a donation where possible but, as always, were considerate of those smaller charities encountering the rising cost of living. Membership donations for 2023/24 exceeded those of 2022/23 by **30%** following a membership donation review by the Board of Trustees. The purpose of the review was to consider the benefits of **Cancer52** membership and to create a fairer and more structured approach to the membership donations. Membership donations remain based on charity income level, but are now spread out across more income bands, to place a more appropriate level at either end of the spectrum.

## Individual donations

Donations are welcome from any individuals or organisations who recognise the value of **Cancer52**'s contribution in supporting people with rare and less common cancers.

During the financial year 2023-24, **Cancer52** received over £21,000 from a variety of platforms and individuals. Of particular note, thanks go to the families and friends of Louise Marshall, Alex Sekouras, Lucien Seller, and to Trustee, Dr Max Brodermann for his support in running the Chelmsford Marathon in October 2023.

## Support from industry

In 2023–2024 we received support from Astra Zeneca, BMS, Gilead, GSK, Ipsen, Janssen, Merck, MSD, Novartis, Pfizer, Roche, and Takeda, who all benefited from membership to **Cancer52**'s Corporate Supporter Programme.

**Cancer52** has a clearly written policy to guide its work with the pharmaceutical industry and also follows industry guidelines.<sup>15</sup> Some 52.4% of our funding in 2023/24 came from pharmaceutical companies and comprises support for specific projects as well as unrestricted support.

**Cancer52** believes all its industry partners recognise the value of working with an umbrella organisation that channels one voice for rare and less common cancers.



# Future plans

Cancer52 is proud of its achievements during this year, its major objectives prevail and will be taken forward into 2024–2025.

Cancer52 will provide a strong, unified voice to promote improved diagnosis, treatment and support for those affected by rare and less common cancers so that we see an end to inequalities in diagnosis, treatment and patient outcomes experienced by those with these challenging diseases.

**As part of its three-year strategy, Cancer52 has made progress in its plans to:**

Be a well-resourced organisation making the voice of rare and less common cancers heard through securing TNLCF funding over three years

Retain its market leadership position, build its thought leadership and through The Big Cancer52 Conversation and other projects, increase its collaborative work with the wider rare and less common cancer community

Retain its focus on its aim, mission and values

Place reducing inequalities at the heart of everything it does and making this a key workstream of the **Big Cancer52 Conversation**.

**In the next year, Cancer52 will continue to progress the plans listed above and in addition, will take steps to:**

Review its target audience and messaging and, if necessary, be ready to make changes.

# The acoustics: structure and constitution



## Structure and Governance

**Cancer52** is incorporated as a charitable company limited by guarantee and is a registered charity in England and Wales. It is governed by its Memorandum and Articles of Association, and its work, management, finances and strategy are overseen by a Board of Trustees, who are also the company directors. The Trustees who held office during the financial year and at the date of the report are set out on page 41.

Under the Articles of Association, a minimum of three trustees and a maximum of twelve trustees {directors} can be in office.

The Board has agreed that the usual term of tenure for trustees should be a maximum of two terms of three years each (six years in total), with review and approval by the Board at the end of each term of tenure. In exceptional circumstances, and in order not to lose important or valuable skills, experience and expertise, trustees may serve for a third term of tenure, subject to the approval of the Board. Trustees do not receive remuneration for their duties.

## Public benefit

**Cancer52** encourages and facilitates interaction and collaboration between members and other stakeholders. This support in turn aids members' provision of information and support to people diagnosed with, treated for or living with a rare or less common cancer. Outcomes for people with rare or less common cancers also improve when we drive change and enhancements in the cancer system.



## Purpose

The charity's purposes are set out in its Memorandum and Articles of Association as follows:

To promote and protect the health of people with rare and less common cancers by:

1. Advancing and promoting understanding, awareness, research and learning about rare and less common cancers;
2. Acting as a collective voice and advocating for the needs of individuals affected by a rare or less common cancer in order to improve diagnosis, treatment and long-term support outcomes
3. Supporting, representing and empowering not-for-profit organisations working in the field of rare and less common cancers.

As part of the business planning processes, **Cancer52's** aims and objectives are reviewed each year. This includes looking at how those groups of people we were set up to help have benefited and what has been achieved in previous years. The Charity Commission's general guidance on public benefit was referred to when reviewing **Cancer52's** aims and objectives and also in the planning work for the future.

## Board and management operations and structure

### Board of Trustees

The Board of Trustees meets at least four times a year to review **Cancer52's** work, finances and services, and to agree strategic goals for the charity. In-person board meetings resumed in 2023-24 with a virtual option, and meetings invited the Chief Executive and the Operations Consultant and others as appropriate.

The Chair and other trustees with financial expertise also meet separately with the Chief Executive, Operations Consultant, and **Cancer52's** accountant on a quarterly basis to monitor and scrutinise the financial strategy and operations and make any necessary recommendations to the full Board of Trustees.

### Recruitment and appointment of new Trustees

Anne MacDowell was recruited as the new Chair of the Board in October 2023. Anne replaces Rebecca Porta, CEO of The Urology Foundation and a long-standing Board Member, who served as Interim Chair, with the support of Helen Morement, CEO of AMMF and also a long-standing Board Member.

### Related parties

Related parties are considered to be the trustees and those connected with the trustees, including their close families, business and other charity interests. There have been no transactions with related parties, other than the reimbursement of reasonable travel expenses for the purposes of attendance at Board meetings and other relevant organisational activities.

## Risk assessment and management

The Board of Trustees and the Chief Executive maintain a risk register and assess risk on an annual basis. The trustees are satisfied that major risks to the organisation have been accurately identified and that appropriate systems and procedures for managing those risks are in place.

### Safeguarding

**Cancer52** has a strong commitment to protecting and promoting the health, wellbeing and safety of all engaged in its work. While not a patient representative charity, **Cancer52** still adheres to good safeguarding practice. The Safeguarding Policy is reviewed each year and is accessible on the Governance section of **Cancer52's** website. Each year, all staff and contractors are required to participate in a full day safeguarding training course, provided by an external organisation to ensure everyone is up to date with the latest safeguarding requirements.

**Cancer52** has sought to strengthen its risk management training this year and all staff and contractors are required to take General Data Protection Regulation (GDPR) training.


### Annual review

The Annual Review 2023–2024 was completed and disseminated, with thanks to the Board nominees Nic Puntis and Helen Morement.



# cancer52

the common voice for  
rare & less common cancers



# Money talks: financial review 2023–2024

## Financial statement

As shown in the statement of financial activities on the following pages, in the year 2023–2024

- Reserves brought forward from 2022–2023 were £88,835.
- Income for the financial year was £230,779.
- Expenditure for the current financial year was £268,701, resulting in an anticipated deficit of £37,922.
- Reserves of £50,913 were available at the end of the 2023–2024 financial year.

### Reserves policy

The Board of Trustees' strategy on reserves is for the organisation to maintain sufficient funds to cover the operational running costs in the event of a major setback. This means that we aim to hold approximately six months' annual expenditure in reserve.

At the end of the 2023–2024 financial year, Cancer52's reserves stood at £50,913 which covers the six months running expenses not covered directly by the National Lottery.

The Company has taken advantage of the small companies' exemption in preparing this report. The trustees declare that they have approved the trustees' report (including directors' report) above.

### Signed on behalf of the charity's trustees/directors

Signature \_\_\_\_\_

Anne MacDowell

*Trustee / Director*

Date \_\_\_\_\_

Signature \_\_\_\_\_

Nic Puntis

*Trustee / Director*

Date \_\_\_\_\_



**Section A**

**Independent Examiner's Report**

**Report to the trustees/directors/ members of**

Cancer 52

**On accounts for the year ended**

31<sup>st</sup> March 2024

**Charity no.:**

1174569

**Company no.:**

07994413

**Set out on pages**

**28**

To

**40**

I report to the charity trustees on my examination of the accounts of the Company for the year ended **31<sup>st</sup> March 2024**.

**Responsibilities and basis of report**

As the charity's trustees of the Company (who are also the directors of the company for the purposes of company law), you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ("the 2006 Act").

Having satisfied myself that the accounts of the Company are not required to be audited for this year under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ("the 2011 Act"). In carrying out my examination, I have followed the Directions given by the Charity Commission (under section 145(5)(b) of the 2011 Act.

**Independent examiner's statement**

I have completed my examination. I confirm that no material matters have come to my attention (other than that disclosed below \*) which gives me cause to believe that:

- accounting records were not kept in accordance with section 386 of the Companies Act 2006; or
- the accounts do not accord with such records; or
- the accounts do not comply with relevant accounting requirements under section 396 of the Companies Act 2006 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
- the accounts have not been prepared in accordance with the Charities SORP (FRS102).

**Name:** Jason Dennis

**Relevant professional qualification(s) or body (if any):** AAT - Association of Accounting Technicians  
ATT – Association of Taxation Technicians

**Address:** 31 Clover Way, Paddock Wood, Tonbridge, Kent TN12 6BQ

**Section B**

**Disclosure**

Only complete if the examiner needs to highlight material matters of concern (see CC32, Independent examination of charity accounts: directions and guidance for examiners).

**Give here brief details of any items that the examiner wishes to disclose.**

[Empty box for disclosure details]

# Section A

## Statement of financial activities

(including summary income and expenditure account)

Recommended categories by activity	Guidance Note	Unrestricted	Restricted	Endowment	Total funds	Prior year
		funds	income funds	funds	£	funds
		£	£	£	£	£
		F01	F02	F03	F04	F05
<b>Income (Note 3)</b>						
<b>Income and endowments from:</b>						
Donations and legacies	S01	193,836	36,943	-	230,779	176,598
<b>Total</b>	S07	193,836	36,943	-	230,779	176,598
<b>Expenditure (Notes 4)</b>						
<b>Expenditure on:</b>						
Raising funds	S08	20,493	-	-	20,493	23,566
Charitable activities	S09	206,161	36,047	-	242,208	171,486
Other	S11	6,000	-	-	6,000	3,000
<b>Total</b>	S12	232,654	36,047	-	268,701	198,052
<b>Net income/(expenditure) before tax for the reporting period</b>	S13	(38,818)	896	-	(37,922)	(21,454)
Tax payable	S14	-	-	-	-	-
<b>Net income/(expenditure) after tax before investment gains/(losses)</b>	S15	(38,818)	896	-	(37,922)	(21,454)
Net gains/(losses) on investments	S16	-	-	-	-	-
<b>Net income/(expenditure) Extraordinary items</b>	S17	(38,818)	896	-	(37,922)	(21,454)
<b>Transfers between funds</b>	S18	-	-	-	-	-
<b>Other recognised gains/(losses):</b>	S19	12,583	(12,583)	-	-	-
Gains and losses on revaluation of fixed assets for the charity's own use	S20	-	-	-	-	-
Other gains/(losses)	S21	-	-	-	-	-
<b>Net movement in funds</b>	S22	(26,235)	(11,687)	-	(37,922)	(21,454)
<b>Reconciliation of funds:</b>						
Total funds brought forward	S23	76,252	12,583	-	88,835	110,289
<b>Total funds carried forward</b>	S24	50,017	896	-	50,913	88,835

# Section B

## Balance sheet (as at 31st March 2024)

	Guidance Note	Unrestricted funds £	Restricted income funds £	Endowment funds £	Total this year £	Total last year £
<b>Current assets</b>						
Cash at bank and in hand (Note 9)	B09	111,651	-	-	111,651	92,205
<b>Total current assets</b>	B10	111,651	-	-	111,651	92,205
<b>Creditors and deferred income : amounts falling due within one year (Note 8)</b>						
	B11	60,738	-	-	60,738	3,370
<b>Net current assets/(liabilities)</b>	B12	50,913	-	-	50,913	88,835
<b>Total assets less current liabilities</b>	B13	50,913	-	-	50,913	88,835
<b>Total net assets or liabilities</b>	B16	50,913	-	-	50,913	88,835
<b>Funds of the Charity</b>						
Endowment funds	B17	-	-	-	-	-
Restricted income funds (Note 11)	B18	-	896	-	896	12,583
Unrestricted funds	B19	50,017	-	-	50,017	76,252
Revaluation reserve	B20	-	-	-	-	-
Fair value reserve	B21	-	-	-	-	-
<b>Total funds</b>	B22	50,017	896	-	50,913	88,835

The company was entitled to exemption from audit under s477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to small companies subject to the small companies regime and in accordance with FRS102 SORP.

Signed by one or two trustee/directors on behalf of all the trustees/directors

Name	Signature	Date of approval dd/mm/yyyy
Anne MacDowell		
Nic Puntis		

Signature of Chair authenticating accounts being sent to Companies House

Name	Signature	Date of approval dd/mm/yyyy
Anne MacDowell		

# Section C

## Notes to the accounts

### NOTE 1: Basis of preparation

#### 1.1 Basis of accounting

These accounts have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant note(s) to these accounts.

The accounts have been prepared in accordance with:

- and with\*  the Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued on 16 July 2014
- and with\*  the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102)
- and with the Charities Act 2011.

The charity constitutes a public benefit entity as defined by FRS 102.\*

\* -Tick as appropriate

#### 1.2 Going concern

***If there are material uncertainties related to events or conditions that cast significant doubt on the charity's ability to continue as a going concern, please provide the following details or state "Not applicable", if appropriate:***

An explanation as to those factors that support the conclusion that the charity is a going concern;

***Not applicable***

Disclosure of any uncertainties that make the going concern assumption doubtful;

***Not applicable***

Where accounts are not prepared on a going concern basis, please disclose this fact together with the basis on which the trustees prepared the accounts and the reason why the charity is not regarded as a going concern.

***Not applicable***

### 1.3 Change of accounting policy

The accounts present a true and fair view and no changes have been made to the accounting policies adopted in note { }.

Yes*	<input checked="" type="checkbox"/>	* -Tick as appropriate
No*	<input type="checkbox"/>	

Please disclose:

<i>(i) the nature of the change in accounting policy;</i>	<b>Not applicable</b>
<i>(ii) the reasons why applying the new accounting policy provides more reliable and more relevant information; and</i>	<b>Not applicable</b>
<i>(iii) the amount of the adjustment for each line affected in the current period, each prior period presented and the aggregate amount of the adjustment relating to periods before those presented, 3.44 FRS102 SORP.</i>	<b>Not applicable</b>

### 1.4 Changes to accounting estimates

No changes to accounting estimates have occurred in the reporting period (3.46 FRS102 SORP).

Yes*	<input checked="" type="checkbox"/>	* -Tick as appropriate
No*	<input type="checkbox"/>	

Please disclose:

<i>(i) the nature of any changes;</i>	<b>Not applicable</b>
<i>(ii) the effect of the change on income and expense or assets and liabilities for the current period; and</i>	<b>Not applicable</b>
<i>(iii) where practicable, the effect of the change in one or more future periods.</i>	<b>Not applicable</b>

### 1.5 Material prior year errors

No material prior year error have been identified in the reporting period (3.47 FRS102 SORP).

Yes*	<input checked="" type="checkbox"/>	* -Tick as appropriate
No*	<input type="checkbox"/>	

Please disclose:

<i>(i) the nature of the prior period error;</i>	<b>Not applicable</b>
<i>(ii) for each prior period presented in the accounts, the amount of the correction for each account line item affected; and</i>	<b>Not applicable</b>
<i>(iii) the amount of the correction at the beginning of the earliest prior period presented in the accounts.</i>	<b>Not applicable</b>

## NOTE 2: Accounting policies

### 2.1 INCOME

<b>Recognition of income</b>	<p>These are included in the Statement of Financial Activities (SoFA) when:</p> <ul style="list-style-type: none"> <li>the charity becomes entitled to the resources;</li> <li>it is more likely than not that the trustees will receive the resources;</li> <li>the monetary value can be measured with sufficient reliability.</li> </ul>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">✓</td> <td></td> <td></td> </tr> </tbody> </table>	Yes*	No*	N/a*	✓		
Yes*	No*	N/a*						
✓								
<b>Offsetting</b>	<p>There has been no offsetting of assets and liabilities, or income and expenses, unless required or permitted by the FRS 102 SORP or FRS 102.</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">✓</td> <td></td> <td></td> </tr> </tbody> </table>	Yes*	No*	N/a*	✓		
Yes*	No*	N/a*						
✓								
<b>Grants and donations</b>	<p>Grants and donations are only included in the SoFA when the general income recognition criteria are met (5.10 to 5.12 FRS102 SORP).</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">✓</td> <td></td> <td></td> </tr> </tbody> </table>	Yes*	No*	N/a*	✓		
Yes*	No*	N/a*						
✓								
	<p>In the case of performance related grants, income must only be recognised to the extent that the charity has provided the specified goods or services as entitlement to the grant only occurs when the performance related conditions are met (5.16 FRS 102 SORP).</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> <td style="text-align: center;">✓</td> </tr> </tbody> </table>	Yes*	No*	N/a*			✓
Yes*	No*	N/a*						
		✓						
<b>Legacies</b>	<p>Legacies are included in the SOFA when receipt is probable, that is, when there has been grant of probate, the executors have established that there are sufficient assets in the estate and any conditions attached to the legacy are either within the control of the charity or have been met.</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">✓</td> <td></td> <td></td> </tr> </tbody> </table>	Yes*	No*	N/a*	✓		
Yes*	No*	N/a*						
✓								
<b>Government grants</b>	<p>The charity has received government grants in the reporting period</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">✓</td> <td></td> <td></td> </tr> </tbody> </table>	Yes*	No*	N/a*	✓		
Yes*	No*	N/a*						
✓								
<b>Tax reclaims on donations and gifts</b>	<p>Gift Aid receivable is included in income when there is a valid declaration from the donor. Any Gift Aid amount recovered on a donation is considered to be part of that gift and is treated as an addition to the same fund as the initial donation unless the donor or the terms of the appeal have specified otherwise.</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">✓</td> <td></td> <td></td> </tr> </tbody> </table>	Yes*	No*	N/a*	✓		
Yes*	No*	N/a*						
✓								
<b>Contractual income and performance related grants</b>	<p>This is only included in the SoFA once the charity has provided the related goods or services or met the performance related conditions.</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> <td style="text-align: center;">✓</td> </tr> </tbody> </table>	Yes*	No*	N/a*			✓
Yes*	No*	N/a*						
		✓						
<b>Donated goods</b>	<p>Donated goods are measured at fair value (the amount for which the asset could be exchanged) unless impractical to do so.</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">✓</td> <td></td> <td></td> </tr> </tbody> </table>	Yes*	No*	N/a*	✓		
Yes*	No*	N/a*						
✓								
	<p>The cost of any stock of goods donated for distribution to beneficiaries is deemed to be the fair value of those gifts at the time of their receipt and they are recognised on receipt. In the reporting period in which the stocks are distributed, they are recognised as an expense at the carrying amount of the stocks at distribution.</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> <td style="text-align: center;">✓</td> </tr> </tbody> </table>	Yes*	No*	N/a*			✓
Yes*	No*	N/a*						
		✓						
	<p>Donated goods for resale are measured at fair value on initial recognition, which is the expected proceeds from sale less the expected costs of sale, and recognised in 'Income from other trading activities' with the corresponding stock recognised in the balance sheet. On its sale the value of stock is charged against 'Income from other trading activities' and the proceeds from sale are also recognised as 'Income from other trading activities'.</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> <td style="text-align: center;">✓</td> </tr> </tbody> </table>	Yes*	No*	N/a*			✓
Yes*	No*	N/a*						
		✓						
	<p>Goods donated for on-going use by the charity are recognised as tangible fixed assets and included in the SoFA as incoming resources when receivable.</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> <td style="text-align: center;">✓</td> </tr> </tbody> </table>	Yes*	No*	N/a*			✓
Yes*	No*	N/a*						
		✓						
	<p>Gifts in kind for use by the charity are included in the SoFA as income from donations when receivable.</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">✓</td> <td></td> <td></td> </tr> </tbody> </table>	Yes*	No*	N/a*	✓		
Yes*	No*	N/a*						
✓								
<b>Donated services and facilities</b>	<p>Donated services and facilities are included in the SOFA when received at the value of the gift to the charity provided the value of the gift can be measured reliably.</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> <td style="text-align: center;">✓</td> </tr> </tbody> </table>	Yes*	No*	N/a*			✓
Yes*	No*	N/a*						
		✓						
	<p>Donated services and facilities that are consumed immediately are recognised as income with an equivalent amount recognised as an expense under the appropriate heading in the SOFA.</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> <td style="text-align: center;">✓</td> </tr> </tbody> </table>	Yes*	No*	N/a*			✓
Yes*	No*	N/a*						
		✓						

<b>Support costs</b>	The charity has incurred expenditure on support costs.	Yes	No	N/a
			✓	
<b>Volunteer help</b>	The value of any voluntary help received is not included in the accounts but is described in the trustees' annual report.	Yes*	No*	N/a*
		✓		
<b>Income from interest, royalties and dividends</b>	This is included in the accounts when receipt is probable and the amount receivable can be measured reliably.	Yes*	No*	N/a*
		✓		
<b>Income from membership</b>	Membership subscriptions received in the nature of a gift are recognised in Donations	Yes*	No*	N/a*

## 2.2 EXPENDITURE AND LIABILITIES

<b>Liability recognition</b>	Liabilities are recognised where it is more likely than not that there is a legal or constructive obligation committing the charity to pay out resources and the amount of the obligation can be measured with reasonable certainty.	Yes*	No*	N/a*
		✓	✓	✓
<b>Governance and support costs</b>	Support costs have been allocated between governance costs and other support. Governance costs comprise all costs involving public accountability of the charity and its compliance with regulation and good practice.  Support costs include central functions and have been allocated to activity cost categories on a basis consistent with the use of resources, eg allocating property costs by floor areas, or per capita, staff costs by the time spent and other costs by their usage.	Yes*	No*	N/a*
				✓
<b>Grants with performance conditions</b>	Where the charity gives a grant with conditions for its payment being a specific level of service or output to be provided, such grants are only recognised in the SoFA once the recipient of the grant has provided the specified service or output.	Yes*	No*	N/a*
				✓
<b>Grants payable without performance conditions</b>	Where there are no conditions attaching to the grant that enables the donor charity to realistically avoid the commitment, a liability for the full funding obligation must be recognised.	Yes*	No*	N/a*
				✓
<b>Redundancy cost</b>	The charity made no redundancy payments during the reporting period.	Yes*	No*	N/a*
		✓		
<b>Deferred income</b>	No material item of deferred income has been included in the accounts.	Yes*	No*	N/a*
			✓	
<b>Creditors</b>	The charity has creditors which are measured at settlement amounts less any trade discounts	Yes*	No*	N/a*
				✓
<b>Provisions for liabilities</b>	A liability is measured on recognition at its historical cost and then subsequently measured at the best estimate of the amount required to settle the obligation at the reporting date	Yes*	No*	N/a*
				✓
<b>Basic financial instruments</b>	The charity accounts for basic financial instruments on initial recognition as per paragraph 10.7 FRS102 SORP. Subsequent measurement is as per paragraphs 11.17 to 11.19, FRS102 SORP.	Yes*	No*	N/a*
				✓

## 2.3 ASSETS

**Tangible fixed assets for use by charity** These are capitalised if they can be used for more than one year, and cost at least

£2,500		
Yes*	No*	N/a*
		✓

They are valued at cost.

The depreciation rates and methods used are disclosed in note 14.

### Intangible fixed assets

The charity has intangible fixed assets, that is, non-monetary assets that do not have physical substance but are identifiable and are controlled by the charity through custody or legal rights. The amortisation rates and methods used are disclosed in note 15.

Yes*	No*	N/a*
		✓

They are valued at cost.

Yes*	No*	N/a*
		✓

### Heritage assets

The charity has heritage assets, that is, non-monetary assets with historic, artistic, scientific, technological, geophysical or environmental qualities that are held and maintained principally for their contribution to knowledge and culture. The depreciation rates and methods used as disclosed in note 16.

Yes*	No*	N/a*
		✓

They are valued at cost.

Yes*	No*	N/a*
		✓

### Investments

Fixed asset investments in quoted shares, traded bonds and similar investments are valued at initially at cost and subsequently at fair value (their market value) at the year end. The same treatment is applied to unlisted investments unless fair value cannot be measured reliably in which case it is measured at cost less impairment.

Yes*	No*	N/a*
		✓

Investments held for resale or pending their sale and cash and cash equivalents with a maturity date of less than 1 year are treated as current asset investments

Yes*	No*	N/a*
		✓

### Stocks and work in progress

Stocks held for sale as part of non-charitable trade are measured at the lower or cost or net realisable value.

Yes*	No*	N/a*
		✓

Goods or services provided as part of a charitable activity are measured at net realisable value based on the service potential provided by items of stock.

Yes*	No*	N/a*
		✓

Work in progress is valued at cost less any foreseeable loss that is likely to occur on the contract.

Yes*	No*	N/a*
		✓

### Debtors

Debtors (including trade debtors and loans receivable) are measured on initial recognition at settlement amount after any trade discounts or amount advanced by the charity. Subsequently, they are measured at the cash or other consideration expected to be received.

Yes*	No*	N/a*
		✓

### Current asset investments

The charity has investments which it holds for resale or pending their sale and cash and cash equivalents with a maturity date less than one year. These include cash on deposit and cash equivalents with a maturity of less than one year held for investment purposes rather than to meet short-term cash commitments as they fall due.

Yes*	No*	N/a*
		✓

They are valued at fair value except where they qualify as basic financial instruments.

Yes*	No*	N/a*
		✓

**POLICIES ADOPTED ADDITIONAL TO OR DIFFERENT FROM THOSE ABOVE**

--	--

## NOTE 3: Income

Analysis of income		Unrestricted funds	income funds	Endowment funds	Total funds £	Prior year £
<b>Donations</b>	Donations and gifts	136,179	-	-	136,179	143,648
	General grants provided by government - TNLCF (National Lottery Community Fund)	-	36,943	-	36,943	-
	Membership subscriptions and sponsorships which are in substance donations	57,657	-	-	57,657	32,950
<b>Total</b>		<b>193,836</b>	<b>36,943</b>	<b>-</b>	<b>230,779</b>	<b>176,598</b>
<b>TOTAL INCOME</b>		<b>193,836</b>	<b>36,943</b>	<b>-</b>	<b>230,779</b>	<b>176,598</b>

## NOTE 4: Analysis of receipts of government grants

	Description	£
<b>Government grant 1</b>	The National Lottery Community Fund - Funding for Core expenditure	36,943
	<b>Total</b>	<b>36,943</b>

£73,886 was received in January 2024 for the period January to June 2024. Therefore 3 months has been deferred £36,943.

## NOTE 5: Expenditure

Analysis	This year				Last year			
	Unrestricted funds	Restricted income funds	Endowment funds	Total funds	Unrestricted funds	Restricted income funds	Endowment funds	Total funds
<b>Expenditure on raising funds</b>	£							
Fundraising consultant services	20,493	-	-	20,493	23,566	-	-	23,566
<b>Total expenditure on raising funds</b>	<b>20,493</b>	<b>-</b>	<b>-</b>	<b>20,493</b>	<b>23,566</b>	<b>-</b>	<b>-</b>	<b>23,566</b>
<b>Expenditure on charitable activities:</b>								
All Member Meetings, Steering Group Meetings, Room Hire, Venue Costs, Conference expenses	4,716	-	-	4,716	5,586	-	-	5,586
Showcase Project	-	-	-	-	-	10,307	-	10,307
Fundraising Platform Website materials (Gift in kind)	-	-	-	-	10,899	-	-	10,899
Merchandise	121	-	-	121	376	-	-	376
Call for Evidence Project	-	-	-	-	2,775	-	-	2,775
Inequalities report	11,565	-	-	11,565	8,980	-	-	8,980
TNLCF - National Lottery funded expenditure	-	36,047	-	36,047	-	-	-	-
NCRI Project	401	-	-	401	1,480	-	-	1,480
Big Cancer 52 Events	17,089	-	-	17,089	-	-	-	-
Pfizer Project Support	186	-	-	186	-	-	-	-
Impact Reporting and Annual Review	1,805	-	-	1,805	1,869	-	-	1,869
Telephone	302	-	-	302	219	-	-	219
Registered Office Change	119	-	-	119	-	-	-	-
IT and Computer running expenses and Website mtce	1,380	-	-	1,380	1,300	-	-	1,300
Policy consultants - Policy Support and Report	33,441	-	-	33,441	21,375	-	-	21,375
Policy Workshop	15,000	-	-	15,000	-	-	-	-
Subscriptions	2,632	-	-	2,632	1,622	-	-	1,622
Operations Management Services	33,146	-	-	33,146	20,861	-	-	20,861
Other Administration Support Services	14,348	-	-	14,348	8,739	-	-	8,739
Insurance	574	-	-	574	556	-	-	556
Parliamentary Event	2,261	-	-	2,261	-	-	-	-
Salaries and Ers NI and Pensions (Non-TNLCF Funded)	47,518	-	-	47,518	65,396	-	-	65,396
Training	866	-	-	866	-	-	-	-
Communications and PR Services	15,767	-	-	15,767	8,803	-	-	8,803
Bank and credit fees	216	-	-	216	216	-	-	216
Trustees/Directors Travel	608	-	-	608	105	-	-	105
Other Travel and Subsistence	563	-	-	563	-	-	-	-
Trustee Recruitment costs and expenses	491	-	-	491	-	-	-	-
Other Recruitment costs	1,046	-	-	1,046	22	-	-	22
<b>Total expenditure on charitable activities</b>	<b>206,161</b>	<b>36,047</b>	<b>-</b>	<b>242,208</b>	<b>161,179</b>	<b>10,307</b>	<b>-</b>	<b>171,486</b>
<b>Other</b>								
Independent Examiner	6,000	-	-	6,000	3,000	-	-	3,000
<b>Total other expenditure</b>	<b>6,000</b>	<b>-</b>	<b>-</b>	<b>6,000</b>	<b>3,000</b>	<b>-</b>	<b>-</b>	<b>3,000</b>
<b>TOTAL EXPENDITURE</b>	<b>232,654</b>	<b>36,047</b>	<b>-</b>	<b>268,701</b>	<b>187,745</b>	<b>10,307</b>	<b>-</b>	<b>198,052</b>

## NOTE 6: Details of certain types of expenditure

### Note 6.1 Fees for examination of the accounts

Please provide details of the amount paid for any statutory external scrutiny of accounts and other services provided by your independent examiner. If nothing was paid please enter '0' in the appropriate box(es).

Independent examiner's fees

This year £	Last year £
6,000	3,000

## NOTE 7: Paid Employees

### 7.1 Staff Costs

	This year £	Last year £
Salaries and wages	60,000	60,000
Social security costs	2,029	2,396
Pension costs (defined contribution scheme)	3,000	3,000
Other employee benefits	-	-
<b>Total staff costs</b>	<b>65,029</b>	<b>65,396</b>

Please note £15,000 Salaries and Wages ; £1,761.35 Social security costs and £750 Pension costs were funded by the The National Lottery Community Fund and are included in the TNLCF - National Lottery Funded Expenditure line in Note 4 instead of Salaries, Employers NI and Pensions.

Please give details of the number of employees whose total employee benefits (excluding employer pension costs) fell within each band of £10,000 from £60,000 upwards. If there are no such transactions, please enter 'true' in the box provided.

No employees received employee benefits (excluding employer pension costs) for the reporting period of more than £60,000

**TRUE**

Band	Number of employees	
	This year	Last year
£60,000 to £69,999	1	1

	This year £	Last year £
Please provide the total amount paid to key management	60,000	60,000

### 6.2 Average head count in the year

The parts of the charity in which the employees work

	This year Number	Last year Number
Fundraising	-	-
Charitable Activities	-	-
Governance	1	1
Other	-	-
<b>Total</b>	<b>1</b>	<b>1</b>

## NOTE 8: Creditors, deferred income and accruals

Please complete this note if the charity has any creditors or accruals.

### 8.1 Analysis of creditors, deferred income and accruals

	Amounts falling due within one year		Amounts falling due after more than one year	
	This year £	Last year £	This year £	Last year £
Accruals	23,425	3,000	-	-
Deferred income	36,943	-	-	-
Other creditors	370	370	-	-
<b>Total</b>	<b>60,738</b>	<b>3,370</b>	<b>-</b>	<b>-</b>

## NOTE 9: Cash at bank and in hand

	This year £	Last year £
Cash at bank and on hand	111,651	92,205
<b>Total</b>	<b>111,651</b>	<b>92,205</b>

## NOTE 10: Fair value of assets and liabilities

10.1 Please provide details of the charity's exposure to credit risk (the risk of incurring a loss due to a debtor not paying what is owed), liquidity risk (the risk of not being able to meet short term financial demands) and market risk (the risk that the value of an investment will fall due to changes in the market) arising from financial instruments to which the charity is exposed at the end of the reporting period and explain how the charity manages those risks.

Credit risk is low due to income being in the form of donations. Cash is the only investment so market risk is low on investment values falling. Liquidity risk is low as costs are managed in relation to income received.	Credit risk is minimal due to income being in the form of donations and there are extensions of credit. Cash is the only investment which is placed in standard bank current and deposit accounts, so market risk is low on investment values falling. Liquidity risk is low as cost expenditures are managed in relation to income received.
---	---

10.2 Please give details of the amount of change in the fair value of basic financial instruments (debtors, creditors, investments (see section 11, FRS 102 SORP)) measured at fair value through the SoFA that is attributable to changes in credit risk.

Not applicable	Not applicable
----------------	----------------

## NOTE 11: Charity funds

### 11.1 Details of material funds held and movements during the CURRENT reporting period

Please give details of the movements of material individual funds in the reporting period together with a balancing figure for 'Other funds' (which should include revaluation reserve and fair value reserve, if applicable). The 'Total funds' figure below should reconcile to 'Total funds' in the balance sheet.

\* Key: PE - permanent endowment funds; EE - expendable endowment funds; R - restricted income funds, including special trusts, of the charity; and U - unrestricted funds

Fund names	Type PE, EE R or UR *	Purpose and Restrictions	Fund balances brought forward £	Income £	Expenditure £	Transfers £	Gains and losses £	Fund balances carried forward £
General Fund	UR	General all purpose no restrictions	76,252	193,836	(232,654)	12,583	-	50,017
Restricted Fund	R	TNLCF - National Lottery Community Fund. Funding for Core Expenditure	-	36,943	(36,047)	-	-	896
Restricted Fund	R	Restricted for Showcase Project	12,583	-	-	(12,583)	-	-
<b>Total Funds as per balance sheet</b>			<b>88,835</b>	<b>230,779</b>	<b>(268,701)</b>	<b>-</b>	<b>-</b>	<b>50,913</b>

Fund balances carried forward include assets and liabilities denominated in a foreign currency  
 Yes\*  No\*

If yes, please state the basis on which the assets and/or liabilities have been translated into sterling (or the currency in which the accounts are drawn up).

--

### 11.2 Details of material funds held and movements during the PREVIOUS reporting period

Please give details of the movements of material individual funds in the reporting period together with a balancing figure for 'Other funds' (which should include revaluation reserve and fair value reserve, if applicable). The 'Total funds' figure below should reconcile to 'Total funds' in the balance sheet.

\* Key: PE - permanent endowment funds; EE - expendable endowment funds; R - restricted income funds, including special trusts, of the charity; and U - unrestricted funds

Fund names	Type PE, EE R or UR *	Purpose and Restrictions	Fund balances brought forward £	Income £	Expenditure £	Transfers £	Gains and losses £	Fund balances carried forward £
General Fund	UR	General all purpose no restrictions	110,289	153,708	(187,745)	-	-	76,252
Restricted Fund	R	Restricted for Showcase Project	-	22,890	(10,307)	-	-	12,583
<b>Total Funds as per balance sheet</b>			<b>110,289</b>	<b>176,598</b>	<b>(198,052)</b>	<b>-</b>	<b>-</b>	<b>88,835</b>

Fund balances carried forward include assets and liabilities denominated in a foreign currency  
 Yes\*  No\*

If yes, please state the basis on which the assets and/or liabilities have been translated into sterling (or the currency in which the accounts are drawn up).

## NOTE 12: Transactions with trustees and relates parties

If the charity has any transactions with related parties (other than the trustee expenses explained in guidance notes) details of such transactions should be provided in this note. If there are no transactions to report, please enter "True" in the box or "False" if there are transactions to report.

### 12.1 Trustee remuneration and benefits

This year

None of the trustees have been paid any remuneration or received any other benefits from an employment with their charity or a related entity (True or False)

TRUE

### 12.2 Trustees' expenses

If the charity has paid trustees expenses for fulfilling their duties, details of such transactions should be provided in this note. If there are no transactions to report, please enter "True" in the box below. If there are transactions to report, please enter "False".

No trustee expenses have been incurred (True or False)

TRUE

Type of expenses reimbursed	This year	Last year
	£	£
Travel	608	-
<b>TOTAL</b>	<b>608</b>	<b>-</b>

Please provide the number of trustees reimbursed for expenses or who had expenses paid by the charity

2

0

### 12.3 Transaction(s) with related parties

Please give details of any transaction undertaken by (or on behalf of) the charity in which a related party has a material interest, including where funds have been held as agent for related parties. If there are no such transactions, please enter 'true' in the box provided.

This year

There have been no related party transactions in the reporting period (True or False)

TRUE

Last year

There have been no related party transactions in the reporting period (True or False)

TRUE

# Administrative details

## TRUSTEES

Anne MacDowell  
Rebecca Porta  
Chair  
Vice Chair  
(until 25th September 2024)

Helen Morement  
Nic Puntis  
Christopher Walden  
Anna Evans  
Dr Max Brodermann  
Michael Draeger  
Sophie Davies  
(until 9th August 2024)

## EXECUTIVE OFFICERS

Baroness Delyth Morgan  
Jane Lyons  
President  
Chief Executive  
(until 15th July 2024)

## REGISTERED OFFICE

Cancer52, 124 City Road, London,  
EC1V 2NX

## WEBSITE

[www.cancer52.org.uk](http://www.cancer52.org.uk)

## BANKERS

Co-operative Bank

# References

- <sup>1</sup> National Cancer Registration and Analysis Service (NCRAS) by Public Health England figures. May 2019
- <sup>2</sup> Cancer Statistics for the UK. Cancer Research UK. Available: <https://www.cancerresearchuk.org/health-professional/cancer-statistics-for-the-uk#heading-Zero>.
- <sup>3</sup> Cancer52 membership research, conducted April 2019
- <sup>4</sup> 2024 Email marketing statistics compilation including open rates, clickthrough rates and click-to-open rates. Smart Insights. Available: <https://www.smartinsights.com/email-marketing/email-communications-strategy/statistics-sources-for-email-marketing/#q4>
- <sup>5</sup> Health and Social Care Select Committee - Future Cancer. Parliamentlive.tv. 21st June 2023. <https://parliamentlive.tv/Event/Index/5530cf3b-17c4-4142-a647-8600c7172409>
- <sup>6</sup> 10-Year Cancer Plan. Call for Evidence. Available: <https://www.gov.uk/government/consultations/10-year-cancer-plan-call-for-evidence>
- <sup>7</sup> Major Conditions Strategy. Call for Evidence. DHSC. <https://www.gov.uk/government/calls-for-evidence/major-conditions-strategy-call-for-evidence/major-conditions-strategy-call-for-evidence>
- <sup>8</sup> 10-Year Cancer Plan. Cancer52 response to the Call for Evidence. Available: [e22361\\_40a4fd86b9f64b2a8eba5697a4b07c51.pdf](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/100000/e22361_40a4fd86b9f64b2a8eba5697a4b07c51.pdf) (usrfiles.com)
- <sup>9</sup> Cancer52 Response to Major Conditions Strategy Framework. September 2023. Available: <https://www.cancer52.org.uk/single-post/cancer52-response-to-the-major-conditions-strategy-strategic-framework>
- <sup>10</sup> Cancer52. The Other Half. A manifesto to transform outcomes for people with rare and less common cancers. Available: [https://e2236186-a9de-45db-b8f6-3f2d6db40cb4.usrfiles.com/ugd/e22361\\_754a20aff7d14b7bab33be31fdb06b3b.pdf](https://www.cancer52.org.uk/other-half-a-manifesto-to-transform-outcomes-for-people-with-rare-and-less-common-cancers)
- <sup>11</sup> NHS Long Term Plan. Available: <https://www.longtermplan.nhs.uk/areas-of-work/cancer/>
- <sup>12</sup> PIF, Cancer52 and NRAS. Fair Market Survey 2023. Available: <https://pifonline.org.uk/resources/publications/fair-market-value-survey-findings/>
- <sup>13</sup> Together for Antibiotics. ABPI. Available: [https://www.togetherforantibiotics.org.uk/resources/?3b293f58a0d649e6a204d1476bc6a631\\_cat=Cancer52&3b293f58a0d649e6a204d1476bc6a631\\_page=1](https://www.togetherforantibiotics.org.uk/resources/?3b293f58a0d649e6a204d1476bc6a631_cat=Cancer52&3b293f58a0d649e6a204d1476bc6a631_page=1)
- <sup>14</sup> ABPI AMR: Resources (togetherforantibiotics.org.uk). Available: <https://www.togetherforantibiotics.org.uk/>

# List of charity members 2023/24

Act for Cancer

[www.actforcancer.org.uk](http://www.actforcancer.org.uk)

Action Against Heartburn

[www.actionagainstheartburn.org.uk](http://www.actionagainstheartburn.org.uk)

Action Bladder Cancer UK

[www.actionbladdercanceruk.org](http://www.actionbladdercanceruk.org)

Action Kidney Cancer

[www.kcsn.org.uk](http://www.kcsn.org.uk)

Action on Womb Cancer

[www.actiononwombcancer.org.uk](http://www.actiononwombcancer.org.uk)

Alike

[www.alike.org.uk](http://www.alike.org.uk)

ALK Positive Lung Cancer

[www.alkpositive.org.uk](http://www.alkpositive.org.uk)

AMMF – The Cholangiocarcinoma Charity

[www.ammf.org.uk](http://www.ammf.org.uk)

Anthony Nolan

[www.anthonynolan.org](http://www.anthonynolan.org)

Association for Multiple Endocrine Neoplasia Disorders (AMEND)

[www.amend.org.uk](http://www.amend.org.uk)

Baggy Trousers UK

[www.baggytrousersuk.org](http://www.baggytrousersuk.org)

Balls to Cancer

[www.ballstocancer.co.uk](http://www.ballstocancer.co.uk)

Barrett's Oesophagus UK

[www.barrettscampaign.org.uk](http://www.barrettscampaign.org.uk)

Blood Cancer UK

[www.bloodcancer.org.uk](http://www.bloodcancer.org.uk)

Bone Cancer Research Trust

[www.bcrct.org.uk](http://www.bcrct.org.uk)

Bowel Research UK

[www.bowelresearchuk.org](http://www.bowelresearchuk.org)

Brain Tumour Research

[www.braintumourresearch.org](http://www.braintumourresearch.org)

Brain Tumour Research Campaign (Wayahead)

[www.btrc-charity.org](http://www.btrc-charity.org)

Brainstrust

[www.brainstrust.org.uk](http://www.brainstrust.org.uk)

British Lymphology Society (BLS)

[www.thebls.com](http://www.thebls.com)

British Thyroid Foundation (BTF-thyroid)

[www.btf-thyroid.org](http://www.btf-thyroid.org)

Butterfly Thyroid Cancer Trust (BTCT)

[www.butterfly.org.uk](http://www.butterfly.org.uk)

Cancer Laryngectomy Trust

[www.cancerlt.org](http://www.cancerlt.org)

Cancer of Unknown Primary (CUP)

Foundation – Jo's friends

[www.cupfoundjo.org](http://www.cupfoundjo.org)

Cancer Support UK

[www.cancersupportuk.org](http://www.cancersupportuk.org)

Childhood Eye Cancer Trust (CHECT)

[www.chect.org.uk](http://www.chect.org.uk)

Children's Cancer and Leukaemia Group (CCLG)

[www.cclg.org.uk](http://www.cclg.org.uk)

Chordoma UK

[www.chordoma-uk.org](http://www.chordoma-uk.org)

Chris Lucas Trust

[www.chrislucastrust.com](http://www.chrislucastrust.com)

Chronic Myeloid Leukaemia (CML) Support Group UK

[www.cmlsupport.org.uk](http://www.cmlsupport.org.uk)

CLL Support Association

[www.clisupport.org.uk](http://www.clisupport.org.uk)

Debbie Fund

[www.debbiefund.org](http://www.debbiefund.org)

East Kent Cancer Cafe

EHE Rare Cancer Charity (UK)

[www.ehercc.org.uk](http://www.ehercc.org.uk)

Ellen MacArthur Cancer Trust  
[www.ellenmacarthurcancertrust.org](http://www.ellenmacarthurcancertrust.org)

Fight Bladder Cancer  
[www.fightbladdercancer.co.uk](http://www.fightbladdercancer.co.uk)

GIST Cancer UK  
[www.gistcancer.org.uk/](http://www.gistcancer.org.uk/)

Grace Kelly Childhood Cancer Trust  
[www.gkcct.org/](http://www.gkcct.org/)

GUTS Charity  
[www.gutscharity.org.uk](http://www.gutscharity.org.uk)

Heartburn Cancer UK  
[www.heartburncanceruk.org](http://www.heartburncanceruk.org)

HLRCC Family Alliance  
[www.hlrccinfo.org](http://www.hlrccinfo.org)

ICPV Independent Cancer Patients' Voice  
[www.icpv.org.uk](http://www.icpv.org.uk)

International Brain Tumour Alliance (IBTA)  
[www.theibta.org](http://www.theibta.org)

It's In The Bag Cancer Support Ltd  
[www.itsinthebag.org.uk](http://www.itsinthebag.org.uk)

It's on the Ball  
[www.itsontheball.org](http://www.itsontheball.org)

Jo's Cervical Cancer Trust  
[www.jostrust.org.uk](http://www.jostrust.org.uk)

Kidney Cancer UK  
[www.kcuk.org.uk](http://www.kcuk.org.uk)

Live Through This  
[www.livethroughthis.co.uk](http://www.livethroughthis.co.uk)

Leukaemia CARE  
[www.leukaemiacare.org.uk](http://www.leukaemiacare.org.uk)

Leukaemia UK  
[www.leukaemiauk.org.uk](http://www.leukaemiauk.org.uk)

London Asbestos Support Awareness Group  
[www.lasag.org.uk/](http://www.lasag.org.uk/)

Lymphoedema Support Network  
[www.lymphoedema.org](http://www.lymphoedema.org)

Lymphoma Action  
[www.lymphoma-action.org.uk](http://www.lymphoma-action.org.uk)

Maggie's Cancer Caring Centres – Maggie's Centres  
[www.maggiescentres.org](http://www.maggiescentres.org)

MDS (Myelodysplastic Syndromes) UK Patient Support Group  
[www.mdspatientsupport.org.uk](http://www.mdspatientsupport.org.uk)

Melanoma Focus  
[www.melanomafocus.com](http://www.melanomafocus.com)

Melanoma UK  
[www.melanomauk.org.uk](http://www.melanomauk.org.uk)

Mesothelioma UK  
[www.mesothelioma.uk.com](http://www.mesothelioma.uk.com)

Mind Over Cancer  
[www.mindovercancer.org.uk/](http://www.mindovercancer.org.uk/)

MPN Voice  
[www.mpnvoice.org.uk](http://www.mpnvoice.org.uk)

Mummy's Star  
[www.mummystar.org](http://www.mummystar.org)

Myeloma UK  
[www.myeloma.org.uk](http://www.myeloma.org.uk)

Neuroblastoma UK  
[www.neuroblastoma.org.uk](http://www.neuroblastoma.org.uk)

Neuroendocrine Cancer UK (NCCUK)  
[www.neuroendocrinecancer.org.uk](http://www.neuroendocrinecancer.org.uk)

North West Cancer Research  
[www.nwcr.org](http://www.nwcr.org)

OcuMel UK  
[www.ocumeluk.org](http://www.ocumeluk.org)

Odyssey  
[www.odyssey.org.uk](http://www.odyssey.org.uk)

Oracle Cancer Trust  
[www.oraclecancertrust.org](http://www.oraclecancertrust.org)

Orchid Cancer Appeal  
[www.orchid-cancer.org.uk](http://www.orchid-cancer.org.uk)

OUTpatients  
<https://outpatients.org.uk/>

Ovacome  
[www.ovacome.org.uk](http://www.ovacome.org.uk)

Ovarian Cancer Action  
[www.ovarian.org.uk](http://www.ovarian.org.uk)

Pancreatic Cancer Action  
[www.pancreaticcanceraction.org](http://www.pancreaticcanceraction.org)

Pancreatic Cancer UK (PCUK)  
[www.pancreaticcancer.org.uk](http://www.pancreaticcancer.org.uk)

Peaches Womb cancer Trust  
[www.peachestrust.org/](http://www.peachestrust.org/)

Pelvic Radiation Disease Association PRDA  
[www.prda.org.uk](http://www.prda.org.uk)

Penny Brohn UK  
[www.pennybrohn.org.uk](http://www.pennybrohn.org.uk)

PLANETS  
[www.planetscharity.org](http://www.planetscharity.org)

Pseudomyxoma Survivor  
[www.pseudomyxomasurvivor.org](http://www.pseudomyxomasurvivor.org)

Ruth Strauss Foundation  
[www.ruthstraussfoundation.com/](http://www.ruthstraussfoundation.com/)

Salivary Gland Cancer UK  
[www.salivaryglandcancer.uk](http://www.salivaryglandcancer.uk)

Sarcoma UK  
[www.sarcoma.org.uk](http://www.sarcoma.org.uk)

Shine Cancer Support  
[www.shinecancersupport.org](http://www.shinecancersupport.org)

Solving Kids' Cancer  
[www.solvingkidscancer.org.uk](http://www.solvingkidscancer.org.uk)

Swallows Head & Neck Cancer Charity  
[www.theswallows.org.uk](http://www.theswallows.org.uk)

Target Ovarian Cancer  
[www.targetovariancancer.org.uk](http://www.targetovariancancer.org.uk)

Team Margot Foundation  
[www.teammargot.com](http://www.teammargot.com)

Teenage Cancer Trust (TCT)  
[www.teenagecancertrust.org](http://www.teenagecancertrust.org)

The Bottom Line  
<https://bottomlinecharity.com/>

The Brain Tumour Charity  
[www.thebraintumourcharity.org](http://www.thebraintumourcharity.org)

The Charley Ashton Foundation

The Ella Dawson Foundation  
<https://www.elladawsonfoundation.org.uk/>

The Eve Appeal  
[www.eveappeal.org.uk](http://www.eveappeal.org.uk)

The Leanne Pero Foundation  
[www.theleanneperofoundation.com](http://www.theleanneperofoundation.com)

The Myrovlytis Trust  
[www.myrovlytistrust.org](http://www.myrovlytistrust.org)

The Northern Ireland Rare Disease Partnership  
[www.nirdp.org.uk](http://www.nirdp.org.uk)

The Robin Cancer Trust  
[www.therobincancertrust.org](http://www.therobincancertrust.org)

The Urology Foundation  
[www.theurologyfoundation.org](http://www.theurologyfoundation.org)

ThymicUK  
[www.thymicuk.org/](http://www.thymicuk.org/)

Thyroid Cancer Support Group Wales  
[www.thyroidsupportwales.co.uk](http://www.thyroidsupportwales.co.uk)

Tom Bowdidge Youth Cancer Foundation  
[www.tombowdidgefoundation.org](http://www.tombowdidgefoundation.org)

Trekstock  
[www.trekstock.com](http://www.trekstock.com)

UCARE  
[www.ucare-cancer.org.uk](http://www.ucare-cancer.org.uk)

UK Masto  
[www.ukmasto.org](http://www.ukmasto.org)

Urostomy Association  
[www.urostomyassociation.org.uk](http://www.urostomyassociation.org.uk)

VHL UK/Ireland  
[www.vhl-uk-ireland.org](http://www.vhl-uk-ireland.org)

Wellbeing of Women  
[www.wellbeingofwomen.org.uk](http://www.wellbeingofwomen.org.uk)

WMUK  
[www.wmuk.org.uk](http://www.wmuk.org.uk)

Womb Cancer Info  
[www.wombcancerinfo.wixsite.com/home](http://www.wombcancerinfo.wixsite.com/home)

Womb Cancer Support UK  
[www.wombcancersupportuk.weebly.com](http://www.wombcancersupportuk.weebly.com)

Worldwide Cancer Research  
[www.worldwidecancerresearch.org](http://www.worldwidecancerresearch.org)

Yorkshire Cancer Community  
[www.yorkshirecancercommunity.co.uk](http://www.yorkshirecancercommunity.co.uk)

Young Lives Vs. Cancer  
[www.younglivesvscancer.org.uk](http://www.younglivesvscancer.org.uk)

Young Tongues  
[www.youngtonguesglobal.com](http://www.youngtonguesglobal.com)



Cancer52 is registered as a charity in England and Wales, **Charity No. 1174569** and as a company limited by guarantee in England and Wales, **Company No. 07994413**

If we **work together**  
we can make as much noise as the big four



**CANCER 52**

England & Wales - Charity number 1174569

---

# Accounts

---

cancer52

# Annual Review

& Financial Statements

1 Apr 2022 – 31 Mar 2023

**Cancer52** is registered as a charity in England and Wales, **Charity No. 1174569** and as a company limited by guarantee in England and Wales, **Company No. 07994413**

**THE COMMON VOICE FOR  
RARE & LESS COMMON CANCERS**

[cancer52.org.uk](https://cancer52.org.uk)

# Contents

<b>LET'S MAKE SOME NOISE</b>	<b>3</b>	<b>FUNDING</b>	<b>14</b>
Foreword	3	The value of our support	14
Welcome to our Annual Review 2022–2023	3	Voluntary member donations	14
		Support from industry	14
<b>STRENGTH IN UNITY: OUR PRINCIPLES</b>	<b>4</b>	<b>FUTURE PLANS</b>	<b>15</b>
Our core principles	4		
<b>UNITING WITH ONE VOICE: WHO WE ARE</b>	<b>5</b>	<b>THE ACOUSTICS: STRUCTURE AND CONSTITUTION</b>	<b>16</b>
The Cancer52 team	5	Structure and governance	16
Our charity members	5	Purpose	16
		Public benefit	16
<b>MAKING THE CANCER52 VOICE HEARD</b>	<b>6</b>	Board and management operations and structure	17
Informing, advising and supporting our members	6		
<b>PARTNERSHIP: REPRESENTATION AND ADVOCACY IN POLICY</b>	<b>8</b>	<b>MONEY TALKS: FINANCIAL REVIEW</b>	<b>19</b>
<b>PARTNERSHIP: COLLABORATION ON BEHALF OF PATIENTS</b>	<b>10</b>	<b>INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF CANCER52</b>	<b>20</b>
Informing our stakeholders	12	Section A	22
		Section B	23
		Section C	24
<b>MAKING THE VOICE OF PEOPLE WITH RARE AND LESS COMMON CANCERS HEARD: OUR HEADLINE ACHIEVEMENTS FOR 2022–2023</b>	<b>13</b>	<b>INDEPENDENT EXAMINER'S REPORT ON THE ACCOUNTS</b>	<b>20</b>
Partnership	13		
Policy	13	<b>ADMINISTRATIVE DETAILS</b>	<b>35</b>
Patients	13	<b>LIST OF CHARITY MEMBERS 2022–2023</b>	<b>37</b>

# Let's make some noise:



Trustees Annual Report and Directors Report  
for the year ended 31st March 2023

## Foreword

Investment and improvement in cancer prevention, diagnosis, treatment and public education programmes has radically changed the outlook for so many patients and their families. Yet despite these important advances, 55% of all UK cancer deaths are from rare and less common cancers. These cancers continue to remain severely under-represented and under-funded across all areas, including policy, services and research.

**Cancer52** is committed to driving change and to improving the outlook for patients and their families. Together with our 111 member charities, policy and decision makers, industry, and those with an interest in rare and less common cancers, we have worked tirelessly during the year to deliver our plans and ambitions for further expansion, widening influence and driving change.

We are incredibly proud of the progress we have made during the year from providing opportunities for our members to showcase their work to participating in strategies on the future of cancer care. Building on these achievements, we look forward to an exciting year ahead.



Rebecca Porta,  
Interim Chair

Our work and progress is only possible because of the support of our rare and less common cancer community. The Trustees and I would like to thank everyone who has contributed towards our efforts and success and in particular our CEO, Jane Lyons and the team for their dedication and commitment.

*Rebecca Porta*

## Welcome to our Annual Review 2022–2023

I'm proud to introduce our Annual Review for the financial year 2022–2023. Throughout the year, the charity has continued to grow, both in terms of its membership and influence. The organisation has used this influence to work with a widening group of stakeholders to deliver ever more ambitious projects.

Core to **Cancer52's** work are the three Ps: **Patients** – building the voice of people affected by rare and less common cancer, **Policy** – ensuring that, together we are heard at the highest level, and **Partnership** – ensuring that we meet challenges and take the opportunities that cross-working enables. It is **Cancer52's** successful collaborations that have allowed it to adapt to new and shifting challenges.

This year, tackling inequalities became essential in everything we set out to do. We know that having a rare or less common cancer is an inequality in itself. Yet people with rare and less common cancers can experience further inequalities based on factors such as age, region, socioeconomic group, ethnicity, and sexual orientation.

With the help of our many members – currently 111 – we will continue to deliver projects and activities that help reduce the inequalities faced by people with a rare or less common cancer.



Jane Lyons, CEO

*Jane Lyons*



# Strength in unity: our principles

**Cancer52** is a national organisation, created in 2007 by Professor Sir Mike Richards, CBE, then National Clinical Director for Cancer, and registered as a charity in England and Wales in September 2017.

We are the unifying body for charitable and not-for-profit organisations working in the field of rare and less common cancers. Currently we represent 111, predominantly small, patient-support and research-focused cancer charities and organisations.

**Cancer52** gets its name from when rare and less common cancers accounted for 52% of all cancer deaths in the UK, despite the fact that only 47% of cancers diagnosed in England are of this type.<sup>1</sup> In 2020, this shifted to 47% of diagnoses yet 55% of cancer deaths.<sup>2</sup>

Our member charities and organisations are united in seeking a better future for everyone affected by rare and less common cancers. We provide a collective voice to champion earlier diagnosis, better treatment, better representation, funding and support for people with cancers other than the four most common cancers (breast, lung, bowel and prostate). **Cancer52** ensures the voices of people with less common cancers do not go unheard.



## Our core principles

### Our aim

**Cancer52's primary aim is to promote improved diagnosis, treatment and support for those affected by rare and less common cancers.**

### Our mission

**Cancer52's mission is to provide a strong, unified voice for rare and less common cancer organisations by representing, speaking, informing, sharing and involving our members in achieving our vision.**

### Our vision

**Cancer52's vision is to end inequalities in diagnosis, treatment and patient outcomes experienced by those with rare and less common cancers compared with the four most common cancers.**

### Our values

**Everything Cancer52 does is underpinned by the aim to be:**  
ambitious | outcomes-focused |  
collaborative | evidence-based | influential  
and to behave with honesty and integrity.

# Uniting with one voice: who we are

**Cancer52 aims to better represent people with rare and less common cancers at a senior policy and decision-making level. Sourcing and bringing together the knowledge and expertise of our many members makes this possible.**

## **The Cancer52 team**

During the year ending 31 March 2023, the core team consisted of:

- **Jane Lyons, CEO:** Responsible for the overall running of the charity.
- **Ainsley Taylor, Operations Manager:** Supporting the CEO on governance, finance, fundraising, administration and the co-ordination of membership donations, recruitment, and supporting the Trustees.
- **Stephanie Judycki, Communications Executive:** Leads on internal and external communications including member e-bulletins, Cancer52 website, and social media.

Our Board of Trustees is listed on page 27.

Brighter Together Consulting worked for Cancer52 on policy and Jason Dennis was our Accountant.

Thanks to you all for your hard work and dedication.

## **Our charity members**

**Cancer52's** members are united in their determination to improve treatment and outcomes for their individual patient groups.

The majority of **Cancer52's** member organisations are small – 65% have an annual income of less than £1 million – with 57% of those having an income of £500,000 and 25% an income of less than £100,000. Almost all our members offer patient support and over two-thirds invest in research.<sup>3</sup>

The full list of **Cancer52's** members at time of going to press can be seen on page 37.

**Cancer52's** active membership continues to grow. During the 2022–23 financial year, we happily welcomed Mind Over Cancer, London Asbestos Support Awareness Group, Cancer Support UK, East Kent Cancer Café, and Peaches Womb Cancer Trust.

We hugely value and appreciate our members' ongoing dedication and commitment to **Cancer52**.

# Making the Cancer52 voice heard

**Cancer52 works tirelessly to support people with rare and less common cancers and to ensure a strong presence in this community.**

- We are represented at the highest level on boards and taskforces.
- We value close teamwork and collaboration.
- We use a range of skills and methods within a flexible structure to help members support patients.

## Informing, advising and supporting our members

### Meeting with our members

Virtual meetings continue to play an important part in our work as they allow our member charities and organisations from across the country to voice their concerns, connect, quickly and easily share information and **hear from thought leaders in the field of rare and less common cancers.**



# 459

**individuals attended All Member Meetings, an increase of 22% on the previous year**



# 183

**attended a working group meeting**



# 200+

**attendance at our monthly CEO meetings**

**All figures represent steady increases on the previous year.**

## Sharing

We want everyone with rare and less common cancers to have the chance to be best supported and make informed choices. We consistently encourage our members to exchange knowledge so that even those supported by charities with limited resources have access to a continuing flow of useful information.

People with cancer are best supported when charities collaborate to make the most of the resources available and do not duplicate efforts. We know that a collaborative voice is a stronger voice.

### Regular members' e-bulletin

- Developments in Government and NHS policy pertinent to cancer
- Dates and details of Cancer52 meetings and meetings of member charities or national organisations
- Information for patients
- Opportunities to get involved with projects that support people with rare and less common cancers
- Patient surveys
- Projects where members wanted to share learning or to raise awareness
- Member and NHS Cancer Programme job opportunities
- Training courses
- NHS and other cancer charity webinars

The open rate for our e-bulletin increased from an already high average of 43% to 59% in March 2023. This is nearly three times more than the market average open rate for newsletter emails.<sup>4</sup> It is clear that our members prize our bulletins as a useful and efficient way of informing their patients of critical events and developments.

### Cancer52 All Member Meetings

Fortnightly virtual meetings continued throughout the financial year. They offered crucial networking opportunities and the chance to help patients by learning from a fantastic calibre of interesting and thought-provoking speakers. Meetings were well attended and warmly welcomed.

*'Thank you for everything you do to bring our community together.'*

Lydia Makaroff, CEO, Fight Bladder Cancer

The meetings are great relationship builders and boost the profile of people with rare and less common cancers.

*'We are very grateful for all the work that you do in shining the light on rare cancers.'*

Karen Ruddock, Founder, ThymicUK

### CEO Calls and Meetings

Monthly video calls provide member CEOs direct access to their peers. Started during the COVID-19 pandemic, these meetings have continued to be incredibly valuable opportunities to raise problems, talk through ideas, share best practice and offer peer support.

### Working Groups

Cancer52's working groups help members who face similar challenges in supporting people with cancer.

*'I've really been so super impressed with the amount of activity generated from Cancer52 which I know comes from you and your small team. Whereas to begin with I struggled a bit to find the relevance and applicability to my charity given we're childhood cancer focused, and further still, disease specific within that – I've experienced a shift and change there and so much of what you are doing is both relatable and helpful to me in my role as CEO and to my wider charity.'*

Gail Jackson, CEO, Solving Kids' Cancer

New groups examined cancer-related menopause, health inequalities, irritable bowel syndrome (IBS) by way of misdiagnosis, and the NHS website cancer pages.

### The Showcase Video project

The Showcase Video project was inspired by the incredible commitment Cancer52's members showed in pulling out all the stops to meet the needs of the people they supported during the COVID-19 pandemic. The video shared:

- The pandemic's impact on members' work
- How they rose to the challenge
- How they used these solutions to improve their way of working post pandemic

Using grants awarded by Pfizer UK and Ipsen, 26 members were interviewed and filmed to showcase how their organisations pivoted to overcome challenges and better support those affected by rare and less common cancers.

**Cancer52** wanted to show what has and continues to be achieved, and so inspire others in the cancer community.

**Cancer52** produced a full **30 minute video**, plus **three minute video** including all participant charities.<sup>5</sup> Furthermore there were individual personalised video clips for each charity to share with their patients, supporters and funders.

On 14th September 2022, the **Cancer52** team was delighted to host a screening of the full 30 minute Showcase Video in Soho, London, bringing together all who had been involved to celebrate what had been achieved for patients.



## Partnership: Representation and advocacy in policy

**Cancer52** represents its members at the highest policy and decision-making level and acts as a conduit to organisations that need to hear the patient voice of people with rare and less common cancers. As a strong and determined alliance, we can make more noise about the need for improvements in cancer services, including those supported by our member charities.

During 2022–2023, **Cancer52** was invited to sit on several NHS England (NHSE) boards and groups where we used our influence to oversee, advise on and implement changes for those affected by cancer.

### House of Commons Health and Social Care Select Committee

**Cancer52** responded to two Health and Social Care Select Committee Inquiries: Cancer Services, and Clearing the Backlog Caused by the Pandemic.<sup>6</sup> **Cancer52**'s CEO, Jane Lyons,

contributed evidence at an oral hearing of the inquiry into cancer services. The Committee's report into Cancer Services made key recommendations using **Cancer52**'s evidence, including calling for an action plan for rare and less common cancers.<sup>7,8</sup>

## 10-Year Cancer Plan

Early in 2022, the Department of Health and Social Care (DHSC) launched a call for evidence for the 10-Year Cancer Plan.<sup>9</sup>

**Cancer52** led the pan cancer charity collaboration, worked with members (including surveying members online) and other charities to help draft a response and attended various evidence-gathering meetings hosted by the DHSC. To bring the views of people with rare and less common cancers into the spotlight, we commissioned a patient survey and incorporated the findings from 259 patients into the **Cancer52** response.<sup>10</sup>

On 24th January 2023, the Department announced that instead of the 10-Year Cancer Plan, a Major Conditions Strategy, would cover six major conditions, including cancer.<sup>11</sup> Fortunately, the original Cancer Plan call for evidence responses will be absorbed and taken into account in this new Strategy. In early 2023, **Cancer52** met the then Cancer Minister Helen Whatley MP; and took part in Major Conditions Strategy roundtables to ensure that rare and less common cancers did not slip down the priority list as the health system looks at six major conditions under one plan.

## Cancer charities

In order to maximise impact for people living with cancer, **Cancer52** also works collaboratively with many charities outside its direct membership.

A key example of this is the One Cancer Voice (OCV) initiative where over 50 charities work together on fundamental policy asks, such as investing in the workforce that helps people with cancer, and increasing spend on diagnostics. **Cancer52** sits on the steering group, instigated and provided the structure and pro bono time to develop the 10-Year Cancer Plan call for evidence, which is now helping to inform the current Major Conditions Strategy.<sup>12</sup>

## Cancer52 Policy and Public Affairs Steering Group

**Cancer52's** Policy and Public Affairs Steering Group (PPASG) met frequently to exchange information and help formulate **Cancer52's** policy asks. They helped to inform responses to the 10-Year Cancer Plan call for evidence and Health and Social Care Select Committee inquiries. During 2022–2023 this group was chaired by Chris Walden, **Cancer52** Trustee and Deputy Director of Policy, Campaigns and Engagement at Blood Cancer UK, with vice chair Bradley Price, Policy and Public Affairs Manager of Sarcoma UK.

## Cancer52 Access to Medicines Working Group

The objective of **Cancer52's** Access to Medicines Working Group is to ensure the role patients play in The National Institute for Health and Care Excellence (NICE) processes and the patient voice is heard at NICE. This group convenes whenever there are issues that have an impact on **Cancer52** members.

# Partnership: Collaboration on behalf of patients

## Working collaboratively across the NHS

### WORKING WITH THE NHS CANCER PROGRAMME

#### NHSE National Cancer Board

Alongside Cancer Research UK and Macmillan Cancer Support, **Cancer52** has a place on the NHSE National Cancer Board. Together we provide strategic leadership across the healthcare sector in delivering the cancer ambitions inside the NHS Long Term Plan.<sup>13</sup>

**Cancer52** also holds a place on the following NHSE cancer programme groups:

- Cancer Campaigns Oversight Group
- Early Detection Task and Finish Group
- The Cancer Patient Experience Survey Advisory Group
- The Cancer Patient Experience Survey Reporting Sub Group
- Cancer Data and Analytics Advisory Group (CDAAG)
- and chairs the quarterly NHSE Cancer Charity Forum

#### NHSE Cancer Psychosocial Support

**Cancer52** recognises the importance of improving psychosocial support for cancer patients. In addition to contributing to the NHSE Cancer Psychosocial Task Force, **Cancer52** spoke at, ran sessions and had a stand at a large one-day NHSE Cancer Psychosocial Task Force Conference in London on 6th December 2022.

The conference worked to improve psychosocial support for cancer patients by linking up the NHS Cancer Alliances to the support provided by charities. Member charities that were provided

with a platform at the event via **Cancer52** were: Neuroendocrine Cancer UK, Pancreatic Cancer UK, Jo's Cervical Cancer Trust, Young Lives vs Cancer, Kidney Cancer UK, Brainstrust, Mesothelioma UK, Cancer Support UK, and Ovacom.



**Dr Helen Bulbeck,**  
**Co-founder, Brainstrust.**

#### NHSE's national *Help Us, Help You* Campaign

In order to boost symptom awareness, **Cancer52** led on a programme to extend the impact of *Help Us, Help you* by working with member charities to target traditionally hard-to-reach communities and areas of high deprivation. Working to raise awareness of potential symptoms of urinal and abdominal cancers, with the aim of improving diagnosis rates, groups from member charities – including The Urology Foundation, Target Ovarian Cancer, Ovacom, UCARE, and Wellbeing of Women – ran successful events with co-branded NHS and charity assets at locations such as gyms, libraries, mosques and shopping centres.



## Working collaboratively across the wider cancer community

**Cancer52** worked closely with the UK cancer community to amplify the voice of people with rare and less common cancers.

### Charity Medicines Access Coalition (CMAC)

Many people need quicker access to new and innovative medicines. The CMAC, an umbrella group of charities, works to find a long-term solution to this problem. A key achievement was setting out a shared vision voluntary scheme for branded medicines pricing and access (VPAS).

**Cancer52** joined forces with CMAC and the Blood Cancer Alliance with the aim of ensuring people and communities benefit from new treatments, the NHS makes best use of its budget and the UK is an attractive location for global life science research investment. Together nearly 200 charities were represented and a call made for six key tests to be met under the next VPAS scheme within the 'Voluntary scheme for branded medicines pricing and access (VPAS) – charity joint statement'.<sup>14</sup>



### Children and Young People Cancer Coalition

Many of our member charities support children and young people with cancer and these charities have together formed the Children and Young People Cancer Coalition. **Cancer52** sits on the steering group and supports the work of charities in this field.

### National Voices

This wide-ranging coalition of healthcare charities helps **Cancer52** engage where topics are particularly relevant to people with rare and less common cancers.

### Specialised Healthcare Alliance

This Alliance campaigns on behalf of those with rare and complex conditions. **Cancer52** is a member and attends briefings on wider topics affecting people with rare cancers.

### The Association of the British Pharmaceutical Industry (ABPI)

**Cancer52**'s CEO sat on the Advisory Council for the first 18 months of its inception. The CEO also sat on the steering group that plans the meetings and organises speakers for the Patient Organisation Forum briefings.

In 2022 **Cancer52** worked with the ABPI on a further Anti-Microbial Resistance campaign specific to people living with rare and less common cancers called Together for Antibiotics.<sup>14,15</sup>

### Signposting across patient information

**Cancer52** has led work that helps patients and their loved ones to access patient information and patient support that is relevant to their cancer type. **Cancer52** has worked with both the NHS and Macmillan Cancer Support to initiate new links with their online patient information to signpost to smaller charities focused on rare and less common cancers.

## Informing our stakeholders

As an organisation, and also as our members' representatives, **Cancer52** is in ongoing communication with members of other charities, NHS professionals and administrators, and anyone who has influence in the rare and less common cancer field.

### Cancer52 Annual Stakeholder Event

The Annual All Stakeholder Event took place on 12th October 2022, in central London with the theme of inequalities – *Taking Action on Inequalities in Rare and Less Common Cancers*. Following an inspiring keynote speech by Professor Bola Owolabi, Director of Health Inequalities at NHS England and NHS Improvement, Yaser Martini of member charity, Team Margot, gave a deeply personal account of inequalities in care as he spoke of his late daughter, Margot's experience.

Will Quince MP, Minister of State at DHSC and the Government lead for cancer also joined the event where **Cancer52** members Ovacom, Young Lives vs Cancer and Trekstock provided informative case studies on reducing inequalities. Jodie Moffat, Deputy Director – Policy and Strategy, from NHSE Cancer Programme also spoke. Our thanks to our Inequalities Working Group chair, Sonia Malik, Head of Policy and Influencing at Young Lives vs Cancer who chaired the day long event.

## Website

The **Cancer52** website acts as a central point for information and spreads the message that patient experience, treatment and outcomes will only improve with more time, money and effort focused on coping with rare and less common cancers.

The website links to all member organisations, plus the sponsors and groups **Cancer52** collaborates with, offering a useful portal for sharing information between members, patients, and the general public. **Cancer52** posted reports on its activities during the year and featured a news stream of prominent issues.

Website users can access reports together with informative videos, contact and donation opportunities.

## Social media

**Cancer52** has been especially active this year on Facebook and Twitter, and has added a LinkedIn page, gathering over 3,000 followers across these social media channels. **Cancer52** uses social media to communicate with members and the wider public, to distribute new information and to react to events that impact the rare and less common cancer community.



Professor Bola Owolabi



Will Quince MP



Yaser Martini



# Making the voice of people with rare and less common cancers heard: our headline achievements for 2022–2023

## Partnership

### Informing, sharing with, and empowering our members

**Cancer52** membership and engagement levels have increased significantly in 2022–2023. We are grateful for the engagement and significant positive feedback from our members. This confirms that our redoubled efforts to improve our communications through our e-bulletins, All Member Meetings, CEO calls and meetings, group meetings, patient surveys, CEO survey and CEO briefings have been well received.

## Policy

### Responding collectively to the changing political cancer priorities

**Cancer52** continues to work alongside the NHSE Cancer Programme to improve outcomes for those with rare and less common cancers and to meet the early diagnosis target of diagnosing 75% of all cancers at stage I and II by 2028. We also worked collaboratively with our members and the wider cancer charity community to respond effectively to the Government's 10-year Cancer Plan Call for Evidence, which will now be used to input into the Government's Major Conditions Strategy.

## Patients

### Advocating for those affected by rare and less common cancers through collaboration

**Cancer52** continues to consistently take the shared patient voice to influencers and policy decision makers. In communities we facilitated work to provide information on lesser known cancer symptoms to people within areas of high socioeconomic deprivation, with the aim of improving earlier diagnosis rates for groups that traditionally can be harder to reach.



# Funding

In 2022–2023, **Cancer52** received funding from a variety of sources: donations from members; individual donations; and support from pharmaceutical companies.

## The value of our support

We appreciate the valuable time, expertise and energy generously donated by our members.

**Cancer52** is hugely grateful to every donor and supporter for their financial support which helps propel us towards achieving our objectives. Our charity members represent a very significant contribution in terms of the number and variety of organisations that support **Cancer52** financially.

## Voluntary member donations

The vast majority of our financial supporters are our member charities from whom we request a voluntary donation aligned to their income.

In this financial year membership donations totalled a record £33,280 from 62 member charities. **Cancer52** asked all members to pay a donation where possible but were considerate of those smaller charities encountering the lasting impact of the Covid-19 pandemic and the rising cost of living. Membership donations for 2022/23 exceeded those of 2021/22.

## Individual donations

Donations are welcome from any individuals or organisations who recognise the value of our contribution to supporting people with rare and less common cancers.

During the financial year 2022–23, **Cancer52** received almost £18,000 from a variety of platforms and individuals. Of particular note we thank the family and friends of Lucien Seller for their fundraising in Cardiff and Swansea, and Minister Will Quince MP for running the Brighton Marathon on behalf of **Cancer52**.

## Support from industry

In 2022–2023 we received support from Abbvie, Gilead, GSK, Janssen, Merck, Roche, Sanofi and Takeda, who all all joined **Cancer52**'s Corporate Supporter Programme.

**Cancer52** has a clear, written policy to guide its work with the pharmaceutical industry and also abides by industry guidelines.<sup>15</sup> Some 58.9% of our funding comes from pharmaceutical companies and comprises support for specific projects as well as unrestricted support.

**Cancer52** believes all our industry partners recognise the value of working with an umbrella body that channels one voice for rare and less common cancers.



# Future plans

**Cancer52 is proud of its achievements during this year, our major objectives prevail and we will take them forward into 2023–2024.**

**We will provide a strong, unified voice to promote improved diagnosis, treatment and support for those affected by rare and less common cancers so that we see an end to inequalities in diagnosis, treatment and patient outcomes experienced by those with these challenging diseases.**

**As part of its three-year strategy, Cancer52 has made progress in its plans to:**

Retain its market leadership position, build its thought leadership and increase its collaborative work with the wider rare and less common cancer community.

Retain its focus on its aim, mission and values

Place reducing inequalities at the heart of everything it does.

Be a well-resourced organisation making the voice of rare and less common cancers heard wherever decisions are taken on the treatment and care of people with these cancers.

# The acoustics: structure and constitution




## Structure and governance

**Cancer52** is incorporated as a charitable company limited by guarantee and is a registered charity in England and Wales. It is governed by its Memorandum and Articles of Association, and its work, management, finances and strategy are overseen by a Board of Trustees, who are also the company directors. The Trustees who held office during the financial year and at the date of the report are set out on page 35.

Under the Articles of Association, a minimum of three trustees and a maximum of twelve trustees can be in office. At Annual General Meetings, one-third of the existing directors must retire by rotation based on the longest serving directors retiring first. Retiring directors may be re-appointed at Annual General Meetings by the vote of existing directors. New directors may only be appointed at Annual General Meetings where the notice and approval requirements set out in the Articles of Association have been satisfied.

The Board has agreed that the usual term of tenure for trustees should be a maximum of two terms of three years each (six years in total), with review and approval by the Board at the end of each term of tenure. In exceptional circumstances, and in order not to lose important or valuable skills, experience and expertise, trustees may serve for a third term of tenure, subject to the approval of the Board. Trustees do not receive remuneration for their duties.



## Purpose

The charity's purposes are set out in its Memorandum and Articles of Association as follows:

To promote and protect the health of people with rare and less common cancers by:

1. Advancing and promoting understanding, awareness, research and learning about rare and less common cancers;
2. Acting as a collective voice and advocating for the needs of individuals affected by a rare or less common cancer in order to improve diagnosis, treatment and long-term support outcomes
3. Supporting, representing and empowering not-for-profit organisations working in the field of rare and less common cancers.

## Public benefit

Interaction and collaboration between **Cancer52's** members delivers public benefit by providing information and support to people diagnosed with, treated for or living with a rare or less common cancer. Outcomes for people with rare or less common cancers are also improved when we drive change and enhancements in the cancer system.

As part of our business planning processes, we review our aims and objectives each year. This includes looking at how we benefited those groups of people we were set up to help and what we achieved in previous years. We refer to the Charity Commission's general guidance on public benefit when reviewing our aims and objectives and in planning our work for the future.

## Board and management operations and structure

### Board of Trustees

The Board of Trustees meets at least four times a year to review **Cancer52's** work, finances and services, and to agree strategic goals for the charity. In-person board meetings resumed in 2022–23 with a virtual option, and meetings invited the Chief Executive and the Operations Manager and others as appropriate.

The Chair and other trustees with financial expertise also meet separately with the Chief Executive, Operations Manager, and **Cancer52's** accountant on a quarterly basis to monitor and scrutinise the financial strategy and operations and make any necessary recommendations to the full Board of Trustees.

### Recruitment and appointment of new Trustees

Jonathan Pearce, Chair of the Board for over seven years stood down at the start of the financial year, whilst continuing to act as Trustee. Rebecca Porta, CEO of The Urology Foundation and a long-standing Board Member, stepped in as Interim Chair, with the support of Helen Morement, CEO of AMMF and also a long-standing Board Member. A replacement Chair is being recruited.

### Related parties

Related parties are considered to be the trustees and those connected with the trustees, including their close families, business and other charity interests. There have been no transactions with

related parties, other than the reimbursement of reasonable travel expenses for the purposes of attendance at Board meetings and other relevant organisational activities.

## Risk assessment and management

The Board of Trustees and the Chief Executive maintain a risk register and assess risk on an annual basis. The trustees are satisfied that major risks to the organisation have been accurately identified and that appropriate systems and procedures for managing those risks are in place.

## Safeguarding

**Cancer52** has a strong commitment to protecting and promoting the health, wellbeing and safety of all engaged in our work. While we are not a patient representative charity, we still adhere to good safeguarding practice. Our Safeguarding Policy is reviewed each year and is accessible on the Governance section of our website. All new staff and volunteers are required to participate in a full day safeguarding training course, provided by an external organisation, and this is undertaken annually to ensure staff and volunteers are up to date with training.

**Cancer52** has sought to strengthen our risk management training this year and all employees are required to take General Data Protection Regulation (GDPR) training.

## Annual review

The Annual Review 2022–2023 was completed and disseminated, with thanks to the Board nominees Chris Walden and Helen Morement.



# cancer52

the common voice for  
rare & less common cancers



# Money talks: financial review 2022–2023

## Financial statement

As shown in the statement of financial activities on the following pages, in the year 2022–2023

- Reserves brought forward from 2021–2022 were £110,289.
- Income for the financial year was £176,598.
- Expenditure for the current financial year was £198,052, resulting in an anticipated deficit of £21,454.
- Reserves of £88,835 were available at the end of the 2022–2023 financial year.

### Reserves policy

The Board of Trustees' strategy on reserves is for the organisation to maintain sufficient funds to cover the operational running costs in the event of a major setback. This means that we aim to hold approximately six months' annual expenditure in reserve.

At the end of the 2022–2023 financial year, our reserves stood at £88,835, which adequately covers the six months required.

The Company has taken advantage of the small companies' exemption in preparing this report. The trustees declare that they have approved the trustees' report (including directors' report) above.

### Signed on behalf of the charity's trustees/directors

Signature \_\_\_\_\_

Rebecca Porta

*Trustee / Director*

Date \_\_\_\_\_

Signature \_\_\_\_\_

Nic Puntis

*Trustee / Director*

Date \_\_\_\_\_



**Section A Independent Examiner's Report**

**Report to the trustees/directors/ members of**

Cancer 52

**On accounts for the year ended**

31<sup>st</sup> March 2023

<b>Charity no.:</b>	1174569	<b>Company no.:</b>	07994413
---------------------	---------	---------------------	----------

**Set out on pages**

**22 To 34**

I report to the charity trustees on my examination of the accounts of the Company for the year ended **31<sup>st</sup> March 2023**.

**Responsibilities and basis of report**

As the charity's trustees of the Company (who are also the directors of the company for the purposes of company law), you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ("the 2006 Act").

Having satisfied myself that the accounts of the Company are not required to be audited for this year under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ("the 2011 Act"). In carrying out my examination, I have followed the Directions given by the Charity Commission (under section 145(5)(b) of the 2011 Act.

**Independent examiner's statement**

I have completed my examination. I confirm that no material matters have come to my attention (other than that disclosed below \*) which gives me cause to believe that:

- accounting records were not kept in accordance with section 386 of the Companies Act 2006; or
- the accounts do not accord with such records; or
- the accounts do not comply with relevant accounting requirements under section 396 of the Companies Act 2006 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
- the accounts have not been prepared in accordance with the Charities SORP (FRS102).

**Name:** Jason Dennis

**Relevant professional qualification(s) or body (if any):** AAT - Association of Accounting Technicians  
ATT – Association of Taxation Technicians

**Address:** 31 Clover Way, Paddock Wood, Tonbridge, Kent TN12 6BQ

**Section B Disclosure**

Only complete if the examiner needs to highlight material matters of concern (see CC32, Independent examination of charity accounts: directions and guidance for examiners).

**Give here brief details of any items that the examiner wishes to disclose.**

[Empty box for disclosure details]

# Section A

## Statement of financial activities

(including summary income and expenditure account)

Recommended categories by activity	Guidance	Unrestricted	Restricted	Endowment	Total funds	Prior year
		funds	income funds	funds	£	funds
		£	£	£	£	£
		F01	F02	F03	F04	F05
<b>Income (Note 3)</b>						
<b>Income and endowments from:</b>						
Donations and legacies	S01	153,708	22,890	-	176,598	144,709
<b>Total</b>	S07	153,708	22,890	-	176,598	144,709
<b>Expenditure (Notes 4)</b>						
<b>Expenditure on:</b>						
Raising funds	S08	23,566	-	-	23,566	-
Charitable activities	S09	161,179	10,307	-	171,486	148,750
Other	S11	3,000	-	-	3,000	2,400
<b>Total</b>	S12	187,745	10,307	-	198,052	151,150
<b>Net income/(expenditure) before tax for the reporting period</b>	S13	(34,037)	12,583	-	(21,454)	(6,441)
Tax payable	S14	-	-	-	-	-
<b>Net income/(expenditure) after tax before investment gains/(losses)</b>	S15	(34,037)	12,583	-	(21,454)	(6,441)
Net gains/(losses) on investments	S16	-	-	-	-	-
<b>Net income/(expenditure)</b>	S17	(34,037)	12,583	-	(21,454)	(6,441)
<b>Extraordinary items</b>	S18	-	-	-	-	-
<b>Transfers between funds</b>	S19	-	-	-	-	-
<b>Other recognised gains/(losses):</b>						
Gains and losses on revaluation of fixed assets for the charity's own use	S20	-	-	-	-	-
Other gains/(losses)	S21	-	-	-	-	-
<b>Net movement in funds</b>	S22	(34,037)	12,583	-	(21,454)	(6,441)
<b>Reconciliation of funds:</b>						
Total funds brought forward	S23	110,289	-	-	110,289	116,730
<b>Total funds carried forward</b>	S24	76,252	12,583	-	88,835	110,289

# Section B

## Balance sheet (as at 31st March 2023)

	Guidance	Unrestricted funds £	Restricted income funds £	Endowment funds £	Total this year £	Total last year £
<b>Current assets</b>						
Cash at bank and in hand (Note 8)	B09	79,622	12,583	-	92,205	135,949
<b>Total current assets</b>	B10	79,622	12,583	-	92,205	135,949
<b>Creditors: amounts falling due within one year (Note 7)</b>						
	B11	3,370	-	-	3,370	25,660
<b>Net current assets/(liabilities)</b>	B12	76,252	12,583	-	88,835	110,289
<b>Total assets less current liabilities</b>	B13	76,252	12,583	-	88,835	110,289
<b>Total net assets or liabilities</b>	B16	76,252	12,583	-	88,835	110,289
<b>Funds of the Charity</b>						
Endowment funds	B17	-	-	-	-	-
Restricted income funds (Note 10)	B18	-	12,583	-	12,583	-
Unrestricted funds	B19	76,252	-	-	76,252	110,289
Revaluation reserve	B20	-	-	-	-	-
Fair value reserve	B21	-	-	-	-	-
<b>Total funds</b>	B22	76,252	12,583	-	88,835	110,289

*The company was entitled to exemption from audit under s477 of the Companies Act 2006 relating to small companies.*

*The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.*

*The directors acknowledge their responsibilities for complying with the requirements of the Companies Act with respect to accounting records and the preparation of accounts.*

*These accounts have been prepared in accordance with the provisions applicable to small companies subject to the small companies regime and in accordance with FRS102 SORP.*

Signed by one or two trustee/directors on behalf of all the trustees/directors

Name	Signature	Date of approval dd/mm/yyyy
Rebecca Porta		
Nic Puntis		

Signature of director authenticating accounts being sent to Companies House

Name	Signature	Date of approval dd/mm/yyyy
Rebecca Porta		

# Section C

## Notes to the accounts

### NOTE 1: Basis of preparation

#### 1.1 Basis of accounting

These accounts have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant note(s) to these accounts.

The accounts have been prepared in accordance with:

- and with\*  the Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued on 16 July 2014
- and with\*  the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102)
- and with the Charities Act 2011.

The charity constitutes a public benefit entity as defined by FRS 102.\*

\* -Tick as appropriate

#### 1.2 Going concern

**If there are material uncertainties related to events or conditions that cast significant doubt on the charity's ability to continue as a going concern, please provide the following details or state "Not applicable", if appropriate:**

An explanation as to those factors that support the conclusion that the charity is a going concern;

**Not applicable**

Disclosure of any uncertainties that make the going concern assumption doubtful;

**Not applicable**

Where accounts are not prepared on a going concern basis, please disclose this fact together with the basis on which the trustees prepared the accounts and the reason why the charity is not regarded as a going concern.

**Not applicable**

#### 1.3 Change of accounting policy

The accounts present a true and fair view and no changes have been made to the accounting policies adopted in note { }.

Yes*	<input checked="" type="checkbox"/>	* -Tick as appropriate
No*	<input type="checkbox"/>	

**Please disclose:**

<b>(i) the nature of the change in accounting policy;</b>	<b>Not applicable</b>
<b>(ii) the reasons why applying the new accounting policy provides more reliable and more relevant information; and</b>	<b>Not applicable</b>

<b><i>(iii) the amount of the adjustment for each line affected in the current period, each prior period presented and the aggregate amount of the adjustment relating to periods before those presented, 3.44 FRS102 SORP.</i></b>	<b><i>Not applicable</i></b>
---	------------------------------

#### **1.4 Changes to accounting estimates**

No changes to accounting estimates have occurred in the reporting period (3.46 FRS102 SORP).

Yes*	<input checked="" type="checkbox"/>	* -Tick as appropriate
No*	<input type="checkbox"/>	

***Please disclose:***

<b><i>(i) the nature of any changes;</i></b>	<b><i>Not applicable</i></b>
<b><i>(ii) the effect of the change on income and expense or assets and liabilities for the current period; and</i></b>	<b><i>Not applicable</i></b>
<b><i>(iii) where practicable, the effect of the change in one or more future periods.</i></b>	<b><i>Not applicable</i></b>

#### **1.5 Material prior year errors**

No material prior year error have been identified in the reporting period (3.47 FRS102 SORP).

Yes*	<input checked="" type="checkbox"/>	* -Tick as appropriate
No*	<input type="checkbox"/>	

***Please disclose:***

<b><i>(i) the nature of the prior period error;</i></b>	<b><i>Not applicable</i></b>
<b><i>(ii) for each prior period presented in the accounts, the amount of the correction for each account line item affected; and</i></b>	<b><i>Not applicable</i></b>
<b><i>(iii) the amount of the correction at the beginning of the earliest prior period presented in the accounts.</i></b>	<b><i>Not applicable</i></b>

## NOTE 2: Accounting policies

### Note 2

### Accounting policies

#### 2.1 INCOME

##### Recognition of income

These are included in the Statement of Financial Activities (SoFA) when:

- the charity becomes entitled to the resources;
- it is more likely than not that the trustees will receive the resources;
- the monetary value can be measured with sufficient reliability.

Yes*	No*	N/a*
✓		

##### Offsetting

There has been no offsetting of assets and liabilities, or income and expenses, unless required or permitted by the FRS 102 SORP or FRS 102.

Yes*	No*	N/a*
✓		

##### Grants and donations

Grants and donations are only included in the SoFA when the general income recognition criteria are met (5.10 to 5.12 FRS102 SORP).

Yes*	No*	N/a*
✓		

In the case of performance related grants, income must only be recognised to the extent that the charity has provided the specified goods or services as entitlement to the grant only occurs when the performance related conditions are met (5.16 FRS 102 SORP).

Yes*	No*	N/a*
		✓

##### Legacies

Legacies are included in the SoFA when receipt is probable, that is, when there has been grant of probate, the executors have established that there are sufficient assets in the estate and any conditions attached to the legacy are either within the control of the charity or have been met.

Yes*	No*	N/a*
✓		

##### Government grants

The charity has received government grants in the reporting period

Yes*	No*	N/a*
	✓	

##### Tax reclaims on donations and gifts

Gift Aid receivable is included in income when there is a valid declaration from the donor. Any Gift Aid amount recovered on a donation is considered to be part of that gift and is treated as an addition to the same fund as the initial donation unless the donor or the terms of the appeal have specified otherwise.

Yes*	No*	N/a*
✓		

##### Contractual income and performance related grants

This is only included in the SoFA once the charity has provided the related goods or services or met the performance related conditions.

Yes*	No*	N/a*
		✓

##### Donated goods

Donated goods are measured at fair value (the amount for which the asset could be exchanged) unless impractical to do so.

Yes*	No*	N/a*
		✓

The cost of any stock of goods donated for distribution to beneficiaries is deemed to be the fair value of those gifts at the time of their receipt and they are recognised on receipt. In the reporting period in which the stocks are distributed, they are recognised as an expense at the carrying amount of the stocks at distribution.

Yes*	No*	N/a*
		✓

Donated goods for resale are measured at fair value on initial recognition, which is the expected proceeds from sale less the expected costs of sale, and recognised in 'Income from other trading activities' with the corresponding stock recognised in the balance sheet. On its sale the value of stock is charged against 'Income from other trading activities' and the proceeds from sale are also recognised as 'Income from other trading activities'.

Yes*	No*	N/a*
		✓

Goods donated for on-going use by the charity are recognised as tangible fixed assets and included in the SoFA as incoming resources when receivable.

Yes*	No*	N/a*
		✓

Gifts in kind for use by the charity are included in the SoFA as income from donations when receivable.

Yes*	No*	N/a*
✓		

<b>Donated services and facilities</b>	Donated services and facilities are included in the SoFA when received at the value of the gift to the charity provided the value of the gift can be measured reliably.	Yes*	No*	N/a*
		<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
	Donated services and facilities that are consumed immediately are recognised as income with an equivalent amount recognised as an expense under the appropriate heading in the SoFA.	Yes*	No*	N/a*
		<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
<b>Support costs</b>	The charity has incurred expenditure on support costs.	Yes*	No*	N/a*
		<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
<b>Volunteer help</b>	The value of any voluntary help received is not included in the accounts but is described in the trustees' annual report.	Yes*	No*	N/a*
		<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Income from interest, royalties and dividends</b>	This is included in the accounts when receipt is probable and the amount receivable can be measured reliably.	Yes*	No*	N/a*
		<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Income from membership subscriptions</b>	Membership subscriptions received in the nature of a gift are recognised in Donations and Legacies.	Yes*	No*	N/a*
		<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	Membership subscriptions which gives a member the right to buy services or other benefits are recognised as income earned from the provision of goods and services as income from charitable activities.	Yes*	No*	N/a*
		<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
<b>Settlement of insurance claims</b>	Insurance claims are only included in the SoFA when the general income recognition criteria are met (5.10 to 5.12 FRS102 SORP) and are included as an item of other income in the SoFA.	Yes*	No*	N/a*
		<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
<b>Investment gains and losses</b>	This includes any realised or unrealised gains or losses on the sale of investments and any gain or loss resulting from revaluing investments to market value at the end of the year.	Yes*	No*	N/a*
		<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>

## 2.2 EXPENDITURE AND LIABILITIES

<b>Liability recognition</b>	Liabilities are recognised where it is more likely than not that there is a legal or constructive obligation committing the charity to pay out resources and the amount of the obligation can be measured with reasonable certainty.	Yes*	No*	N/a*
		<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Governance and support costs</b>	Support costs have been allocated between governance costs and other support. Governance costs comprise all costs involving public accountability of the charity and its compliance with regulation and good practice.	Yes*	No*	N/a*
		<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
	Support costs include central functions and have been allocated to activity cost categories on a basis consistent with the use of resources, eg allocating property costs by floor areas, or per capita, staff costs by the time spent and other costs by their usage.	Yes*	No*	N/a*
		<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
<b>Grants with performance conditions</b>	Where the charity gives a grant with conditions for its payment being a specific level of service or output to be provided, such grants are only recognised in the SoFA once the recipient of the grant has provided the specified service or output.	Yes*	No*	N/a*
		<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
<b>Grants payable without performance conditions</b>	Where there are no conditions attaching to the grant that enables the donor charity to realistically avoid the commitment, a liability for the full funding obligation must be recognised.	Yes*	No*	N/a*
		<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
<b>Redundancy cost</b>	The charity made no redundancy payments during the reporting period.	Yes*	No*	N/a*
		<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Deferred income</b>	No material item of deferred income has been included in the accounts.	Yes*	No*	N/a*
		<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
<b>Creditors</b>	The charity has creditors which are measured at settlement amounts less any trade discounts	Yes*	No*	N/a*
		<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
<b>Provisions for liabilities</b>	A liability is measured on recognition at its historical cost and then subsequently measured at the best estimate of the amount required to settle the obligation at the reporting date	Yes*	No*	N/a*
		<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
<b>Basic financial instruments</b>	The charity accounts for basic financial instruments on initial recognition as per paragraph 10.7 FRS102 SORP. Subsequent measurement is as per paragraphs 11.17 to 11.19, FRS102 SORP.	Yes*	No*	N/a*
		<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>

## 2.3 ASSETS

### Tangible fixed assets for use by charity

These are capitalised if they can be used for more than one year, and cost at least

£2,500		
Yes*	No*	N/a*
<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>

They are valued at cost.

The depreciation rates and methods used are disclosed in note 14.

### Intangible fixed assets

The charity has intangible fixed assets, that is, non-monetary assets that do not have physical substance but are identifiable and are controlled by the charity through custody or legal rights. The amortisation rates and methods used are disclosed in note 15.

Yes*	No*	N/a*
<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>

They are valued at cost.

Yes*	No*	N/a*
<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>

### Heritage assets

The charity has heritage assets, that is, non-monetary assets with historic, artistic, scientific, technological, geophysical or environmental qualities that are held and maintained principally for their contribution to knowledge and culture. The depreciation rates and methods used as disclosed in note 16.

Yes*	No*	N/a*
<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>

They are valued at cost.

Yes*	No*	N/a*
<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>

### Investments

Fixed asset investments in quoted shares, traded bonds and similar investments are valued at initially at cost and subsequently at fair value (their market value) at the year end. The same treatment is applied to unlisted investments unless fair value cannot be measured reliably in which case it is measured at cost less impairment.

Yes*	No*	N/a*
<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>

Investments held for resale or pending their sale and cash and cash equivalents with a maturity date of less than 1 year are treated as current asset investments

Yes*	No*	N/a*
<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>

### Stocks and work in progress

Stocks held for sale as part of non-charitable trade are measured at the lower of cost or net realisable value.

Yes*	No*	N/a*
<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>

Goods or services provided as part of a charitable activity are measured at net realisable value based on the service potential provided by items of stock.

Yes*	No*	N/a*
<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>

Work in progress is valued at cost less any foreseeable loss that is likely to occur on the contract.

Yes*	No*	N/a*
<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>

### Debtors

Debtors (including trade debtors and loans receivable) are measured on initial recognition at settlement amount after any trade discounts or amount advanced by the charity. Subsequently, they are measured at the cash or other consideration expected to be received.

Yes*	No*	N/a*
<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>

### Current asset investments

The charity has investments which it holds for resale or pending their sale and cash and cash equivalents with a maturity date less than one year. These include cash on deposit and cash equivalents with a maturity of less than one year held for investment purposes rather than to meet short-term cash commitments as they fall due.

Yes*	No*	N/a*
<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>

They are valued at fair value except where they qualify as basic financial instruments.

Yes*	No*	N/a*
<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>

### POLICIES ADOPTED ADDITIONAL TO OR DIFFERENT FROM THOSE ABOVE

--

## NOTE 3: Income

Analysis of income		Restricted			Total funds £	Prior year £
		Unrestricted funds	income funds	Endowment funds		
Donations	Donations and gifts	120,758	22,890	-	143,648	114,755
	Membership subscriptions and sponsorships which are in substance donations	32,950	-	-	32,950	29,954
	<b>Total</b>	<b>153,708</b>	<b>22,890</b>	<b>-</b>	<b>176,598</b>	<b>144,709</b>
<b>TOTAL INCOME</b>		<b>153,708</b>	<b>22,890</b>	<b>-</b>	<b>176,598</b>	<b>144,709</b>

## NOTE 4: Expenditure

Analysis	This year				Last year			
	Unrestricted funds	Restricted income funds	Endowment funds	Total funds	Unrestricted funds	Restricted income funds	Endowment funds	Total funds
<b>Expenditure on raising funds</b>	<b>£</b>							
Fundraising consultants	23,566	-	-	23,566	-	-	-	-
<b>Total expenditure on raising funds</b>	<b>23,566</b>	<b>-</b>	<b>-</b>	<b>23,566</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Expenditure on charitable activities:</b>								
All Member Meetings, Steering Group Meetings, Room Hire, Venue Costs	5,586	-	-	5,586	600	-	-	600
Showcase Project	-	10,307	-	10,307	-	-	-	-
Fundraising Platform Website materials (Gift in kind)	10,899	-	-	10,899	-	-	-	-
Merchandise	376	-	-	376	-	-	-	-
Call for Evidence Project	2,775	-	-	2,775	-	-	-	-
Inequalities report	8,980	-	-	8,980	-	-	-	-
Patient Survey Project	-	-	-	-	7,326	-	-	7,326
NCRI Project	1,480	-	-	1,480	-	-	-	-
Pfizer Project Support	-	-	-	-	10,020	-	-	10,020
Impact Reporting and Annual Review	1,869	-	-	1,869	1,505	-	-	1,505
Telephone	219	-	-	219	74	-	-	74
IT and Computer running expenses	1,300	-	-	1,300	443	-	-	443
Policy consultants - Policy Support	21,375	-	-	21,375	19,605	-	-	19,605
Policy Report	-	-	-	-	2,175	-	-	2,175
Subscriptions	1,622	-	-	1,622	1,384	-	-	1,384
Secretarial expenses	29,600	-	-	29,600	31,855	-	-	31,855
Insurance	556	-	-	556	556	-	-	556
Management and Administration	-	-	-	-	4,000	-	-	4,000
Salaries and Employers NI and Pensions	65,396	-	-	65,396	66,060	-	-	66,060
Communications and PR	8,803	-	-	8,803	2,000	-	-	2,000
Bank and credit fees	216	-	-	216	216	-	-	216
Trustees/Directors Travel	105	-	-	105	162	-	-	162
Trustee Recruitment costs and expenses	-	-	-	-	319	-	-	319
Non-Trustee Recruitment	22	-	-	22	450	-	-	450
<b>Total expenditure on charitable activities</b>	<b>161,179</b>	<b>10,307</b>	<b>-</b>	<b>171,486</b>	<b>148,750</b>	<b>-</b>	<b>-</b>	<b>148,750</b>
<b>Other</b>								
Independent Examiner	3,000	-	-	3,000	2,400	-	-	2,400

## NOTE 5: Details of certain types of expenditure

### Note 5.1 Fees for examination of the accounts

*Please provide details of the amount paid for any statutory external scrutiny of accounts and other services provided by your independent examiner. If nothing was paid please enter '0' in the appropriate box(es).*

Independent examiner's fees

This year £	Last year £
3,000	2,400

## NOTE 6: Paid Employees

### 6.1 Staff Costs

	This year £	Last year £
Salaries and wages	60,000	60,000
Social security costs	2,396	3,060
Pension costs (defined contribution scheme)	3,000	3,000
Other employee benefits	-	-
<b>Total staff costs</b>	<b>65,396</b>	<b>66,060</b>

Please give details of the number of employees whose total employee benefits (excluding employer

No employees received employee benefits (excluding employer

Band	Number of employees	
	This year	Last year
£60,000 to £69,999	1	1

Please provide the total amount paid to key management

This year £	Last year £
60,000	60,000

### 6.2 Average head count in the year

The parts of the charity in which the employees work

	This year Number	Last year Number
Fundraising	-	-
Charitable Activities	-	-
Governance	1	1
Other	-	-
<b>Total</b>	<b>1</b>	<b>1</b>

## NOTE 7: Creditors and accruals

### 7.1 Analysis of creditors

	Amounts falling due within one year		Amounts falling due after more than one year	
	This year £	Last year £	This year £	Last year £
Accruals and deferred income	3,000	25,290	-	-
Other creditors	370	370	-	-
<b>Total</b>	<b>3,370</b>	<b>25,660</b>	<b>-</b>	<b>-</b>

## NOTE 8: Cash at bank and in hand

Cash at bank and on hand  
Total

This year £	Last year £
92,205	135,949
92,205	135,949

## NOTE 9: Fair value of assets and liabilities

	This year	Last year
<p><b>9.1 Please provide details of the charity's exposure to credit risk (the risk of incurring a loss due to a debtor not paying what is owed) , liquidity risk (the risk of not being able to meet short term financial demands) and market risk (the risk that the value of an investment will fall due to changes in the market) arising from financial instruments to which the charity is exposed at the end of the reporting period and explain how the charity manages those risks.</b></p>	<p>Credit risk is low due to income being in the form of donations. Cash is the only investment so market risk is low on investment values falling. Liquidity risk is low as costs are managed in relation to income received.</p>	<p>Credit risk is minimal due to income being in the form of donations and there are extensions of credit. Cash is the only investment which is placed in standard bank current and deposit accounts, so market risk is low on investment values falling. Liquidity risk is low as cost expenditures are managed in relation to income received.</p>
<p><b>9.2 Please give details of the amount of change in the fair value of basic financial instruments (debtors, creditors, investments (see section 11, FRS 102 SORP)) measured at fair value through the SoFA that is attributable to changes in credit risk.</b></p>	<p>Not applicable</p>	<p>Not applicable</p>

## NOTE 10: Charity funds

### 10.1 Details of material funds held and movements during the CURRENT reporting period

Please give details of the movements of material individual funds in the reporting period together with a balancing figure for 'Other funds' (which should include revaluation reserve and fair value reserve, if applicable). The 'Total funds' figure below should reconcile to 'Total funds' in the balance sheet.

\* Key: PE - permanent endowment funds; EE - expendable endowment funds; R - restricted income funds, including special trusts, of the charity; and U - unrestricted funds

Fund names	Type PE, EE R or UR *	Purpose and Restrictions	Fund balances brought forward £	Income £	Expenditure £	Transfers £	Gains and losses £	Fund balances carried forward £
General Fund	UR	General all purpose no restrictions	110,289	153,708	(187,745)	-	-	76,252
Restricted Fund	R	Restricted for Showcase Project	-	22,890	(10,307)	-	-	12,583
<b>Total Funds as per balance sheet</b>			<b>110,289</b>	<b>176,598</b>	<b>(198,052)</b>	<b>-</b>	<b>-</b>	<b>88,835</b>

Yes\*

No\*

	✓
--	---

Fund balances carried forward include assets and liabilities denominated in a foreign currency

If yes, please state the basis on which the assets and/or liabilities have been translated into sterling (or the currency in which the accounts are drawn up).

**10.2 Details of material funds held and movements during the PREVIOUS reporting period**

Please give details of the movements of material individual funds in the reporting period together with a balancing figure for 'Other funds' (which should include revaluation reserve and fair value reserve, if applicable). The 'Total funds' figure below should reconcile to 'Total funds' in the balance sheet.

\* Key: PE - permanent endowment funds; EE - expendable endowment funds; R - restricted income funds, including special trusts, of the charity; and U - unrestricted funds

Fund names	Type PE, EE R or UR *	Purpose and Restrictions	Fund balances brought forward £	Income £	Expenditure £	Transfers £	Gains and losses £	Fund balances carried forward £
General Fund	UR	General all purpose no restrictions	116,730	144,709	(151,150)	-	-	110,289
<b>Total Funds as per balance sheet</b>			<b>116,730</b>	<b>144,709</b>	<b>(151,150)</b>	<b>-</b>	<b>-</b>	<b>110,289</b>

Yes\*  No\*

Fund balances carried forward include assets and liabilities denominated in a foreign currency

## NOTE 11: Transactions with trustees and relates parties

*If the charity has any transactions with related parties (other than the trustee expenses explained in guidance notes) details of such transactions should be provided in this note. If there are no transactions to report, please enter "True" in the box or "False" if there are transactions to report.*

### 11.1 Trustee remuneration and benefits

**This year**

None of the trustees have been paid any remuneration or received any other benefits from an employment with their charity or a related entity (True or False)

TRUE

### 11.2 Trustees' expenses

*If the charity has paid trustees expenses for fulfilling their duties, details of such transactions should be provided in this note. If there are no transactions to report, please enter "True" in the box below. If there are transactions to report, please enter "False".*

No trustee expenses have been incurred (True or False)

TRUE

Type of expenses reimbursed	This year	Last year
	£	£
Travel	-	-
<b>TOTAL</b>	-	-

Please provide the number of trustees reimbursed for expenses or who had expenses paid by the charity

0

0

### 11.3 Transaction(s) with related parties

*Please give details of any transaction undertaken by (or on behalf of) the charity in which a related party has a material interest, including where funds have been held as agent for related parties. If there are no such transactions, please enter 'true' in the box provided.*

**This year**

There have been no related party transactions in the reporting period (True or False)

TRUE

**Last year**

There have been no related party transactions in the reporting period (True or False)

TRUE



# Administrative details

## TRUSTEES

Rebecca Porta  
Helen Morement  
Jonathan Pearce  
Nic Puntis  
Christopher Walden  
Anna Evans  
Dr Max Brodermann  
Michael Draeger  
Sophie Davies

Interim Chair  
Supporting Interim Chair

## EXECUTIVE OFFICERS

Baroness Delyth Morgan  
Jane Lyons  
Jonathan Pearce

President  
Chief Executive  
Company secretary

## REGISTERED OFFICE

c/o Teenage Cancer Trust 3rd Floor,  
93 Newman Street, London W1T 3EZ

## WEBSITE

[www.cancer52.org.uk](http://www.cancer52.org.uk)

## BANKERS

Co-operative Bank



# References

- <sup>1</sup> National Cancer Registration and Analysis Service (NCRAS) by Public Health England figures. May 2019
- <sup>2</sup> Cancer Statistics for the UK. Cancer Research UK. Available: <https://www.cancerresearchuk.org/health-professional/cancer-statistics-for-the-uk#heading-Zero>.
- <sup>3</sup> Cancer52 membership research, conducted April 2019
- <sup>4</sup> Average email open rates for 2022. Smart Insights. Available: <https://www.smartinsights.com/email-marketing/email-communications-strategy/statistics-sources-for-email-marketing/#q4>
- <sup>5</sup> Showcase video. Available: <https://www.cancer52.org.uk/single-post/showcase-video>
- <sup>6</sup> Health and Social Care Committee. Clearing the backlog caused by the pandemic. Date Published 14 December 2021. Available: <https://publications.parliament.uk/pa/cm5802/cmselect/cmhealth/599/report.html>
- <sup>7</sup> Health and Social Care Committee Report on Cancer services. Published 5 April 2022 Available: <https://publications.parliament.uk/pa/cm5802/cmselect/cmhealth/551/report.html>
- <sup>8</sup> Health and Social Care Committee Report on Cancer services. Cancer52 response. Available: [https://e2236186-a9de-45db-b8f6-3f2d6db40cb4.usrfiles.com/ugd/e22361\\_78e510b0dba74c90b10311257319e8d5.pdf](https://e2236186-a9de-45db-b8f6-3f2d6db40cb4.usrfiles.com/ugd/e22361_78e510b0dba74c90b10311257319e8d5.pdf)
- <sup>9</sup> 10-Year Cancer Plan. Call for Evidence. Available: <https://www.gov.uk/government/consultations/10-year-cancer-plan-call-for-evidence>
- <sup>10</sup> 10-Year Cancer Plan. Cancer52 response to the Call for Evidence. Available: [e22361\\_40a4fd86b9f64b2a8eba5697a4b07c51.pdf](https://e22361_40a4fd86b9f64b2a8eba5697a4b07c51.pdf) (usrfiles.com)
- <sup>11</sup> Major Conditions Strategy. Call for Evidence. DHSC. <https://www.gov.uk/government/calls-for-evidence/major-conditions-strategy-call-for-evidence/major-conditions-strategy-call-for-evidence>
- <sup>12</sup> 10-Year Cancer Plan. One Cancer Voice (OCV) response to the Call for Evidence. Available: <https://www.cancer52.org.uk/single-post/10-year-cancer-plan-one-cancer-voice-consensus-statement>
- <sup>13</sup> NHS Long Term Plan. Available: <https://www.longtermplan.nhs.uk/areas-of-work/cancer/>
- <sup>14</sup> Cancer52, Charity Medicines Access Coalition (CMAC), and the Blood Cancer Alliance Voluntary scheme for branded medicines pricing and access (VPAS) – charity joint statement. Available: [e22361\\_8374e284269e4137955c466115800d57.pdf](https://e22361_8374e284269e4137955c466115800d57.pdf) (usrfiles.com)
- <sup>15</sup> Together for Antibiotics. ABPI. Available: [https://www.togetherforantibiotics.org.uk/resources/?3b293f58a0d649e6a204d1476bc6a631\\_cat=Cancer52&3b293f58a0d649e6a204d1476bc6a631\\_page=1](https://www.togetherforantibiotics.org.uk/resources/?3b293f58a0d649e6a204d1476bc6a631_cat=Cancer52&3b293f58a0d649e6a204d1476bc6a631_page=1)
- <sup>16</sup> ABPI AMR: Resources (togetherforantibiotics.org.uk). Available: <https://www.togetherforantibiotics.org.uk/>

# List of charity members 2022/23

ACLT (African Caribbean Leukaemia Trust)  
[www.aclt.org](http://www.aclt.org)

Act for Cancer  
[www.actforcancer.org.uk](http://www.actforcancer.org.uk)

Action Against Heartburn  
[www.actionagainstheartburn.org.uk](http://www.actionagainstheartburn.org.uk)

Action Bladder Cancer UK  
[www.actionbladdercanceruk.org](http://www.actionbladdercanceruk.org)

Action Kidney Cancer  
[www.kcsn.org.uk](http://www.kcsn.org.uk)

Action on Womb Cancer  
[www.actiononwombcancer.org.uk](http://www.actiononwombcancer.org.uk)

Alike  
[www.alike.org.uk](http://www.alike.org.uk)

ALK Positive Lung Cancer  
[www.alkpositive.org.uk](http://www.alkpositive.org.uk)

AMMF – The Cholangiocarcinoma Charity  
[www.ammf.org.uk](http://www.ammf.org.uk)

Anthony Nolan  
[www.anthonynolan.org](http://www.anthonynolan.org)

Association for Multiple Endocrine Neoplasia Disorders (AMEND)  
[www.amend.org.uk](http://www.amend.org.uk)

Baggy Trousers UK  
[www.baggytrousersuk.org](http://www.baggytrousersuk.org)

Balls to Cancer  
[www.ballstocancer.co.uk](http://www.ballstocancer.co.uk)

Barrett's Oesophagus UK  
[www.barrettscampaign.org.uk](http://www.barrettscampaign.org.uk)

Blood Cancer UK  
[www.bloodcancer.org.uk](http://www.bloodcancer.org.uk)

Bone Cancer Research Trust  
[www.bcrct.org.uk](http://www.bcrct.org.uk)

Bowel Research UK  
[www.bowelresearchuk.org](http://www.bowelresearchuk.org)

Brain Tumour Research  
[www.braintumourresearch.org](http://www.braintumourresearch.org)

Brain Tumour Research Campaign (Wayahead)  
[www.btrc-charity.org](http://www.btrc-charity.org)

Brainstrust  
[www.brainstrust.org.uk](http://www.brainstrust.org.uk)

British Lymphology Society (BLS)  
[www.thebls.com](http://www.thebls.com)

British Thyroid Foundation (BTF-thyroid)  
[www.btf-thyroid.org](http://www.btf-thyroid.org)

Butterfly Thyroid Cancer Trust (BTCT)  
[www.butterfly.org.uk](http://www.butterfly.org.uk)

Cancer Laryngectomy Trust  
[www.cancerlt.org](http://www.cancerlt.org)

Cancer of Unknown Primary (CUP) Foundation – Jo's friends  
[www.cupfoundjo.org](http://www.cupfoundjo.org)

Cancer Support UK  
[www.cancersupportuk.org](http://www.cancersupportuk.org)

Childhood Eye Cancer Trust (CHECT)  
[www.chect.org.uk](http://www.chect.org.uk)

Children's Cancer and Leukaemia Group (CCLG)  
[www.cclg.org.uk](http://www.cclg.org.uk)

Chordoma UK  
[www.chordoma-uk.org](http://www.chordoma-uk.org)

Chris Lucas Trust  
[www.chrislucastrust.com](http://www.chrislucastrust.com)

Chronic Myeloid Leukaemia (CML) Support Group UK  
[www.cmlsupport.org.uk](http://www.cmlsupport.org.uk)

CLL Support Association  
[www.clisupport.org.uk](http://www.clisupport.org.uk)

Debbie Fund  
[www.debbiefund.org](http://www.debbiefund.org)

DKMS  
[www.dkms.org.uk](http://www.dkms.org.uk)

East Kent Cancer Cafe

EHE Rare Cancer Charity (UK)  
[www.ehercc.org.uk](http://www.ehercc.org.uk)

Ellen MacArthur Cancer Trust  
[www.ellenmacarthurcancertrust.org](http://www.ellenmacarthurcancertrust.org)

Fight Bladder Cancer  
[www.fightbladdercancer.co.uk](http://www.fightbladdercancer.co.uk)

GIST Cancer UK  
[www.gistcancer.org.uk/](http://www.gistcancer.org.uk/)

Grace Kelly Childhood Cancer Trust  
[www.gkcct.org/](http://www.gkcct.org/)

GUTS Charity  
[www.gutscharity.org.uk](http://www.gutscharity.org.uk)

Heartburn Cancer UK  
[www.heartburncanceruk.org](http://www.heartburncanceruk.org)

HLRCC Family Alliance  
[www.hlrccinfo.org](http://www.hlrccinfo.org)

ICPV Independent Cancer Patients' Voice  
[www.icpv.org.uk](http://www.icpv.org.uk)

International Brain Tumour Alliance (IBTA)  
[www.theibta.org](http://www.theibta.org)

It's In The Bag Cancer Support Ltd  
[www.itsinthebag.org.uk](http://www.itsinthebag.org.uk)

It's on the Ball  
[www.itsontheball.org](http://www.itsontheball.org)

Jo's Cervical Cancer Trust  
[www.jostrust.org.uk](http://www.jostrust.org.uk)

Kidney Cancer UK  
[www.kcuk.org.uk](http://www.kcuk.org.uk)

Live Through This  
[www.livethroughthis.co.uk](http://www.livethroughthis.co.uk)

Leukaemia CARE  
[www.leukaemiacare.org.uk](http://www.leukaemiacare.org.uk)

Leukaemia UK  
[www.leukaemiauk.org.uk](http://www.leukaemiauk.org.uk)

London Asbestos Support Awareness Group  
[www.lasag.org.uk/](http://www.lasag.org.uk/)

Lymphoedema Support Network  
[www.lymphoedema.org](http://www.lymphoedema.org)

Lymphoma Action  
[www.lymphoma-action.org.uk](http://www.lymphoma-action.org.uk)

Maggie's Cancer Caring Centres – Maggie's Centres  
[www.maggiescentres.org](http://www.maggiescentres.org)

MDS (Myelodysplastic Syndromes) UK Patient Support Group  
[www.mdspatientsupport.org.uk](http://www.mdspatientsupport.org.uk)

Melanoma Focus  
[www.melanomafocus.com](http://www.melanomafocus.com)

Melanoma UK  
[www.melanomauk.org.uk](http://www.melanomauk.org.uk)

Mesothelioma UK  
[www.mesothelioma.uk.com](http://www.mesothelioma.uk.com)

Mind Over Cancer  
[www.mindovercancer.org.uk/](http://www.mindovercancer.org.uk/)

MPN Voice  
[www.mpnvoice.org.uk](http://www.mpnvoice.org.uk)

Mummy's Star  
[www.mummysstar.org](http://www.mummysstar.org)

Myeloma UK  
[www.myeloma.org.uk](http://www.myeloma.org.uk)

Neuroblastoma UK  
[www.neuroblastoma.org.uk](http://www.neuroblastoma.org.uk)

Neuroendocrine Cancer UK (NCUK)  
[www.neuroendocrinecancer.org.uk](http://www.neuroendocrinecancer.org.uk)

North West Cancer Research  
[www.nwcr.org](http://www.nwcr.org)

OcuMel UK  
[www.ocumeluk.org](http://www.ocumeluk.org)

Oracle Cancer Trust  
[www.oraclecancertrust.org](http://www.oraclecancertrust.org)

Orchid Cancer Appeal  
[www.orchid-cancer.org.uk](http://www.orchid-cancer.org.uk)

Ovacome  
[www.ovacome.org.uk](http://www.ovacome.org.uk)

Ovarian Cancer Action  
[www.ovarian.org.uk](http://www.ovarian.org.uk)

Pancreatic Cancer Action  
[www.pancreaticcanceraction.org](http://www.pancreaticcanceraction.org)

Pancreatic Cancer UK (PCUK)  
[www.pancreaticcancer.org.uk](http://www.pancreaticcancer.org.uk)

Paul's Cancer Support Centre  
[www.pauls.org.uk](http://www.pauls.org.uk)

Peaches Womb cancer Trust  
[www.peachestrust.org/](http://www.peachestrust.org/)

Pelvic Radiation Disease Association PRDA  
[www.prda.org.uk](http://www.prda.org.uk)

Penny Brohn UK  
[www.pennybrohn.org.uk](http://www.pennybrohn.org.uk)

PLANETS  
[www.planetscharity.org](http://www.planetscharity.org)

Pseudomyxoma Survivor  
[www.pseudomyxomasurvivor.org](http://www.pseudomyxomasurvivor.org)

Salivary Gland Cancer UK  
[www.salivaryglandcancer.uk](http://www.salivaryglandcancer.uk)

Sarcoma UK  
[www.sarcoma.org.uk](http://www.sarcoma.org.uk)

Shine Cancer Support  
[www.shinecancersupport.org](http://www.shinecancersupport.org)

Solving Kids' Cancer  
[www.solvingkidscancer.org.uk](http://www.solvingkidscancer.org.uk)

Swallows Head & Neck Cancer Charity  
[www.theswallows.org.uk](http://www.theswallows.org.uk)

Target Ovarian Cancer  
[www.targetovariancancer.org.uk](http://www.targetovariancancer.org.uk)

Team Margot Foundation  
[www.teammargot.com](http://www.teammargot.com)

Teenage Cancer Trust (TCT)  
[www.teenagecancertrust.org](http://www.teenagecancertrust.org)

The Brain Tumour Charity  
[www.thebraintumourcharity.org](http://www.thebraintumourcharity.org)

The Charley Ashton Foundation

The Eve Appeal  
[www.eveappeal.org.uk](http://www.eveappeal.org.uk)

The Mavis Nye Foundation  
[www.mavisnyefoundation.com](http://www.mavisnyefoundation.com)

The Myrovlytis Trust  
[www.myrovlytistrust.org](http://www.myrovlytistrust.org)

The Northern Ireland Rare Disease Partnership  
[www.nirdp.org.uk](http://www.nirdp.org.uk)

The Robin Cancer Trust  
[www.therobincancertrust.org](http://www.therobincancertrust.org)

The Urology Foundation  
[www.theurologyfoundation.org](http://www.theurologyfoundation.org)

ThymicUK  
[www.thymicuk.org/](http://www.thymicuk.org/)

Thyroid Cancer Support Group Wales  
[www.thyroidsupportwales.co.uk](http://www.thyroidsupportwales.co.uk)

Tom Bowdidge Youth Cancer Foundation  
[www.tombowdidgefoundation.org](http://www.tombowdidgefoundation.org)

Trekstock  
[www.trekstock.com](http://www.trekstock.com)

UCARE  
[www.ucare-cancer.org.uk](http://www.ucare-cancer.org.uk)

UK Masto  
[www.ukmasto.org](http://www.ukmasto.org)

Urostomy Association  
[www.urostomyassociation.org.uk](http://www.urostomyassociation.org.uk)

VHL UK/Ireland  
[www.vhl-uk-ireland.org](http://www.vhl-uk-ireland.org)

Wellbeing of Women  
[www.wellbeingofwomen.org.uk](http://www.wellbeingofwomen.org.uk)

Wendy Gough Cancer Awareness Foundation  
[www.wgcaf.com](http://www.wgcaf.com)

WMUK  
[www.wmuk.org.uk](http://www.wmuk.org.uk)

Womb Cancer Info  
[www.wombcancerinfo.wixsite.com/home](http://www.wombcancerinfo.wixsite.com/home)

Womb Cancer Support UK  
[www.wombcancersupportuk.weebly.com](http://www.wombcancersupportuk.weebly.com)

Yorkshire Cancer Community  
[www.yorkshirecancercommunity.co.uk](http://www.yorkshirecancercommunity.co.uk)

Young Lives Vs. Cancer  
[www.younglivesvscancer.org.uk](http://www.younglivesvscancer.org.uk)



**Cancer52** is registered as a charity in England and Wales, **Charity No. 1174569** and as a company limited by guarantee in England and Wales, **Company No. 07994413**

If we **work together**  
we can make as much noise as the big four



**CANCER 52**

England & Wales - Charity number 1174569

---

# Accounts

---

# cancer52

the common voice for  
rare & less common cancers

Cancer52 is registered as  
a charity in England and Wales,  
Charity No. 1174569 and as a  
company limited by guarantee  
in England and Wales,  
Company No. 07994413

## Annual Review

& Financial Statements

1 Apr 2021 – 31 Mar 2022

[cancer52.org.uk](https://cancer52.org.uk)

# Contents

## **WELCOME: TRUSTEES ANNUAL REPORT AND DIRECTORS REPORT FOR THE YEAR ENDED 31ST MARCH 2022**

Foreword	3
Welcome to our Annual Review 2021–2022	3

<b>STRENGTH IN UNITY: OUR PRINCIPLES</b>	<b>4</b>
Our core principles	4

<b>UNITING WITH ONE VOICE: WHO WE ARE</b>	<b>5</b>
The Cancer52 team	5
Our charity members	5
The Impact of Covid-19	5

<b>MAKING THE CANCER52 VOICE HEARD</b>	<b>6</b>
Informing, advising and supporting our members	6

<b>PARTNERSHIP: REPRESENTATION AND ADVOCACY IN POLICY</b>	<b>8</b>
---	----------

<b>PARTNERSHIP: COLLABORATION ON BEHALF OF THE PATIENTS</b>	<b>10</b>
Informing our stakeholders	12

<b>MAKING THE VOICE OF PEOPLE WITH RARE AND LESS COMMON CANCERS HEARD: OUR HEADLINE ACHIEVEMENTS FOR 2021–2022</b>	<b>13</b>
Partnership	13
Policy	13
Patients	13

<b>FUNDING</b>	<b>14</b>
The value of our support	14
Voluntary member donations	14
Support from industry	14

<b>FUTURE PLANS</b>	<b>15</b>
---------------------	-----------

<b>THE ACOUSTICS: STRUCTURE AND CONSTITUTION</b>	<b>16</b>
Structure and governance	16
Purpose	16
Public benefit	16
Board and management operations and structure	17

<b>MONEY TALKS: FINANCIAL REVIEW 2020–2021</b>	<b>19</b>
--	-----------

<b>INDEPENDENT EXAMINERS' REPORT TO THE TRUSTEES OF CANCER52</b>	<b>20</b>
Independent examiner's report to the trustees of Cancer52	20
Section A	22
Section B	23
Section C	24

<b>ADMINISTRATIVE DETAILS</b>	<b>35</b>
-------------------------------	-----------

<b>REFERENCES</b>	<b>36</b>
-------------------	-----------

<b>LIST OF CHARITY MEMBERS 2020–2021</b>	<b>37</b>
--	-----------



# Welcome:

Trustees Annual Report and Directors Report  
for the year ended 31st March 2022

## Foreword

The year 2022 marks my seventh and final year as Chair of **Cancer52**. As I look back, I've been proud to witness the organisation grow in stature. It successfully built on its core remit, to advance collaborative policy leadership for the rare and less common cancer community, all while maintaining steadfast support for its members, enabling them to navigate challenges together, including a health system and Government still in the throes of dealing with the COVID-19 pandemic.

Laying this groundwork means **Cancer52** is ready for an exciting future of further expansion and widening influence.



Jonathan Pearce, Chair

## Welcome to our Annual Review 2021-22

We are delighted to welcome readers to this Annual Review, which covers the year to the end of March 2022.

It has been a challenging year but we have grown our membership and our influence and worked with a widening group of stakeholders to deliver ever more ambitious projects. All of this could only have been achieved with our small but dedicated and committed team, and my thanks to them.

And now – as the world opens up again to human rather than technological interaction – our opportunities to network and share our aims and values are growing. With the help of our many partners we will continue to deliver on projects and activities that help build the voice of the hundreds of thousands of people with a rare or less common cancer.

My thanks to Jonathan for his ongoing support over the years. We will miss him as chair but are delighted that he will stay on as a trustee.

Finally huge thanks to all those working within the NHS to support people with a rare or less common cancer. We salute your dedication, knowledge, and work ethic.



Jane Lyons, CEO



# Strength in unity: our principles

**Cancer52** is a national organisation, created in 2007 by Professor Sir Mike Richards, CBE, then National Cancer Director, and was registered as a charity in England and Wales in September 2017.

We are a unifying body for charitable and not-for-profit organisations working in the field of rare and less common cancers. We represent well over 100, predominantly small, patient-support and research-focused cancer charities and organisations.

**Cancer52** gets its name from when rare and less common cancers accounted for 52% of all cancer deaths in the UK, despite the fact that only 47% of cancers diagnosed in England are of this type.<sup>1</sup> In 2020, this shifted to 47% of diagnoses yet 55% of cancer deaths.<sup>2</sup>

Our member charities and organisations are united in seeking a better future for everyone affected by rare and less common cancers. We provide a collective voice to champion earlier diagnosis, better treatment, better representation, funding and support for people with cancers other than the four most common cancers (breast, lung, bowel and prostate). **Cancer52** ensures the voice of people with rare and less common cancers does not go unheard.



## Our core principles

### Our aim

Our primary aim is to promote improved diagnosis, treatment and support for those affected by rare and less common cancers.

### Our mission

Our mission is to provide a strong, unified voice for rare and less common cancer organisations by representing, speaking, informing, sharing and involving our members in achieving our vision.

### Our vision

Our vision is to see an end to the inequalities in diagnosis, treatment and patient outcomes experienced by those with these challenging diseases compared with the four most common cancers.

### Our values

Everything we do is underpinned by our values, which are to be:  
ambitious | outcomes-focused |  
collaborative | evidence-based | influential  
and to behave with honesty and integrity.

# Uniting with one voice: who we are

**Cancer52 aims to better represent people with rare and less common cancers at a senior policy and decision-making level. Sourcing and bringing together the knowledge and expertise of our many members makes this possible.**

## The Cancer52 team

During the year ending 31 March 2022, the core team consisted of:

- **Jane Lyons, CEO:** Responsible for the overall running of the charity.
- **Ainsley Taylor, Operations Manager:** Supporting the CEO on governance, finance, fundraising, administration and the co-ordination of membership donations, recruitment, and supporting the Trustees.
- **Stephanie Judycki, Communications Executive:** Leads on internal and external communications including member e-bulletins, Cancer52 website, and social media.

Our Board of Trustees is listed on page 35.

Consultants, Laura Thomas and Jennifer Mitchell, from Brighter Together Consulting worked with us on policy and Jason Dennis ran our finances.

Thanks to you all for your hard work and dedication.

## Our charity members

Our members are united in their determination to improve treatment and outcomes for their individual patient groups.

They are mostly small but fiercely dedicated organisations that offer patient support, often with a research focus.

The vast majority (75%) of our membership have an annual income of less than £1 million, with 67% on an income of less than £500,000 and 38% with an income of less than £100,000. Almost all our members offer patient support and over two-thirds invest in research.<sup>3</sup>

The full list of **Cancer52's** members for the financial year 2021-22, can be seen on page 37.

Our active membership continues to grow, and during the financial year 2021-22, 10 new charities of varying sizes joined Cancer52. We happily welcomed: *Live Through This, Leukaemia UK, North West Cancer Research, Paul's Cancer Support Centre, Penny Brohn UK, The Charley Ashton Foundation, The Myrovlytis Trust, The Urology Foundation, ThymicUK, and Wendy Gough Cancer Awareness Foundation.*

We hugely value and appreciate our members' ongoing dedication and commitment to **Cancer52**.

## The impact of Covid-19

Despite Covid-19's continued impact we maintained a high level of engagement with our members and their patient groups during the slow return to normal.

We are proud of our ongoing learning and how we have adapted to deeply challenging and complex circumstances across the health system, especially when Covid relief funds were wound down.

## Helping members keep patients informed

While we join others in welcoming the gradual return to new normal, our focus remains on the threat of infection for patients who are immunosuppressed.

**Cancer52**, among other charities, supported the Deputy Chief Medical Officer (DMCO) and Department of Health and Social Care (DHSC) in England to cascade critical information to the public. We knew that shielding was a key issue for those living with cancer so joined the DHSC Shielding Advisory Group meetings to help share salient information on any changes in shielding advice.

# Making the Cancer52 voice heard

**We work tirelessly to support people with rare and less common cancers and to ensure we have a strong presence in the rare and less common cancer community.**

- We are represented at the highest level on boards and task forces.
- We value close teamwork and collaboration.
- Our flexible structure allows us to utilise a range of skills and methods to help our members support patients.

From telephone conversations and surveys to seats on influential national cancer bodies, we take every opportunity to represent people with rare and less common cancers.

## Informing, advising and supporting our members

Regular e-bulletins kept our members informed and bimonthly virtual meetings offered a chance to voice any questions and concerns and communicate shared learnings. New monthly virtual CEO Meetings linked together CEOs on higher level activities.

### Meeting with our members

Our virtual meetings remain in place, as over the year they empowered charities from across the country to connect, and quickly and easily share information.



**376**

individuals attending  
All Member Meetings



**150+**

attended one of our many  
working group meetings



**200+**

people attended our  
monthly CEO meetings

## Sharing

We want everyone with rare and less common cancers to have the chance to be best supported and make informed choices. We consistently encourage our members to talk to each other and the resulting knowledge exchange means that even those supported by charities with limited resources have access to continuing flow of useful information.

Creating collaboration helps charities from duplicating effort and frees up resources to better support people with cancer. We know that a collaborative voice is a stronger voice.

*'I'm very impressed by everything that you're doing at the moment – Cancer52 is certainly having a big impact and we are proud to be a member.'*

Lydia Makaroff, CEO, Fight Bladder Cancer

## Regular members' e-bulletin

Throughout this financial year, our weekly or biweekly e-bulletin updated our members on:

- Dates and details of Cancer52 meetings and meetings by member charities or national organisations;
- Updated information for sharing with patients;
- Opportunities to get involved with projects that support people with rare and less common cancers;

# We want everyone with rare and less common cancers to have the chance to be best supported and make informed choices.

- Patient surveys;
- Projects where members wanted to share learning or to raise awareness
- Member and NHS Cancer Programme job vacancies
- Training courses
- NHS and other cancer charity webinars
- Developments in health policy pertinent to cancer, such as the DHSC 10-Year Cancer Plan

The e-bulletins have an average 40% open rate and 8.3% click-through rate, which is significantly more than the industry average.<sup>4</sup> It shows members prize our bulletins as a useful and efficient way of disseminating information so that they and their patients are aware of critical events, activities and developments.

*'Thank you Cancer52 for your sterling work for the cause of the rare and less common cancer communities.'*

Helen Morement, CEO, AMMF

## CANCER52 ALL MEMBER MEETINGS

Fortnightly virtual meetings continued throughout the financial year. They offer ideal networking opportunities and the chance to help patients by learning from interesting and thought-provoking speakers. Meetings were warmly welcomed and well attended, most notably the launch of the "DoYouCUs?" Campaign, which attracted nearly 50 attendees.

The meetings are great relationship builders and boost the profile of people with rare and less common cancers.

## CEO CALLS AND MEETINGS

Monthly video calls started in August 2020 and provide member CEOs direct access to their peers. These meetings have become incredibly valuable opportunities to raise problems, talk through ideas, share best practice or discuss ways of increasing awareness and boosting the sector's profile.

*'Cancer52 has created our network, fab having peers we can reach. We have a real sense of community.'*

Liz Darlison, CEO, Mesothelioma UK

## WORKING GROUPS

Some of our members face similar challenges in supporting people with cancer so we set up additional working groups on specific shared areas. New groups examined cancer-related menopause, health inequalities, IBS (by way of misdiagnosis), and the NHS website cancer pages.



# Partnership: Representation and advocacy in policy

**Cancer52 represents its members at the highest level and acts as a conduit to organisations that need to hear the patient voice of people with rare and less common cancers. As a strong and determined alliance, we can make more noise about the need for improvements in cancer services, including those supported by our member charities.**

During 2021–2022, we were invited to sit on several NHS England (NHSE) boards and groups where we used our influence to oversee, advise on and implement the NHS Long Term Plan (LTP)<sup>5</sup> for cancer.

## **HEALTH AND SOCIAL CARE SELECT COMMITTEE**

**Cancer52** responded to two Health and Social Care Select Committee Inquiries: Cancer Services and Clearing the Backlog Caused by the Pandemic.<sup>6</sup> **Cancer52's** CEO, Jane Lyons, contributed evidence at an oral hearing of the inquiry into cancer services. The resulting Health and Social Care Committee Report on Cancer services made key recommendations using **Cancer52's** evidence, including recommending an action plan for rare and less common cancers.<sup>7</sup>

## **CANCER CHARITIES**

**Cancer52** also works collaboratively with many charities outside its direct membership where this has more impact for people living with cancer.

A key example of this is the One Cancer Voice (OCV) initiative where over 50 charities work together on fundamental policy asks such as investing in the workforce that helps people with cancer, and increasing spend on diagnostics. We sit on the steering group and instigated and provided the structure and pro bono time to develop the pan cancer charity

response to the Cancer Plan call for evidence in spring 2022.<sup>8</sup>

## **CANCER52 POLICY AND PUBLIC AFFAIRS STEERING GROUP**

Our Policy and Public Affairs Steering Group (PPASG) met frequently to exchange information and help formulate **Cancer52's** policy asks. They helped to inform our responses to the Cancer Plan call for evidence and Health and Social Care Select Committee inquiries. During 2020–2021 this group was chaired by Chris Walden, **Cancer52** Trustee and Deputy Director of Policy, Campaigns and Engagement at Blood Cancer UK, with vice chair Bradley Price, Policy and Public Affairs Manager of Sarcoma UK. The discussions help develop **Cancer52** policy.

## **CANCER52 NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) WORKING GROUP ACCESS TO MEDICINES WORKING GROUP**

This group convenes whenever issues impact several **Cancer52** members, most often looking at the role of patients in NICE processes and the ability to get the patient voice heard at NICE.<sup>9</sup>

## 10-YEAR CANCER PLAN

Early in 2022 we were invited to join a round table hosted by the then Secretary of State for Health and Social Care, the Rt Hon Sajid Javid MP, where he launched a call for evidence for his new 10-year plan for cancer.<sup>10</sup>

At time of writing the Plan is still being developed while ministerial appointments settle.

**Cancer52** led the pan cancer charity collaboration, worked with members (including surveying members online) and other charities to help draft our own response and attended various evidence-gathering meetings hosted by the DHSC. To push views of people with rare and less common cancers into the spotlight we commissioned a patient survey and incorporated the findings from 259 patients into our response.<sup>11</sup>

# 259

We commissioned a patient survey and incorporated the findings from 259 patients into our response



The Pan Cancer Charity Collaboration

# Partnership: Collaboration on behalf of patients

## MAKING THE VOICE OF PEOPLE WITH RARE AND LESS COMMON CANCERS HEARD

Working closely with the pharmaceutical company Pfizer, **Cancer52** launched the awareness raising campaign Do You C Us? in the summer of 2021. A campaign website was created featuring facts and figures and patient videos.<sup>12</sup> The campaign was launched virtually at a parliamentary event hosted by Paul Bristow MP and joined by **Cancer52** members and other MPs. The team also worked to secure press and social media coverage.

## Working collaboratively across the NHS

### WORKING WITH THE NHS CANCER PROGRAMME

#### NATIONAL CANCER BOARD

Alongside Cancer Research UK and Macmillan Cancer Support, we have a place on the NHSE National Cancer Board. Together we provide strategic leadership across the healthcare sector in the delivery of the cancer ambitions inside the NHS Long Term Plan.<sup>5</sup>

**Cancer52** also holds a place on the following NHSE cancer programme groups:

- Cancer Campaigns Oversight Group;
- Early Detection Task and Finish Group;
- The Cancer Patient Experience Survey Advisory Group;
- The Cancer Patient Experience Survey Reporting Sub Group;
- NHSE Cancer Charity Forum;

#### NHSE'S HELP US, HELP YOU CAMPAIGN

**Cancer52** helped ensure that the voice of people with rare and less common cancers were heard in this national cancer symptom awareness campaign. **Cancer52** worked with partners in NHSE to drive interest amongst members and then facilitate their involvement. As a result, NHSE collaborated with the following **Cancer52** members on the Clear on Cancer – Help Us, Help You national campaign to create co-branded stills and videos:

- Fight Bladder Cancer;
- Bone Cancer Research Trust;
- It's on the Ball
- Leukaemia UK
- Brain Tumour Charity

**Cancer52 helped ensure that the voice of people with rare and less common cancers were heard in this national cancer symptom awareness campaign.**



## Working collaboratively across the wider cancer community

We also worked closely with a number of other organisations within the UK cancer community where it served the purpose of ensuring the voice of people with rare and less common cancers was better heard.

### CHARITY MEDICINES ACCESS COALITION (CMAC)

Many people need quicker access to new and innovative medicines. This umbrella group of charities works to find a long-term solution to this problem. We are grateful to member charities for representing us on this Coalition.

### CHILDREN AND YOUNG PEOPLE CANCER COALITION

Many of our member charities support children and young people with cancer and these charities have formed the Children and Young People Cancer Coalition. We sit on the steering group and support the work of charities in this field.

### NATIONAL VOICES

This wide-ranging coalition of healthcare charities helps us engage where topics are particularly relevant to people with rare and less common cancers.

### SPECIALISED HEALTHCARE ALLIANCE

This Alliance campaigns on behalf of those with rare and complex conditions. **Cancer52** is a member and attends briefings on wider topics affecting people with rare cancers.

### THE ASSOCIATION OF THE BRITISH PHARMACEUTICAL INDUSTRY

Our CEO sits on the newly formed ABPI Patient Advisory Council.

The ABPI holds quarterly meetings of its Patient Organisation Forum. We join the briefings alongside other charities and sit on the steering group that plans the meetings and organises speakers.

In February 2022, **Cancer52** worked with the Association of the British Pharmaceutical Industry (ABPI) on an Anti-Microbial Resistance campaign specific to people living with rare and less common cancers called Together for Antibiotics.<sup>13,14</sup>



Don't let cancer play on your mind



Clear on cancer Help us help you



Don't let cancer play on your mind



Clear on cancer Help us help you

## Informing our stakeholders

Collectively, and also as our member representatives, we are in ongoing communication with members of other charities, NHS professionals and administrators, and anyone who has influence in the rare and less common cancer field.

### Cancer52 Annual Stakeholder Meetings

Our annual Stakeholder Meeting offers a great opportunity for all our members to engage with senior level speakers and industry representatives.

Due to the ongoing COVID-19 pandemic the Annual All Stakeholder Meeting was held virtually in October 2021. The theme was Early Diagnosis, and it was attended by 75 delegates representing members, industry, the Government and NHS.

For the first time in two years, we plan to go back to an in-person event for October 2022.

### Website

Our website acts as a central point for information and spreads the message that patient experience, treatment and outcomes will only improve with more time, money and effort focused on coping with rare and less common cancers.

The site includes links to all member organisations, plus the sponsors and groups we collaborate with to offer a useful portal for sharing information between members, patients, and the general public. We posted reports on our activities during the year and featured a news stream of prominent issues.

Website users can access reports together with informative videos, announcements of upcoming conferences or meetings, contact and donation opportunities.

### Social media and media

We have been especially active during this year on Facebook and Twitter, gathering a total of 2,500 followers to date. We use our social media channels to distribute new information, react to events and communicate with our members. We excel at supporting member charities on Twitter by reposting their awareness campaigns and fundraising activities and facilitating engagement with patients. This can be especially effective to amplify awareness of a rare or less common type of cancer by tagging several members into a post to help create a unified voice for patients.





# Making the voice of people with rare and less common cancers heard: our headline achievements for 2021–2022

We are proud of our achievements during what has been a challenging year for us, our members and the for the NHS.

## Partnership

### INFORMING, SHARING WITH, AND EMPOWERING OUR MEMBERS

We are grateful for the engagement and significant positive feedback from our members. This confirms that our redoubled efforts to improve our communications through our e-bulletins, All Member Meetings, CEO calls and meetings, group meetings, patient surveys, CEO survey and CEO briefings have been well received.

Our membership and engagement levels increased significantly.

## Policy

### RESPONDING COLLECTIVELY TO THE CHANGING POLITICAL CANCER PRIORITIES

We continue to work alongside NHSE Cancer Programme to improve outcomes for those with rare and less common cancers and to meet the early diagnosis target of diagnosing 75% of all cancers at stage I and II by 2028. We also worked collaboratively with our members and the wider cancer charity community to respond effectively to the Government's 10-year Cancer Plan Call for Evidence.

## Patients

### ADVOCATING FOR THOSE AFFECTED BY RARE AND LESS COMMON CANCERS THROUGH COLLABORATION

We raise the profile of patients with a rare and less common cancer by consistently taking the patient voice to influencers and policy makers. We have a unique place in the cancer community and take every opportunity to make this patient voice heard.



# Our support: sources of funding

In 2021–2022, we received funding from a variety of sources: donations from members; individual donations; and support from pharmaceutical companies.

## The value of our support

We equally appreciate the valuable time, expertise and energy generously donated by our members.

We are hugely grateful to every donor and supporter for their financial support which helps propel us towards achieving our objectives. The financial benefaction of our charity members represents a very significant contribution in terms of the number and variety of organisations that support **Cancer52**.

## Voluntary member donations

The vast majority of our financial supporters are our member charities from whom we request a voluntary donation to our work that is aligned to their income. We aim to offer free membership to smaller charities with financial challenges although, in many cases, they contribute as they value the work we do together.

Despite the continuing the Covid-19 pandemic, donations totalled £27,950 from 45 member charities and, although we continued to waive donations to all member charities with an income of less than £500,000, membership donations for 2021/22 exceeded those of 2020/21.

## Individual donations

Donations are welcome from any individuals or organisations who recognise the value of our contribution to supporting people with rare and less common cancers.

During the financial year 2021-22, **Cancer52** received almost £19,000 from a variety of platforms and individuals.

## Support from industry

In 2021–2022 we received support from Abbvie, BMS, Gilead, GSK, Ipsen, Roche, Sanofi and Takeda, who all benefited from membership of **Cancer52's** Corporate Supporter Programme.

**Cancer52** has a clear policy when working with the pharmaceutical industry and abides by industry guidelines.<sup>6</sup> Some 62.7% of our funding comes from pharmaceutical companies. This comprises support for specific projects as well as unrestricted support.

We believe all our industry partners recognise the value of dealing with an umbrella body that channels one voice for rare and less common cancers.

Working with **Cancer52** offers a unique opportunity to engage with the voice of people with rare and less common cancers, and benefit from the expertise and knowledge gained through our relationships with member organisations.



# Future plans

Cancer52 is proud of its achievements during this unprecedented year. Our major objectives prevail and we will take them forward into 2022–2023.

We will provide a strong, unified voice to promote improved diagnosis, treatment and support for those affected by rare and less common cancers so that we see an end to inequalities in diagnosis, treatment and patient outcomes experienced by those with these challenging diseases.

In three years' time, Cancer52 will:


## UK wide

Be a well-resourced organisation making the voice of rare and less common cancers heard across the four nations of the UK wherever decisions are taken on the treatment and care of people with these cancers.



## Leadership

Have retained its market leadership position but built its thought leadership and increased its collaborative work with fellow cancer charities and alliances.



## Alignment

Have reviewed its target audiences and brand name and, if necessary, be ready to take steps to change it.

## Inequalities focus

Have retained its focus on its aim, mission and values whilst placing reducing inequalities at the heart of everything it does



# The acoustics: structure and constitution



## Structure and governance

**Cancer52** is incorporated as a charitable company limited by guarantee and is a registered charity in England and Wales. It is governed by its Memorandum and Articles of Association, and the work, management, finances and strategy of the charity are overseen by a Board of Trustees, who are also the company directors. The Trustees who held office during the financial year and at the date of the report are set out on page 35.

Under the Articles of Association, a minimum of three trustees and a maximum of twelve trustees can be in office. At Annual General Meetings, one-third of the existing directors must retire by rotation based on the longest serving directors retiring first. Retiring directors may be re-appointed at Annual General Meetings by the vote of existing directors. New directors may only be appointed at Annual General Meetings where the notice and approval requirements set out in the Articles of Association have been satisfied.

The Board has agreed that the usual term of tenure for trustees should be a maximum of two terms of three years each (six years in total), with review and approval by the Board at the end of each term of tenure. In exceptional circumstances, and in order not to lose important or valuable skills, experience and expertise, trustees may serve for a third term of tenure, subject to the approval of the Board. Trustees do not receive remuneration for their duties.



## Purpose

The charity's purposes are set out in its Memorandum and Articles of Association as follows:

To promote and protect the health of people with rare and less common cancers by:

1. Advancing and promoting understanding, awareness, research and learning about rare and less common cancers;
2. Acting as a collective voice and advocating for the needs of individuals affected by a rare or less common cancer in order to improve diagnosis, treatment and long-term support outcomes; and
3. Supporting, representing and empowering not-for-profit organisations working in the field of rare and less common cancer.

## Public benefit

Our work delivers public benefit by providing information and support to people diagnosed with, treated for or living with a rare or less common cancer through the services, interactions and collaboration that we facilitate between our members. We drive change and enhancements in the cancer system to improve outcomes for people affected by a rare or less common cancer.

As part of our business planning processes, we review our aims and objectives each year, which includes looking at what we have achieved in previous years, and how our activities have benefited those groups of people we were set up to help. We have referred to the Charity Commission's general guidance on public benefit when reviewing our aims and objectives, and in planning our work for the future.

## **Board and management operations and structure**

### **Board of Trustees**

The Board of Trustees meets at least four times a year to review the organisation's work, finances and services, and to agree strategic goals for the charity. Board meetings were virtual throughout 2021–2022 and invited the Chief Executive and the Operations Manager and others as appropriate.

The chair and other trustees with financial expertise also meet separately with the Chief Executive, Operations Manager, and the charity's accountant on a quarterly basis to monitor and scrutinise the charity's financial strategy and operations and make any necessary recommendations to the full Board of Trustees.

### **Recruitment and appointment of new trustees**

Following the resignation of two trustees in 2020, the Board decided not to recruit and appoint new trustees during the Covid-19 pandemic. However, in Spring 2021, a schedule and criteria to recruit new trustees was implemented.

Our recruitment drive welcomed in five new Trustees, Anna Evans, Catherine Hodgson, Dr Max Brodermann, Michael Draeger and Sophie Davies. Each brought a wealth of knowledge and insight to the Board.

In March 2022, Catherine Hodgson resigned from the Board of Trustees as a result of leaving the sector to pursue other avenues. We pass our thanks to Catherine for her contribution to the Board during her time with us.

### **Related parties**

The only related parties are considered to be the trustees and those connected with the trustees, including their close families, business and other charity interests. There have been no transactions with related parties, other than the reimbursement of reasonable travel expenses for the purposes of attendance at Board meetings and other relevant organisational activities.

### **Risk assessment and management**

The Board of Trustees and the chief executive maintain a risk register and assess risks on an annual basis. The trustees are satisfied that the major risks to the organisation have been accurately identified and that appropriate systems and procedures for managing those risks are in place.

### **Safeguarding**

We have a strong commitment to protecting and promoting the health, wellbeing and safety of all engaged in our work. While we are not a patient representative charity, we still adhere to good safeguarding practice. Our Safeguarding Policy is reviewed each year and is accessible on the Governance section of our website. All new staff and volunteers are required to participate in a full day safeguarding training course, provided by an external organisation.

### **Annual review**

The Annual Review 2021–2022 was completed and disseminated, with thanks to the Board nominees Chris Walden and Helen Morement, and to external copywriter and designers.



# cancer 52

the common voice for  
rare & less common cancers



# Money talks: financial review 2021-2022

## Financial statement

As shown in the statement of financial activities on the following pages, in the year 2021–2022:

- reserves brought forward from 2020–2021 were £116,730
- income for the financial year was £144,709
- expenditure for the current financial year was £151,150, resulting in a small, anticipated deficit of £6,441
- reserves of £110,289 were available at the end of the 2021–2022 financial year

### Reserves policy

The Board of Trustees' strategy on reserves is for the organisation to maintain sufficient funds to cover the operational running costs in the event of a major setback. This means that we aim to hold approximately six months' annual expenditure in reserve.

At the end of the 2021–2022 financial year, our reserves stood at £110,289, which adequately covers the six months required.

The Company has taken advantage of the small companies' exemption in preparing this report. The trustees declare that they have approved the trustees' report (including directors' report) above.

### Signed on behalf of the charity's trustees/directors

Signature \_\_\_\_\_

Jonathan Pearce

*Trustee / Director*

Date \_\_\_\_\_

Signature \_\_\_\_\_

Nic Puntis

*Trustee / Director*

Date \_\_\_\_\_



**Section A Independent Examiner's Report**

**Report to the trustees/directors/members of**

Cancer 52

**On accounts for the year ended**

31<sup>st</sup> March 2022

**Charity no.:**

1174569

**Company no.:**

07994413

**Set out on pages**

**22 To 34**

I report to the charity trustees on my examination of the accounts of the Company for the year ended **31<sup>st</sup> March 2022**.

**Responsibilities and basis of report**

As the charity's trustees of the Company (who are also the directors of the company for the purposes of company law), you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ("the 2006 Act").

Having satisfied myself that the accounts of the Company are not required to be audited for this year under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ("the 2011 Act"). In carrying out my examination, I have followed the Directions given by the Charity Commission (under section 145(5)(b) of the 2011 Act.

**Independent examiner's statement**

I have completed my examination. I confirm that no material matters have come to my attention (other than that disclosed below \*) which gives me cause to believe that:

- accounting records were not kept in accordance with section 386 of the Companies Act 2006; or
- the accounts do not accord with such records; or
- the accounts do not comply with relevant accounting requirements under section 396 of the Companies Act 2006 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
- the accounts have not been prepared in accordance with the Charities SORP (FRS102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

*\* Please delete the words in the brackets if they do not apply.*

**Signed:**

**Date:**

21<sup>st</sup> July 2022

**Name:** Jason Dennis

**Relevant professional qualification(s) or body (if any):** AAT - Association of Accounting Technicians  
ATT – Association of Taxation Technicians

**Address:** 31 Clover Way, Paddock Wood, Tonbridge, Kent TN12 6BQ

**Section B Disclosure**

Only complete if the examiner needs to highlight material matters of concern (see CC32, Independent examination of charity accounts: directions and guidance for examiners).

Give here brief details of any items that the examiner wishes to disclose.

# Section A

## Statement of financial activities

(including summary income and expenditure account)

Recommended categories by activity	Guidance Note	Unrestricted funds	Restricted income funds	Endowment funds	Total funds	Prior year funds
		£ F01	£ F02	£ F03	£ F04	£ F05
<b>Income (Note 3)</b>						
Income and endowments from:						
Donations and legacies	S01	144,709	-	-	144,709	175,695
<b>Total</b>	S07	144,709	-	-	144,709	175,695
<b>Expenditure (Notes 4)</b>						
Expenditure on:						
Raising funds	S08	-	-	-	-	1,125
Charitable activities	S09	148,750	-	-	148,750	123,103
Other	S11	2,400	-	-	2,400	1,800
<b>Total</b>	S12	151,150	-	-	151,150	126,028
<b>Net income/(expenditure) before tax for the reporting period</b>	S13	(6,441)	-	-	(6,441)	49,667
Tax payable	S14	-	-	-	-	-
<b>Net income/(expenditure) after tax before investment gains/(losses)</b>	S15	(6,441)	-	-	(6,441)	49,667
Net gains/(losses) on investments	S16	-	-	-	-	-
<b>Net income/(expenditure)</b>	S17	(6,441)	-	-	(6,441)	49,667
<b>Extraordinary items</b>	S18	-	-	-	-	-
<b>Transfers between funds</b>	S19	-	-	-	-	-
<b>Other recognised gains/(losses):</b>						
Gains and losses on revaluation of fixed assets for the charity's own use	S20	-	-	-	-	-
Other gains/(losses)	S21	-	-	-	-	-
<b>Net movement in funds</b>	S22	(6,441)	-	-	(6,441)	49,667
<b>Reconciliation of funds:</b>						
Total funds brought forward	S23	116,730	-	-	116,730	67,063
<b>Total funds carried forward</b>	S24	110,289	-	-	110,289	116,730

# Section B

## Balance sheet (as at 31st March 2021)

	Guidance Note	Unrestricted funds £	Restricted income funds £	Endowment funds £	Total this year £	Total last year £
<b>Current assets</b>						
Cash at bank and in hand (Note 24)	B09	135,949	-	-	135,949	118,530
<b>Total current assets</b>	B10	135,949	-	-	135,949	118,530
<b>Creditors: amounts falling due within one year (Note 20)</b>						
	B11	25,660	-	-	25,660	1,800
<b>Net current assets/(liabilities)</b>	B12	110,289	-	-	110,289	116,730
<b>Total assets less current liabilities</b>	B13	110,289	-	-	110,289	116,730
<b>Total net assets or liabilities</b>	B16	110,289	-	-	110,289	116,730
<b>Funds of the Charity</b>						
Endowment funds (Note 27)	B17	-	-	-	-	-
Restricted income funds (Note 27)	B18	-	-	-	-	-
Unrestricted funds	B19	110,289	-	-	110,289	116,730
Revaluation reserve	B20	-	-	-	-	-
Fair value reserve	B21	-	-	-	-	-
<b>Total funds</b>	B22	110,289	-	-	110,289	116,730

The company was entitled to exemption from audit under s477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to small companies subject to the small companies regime and in accordance with FRS102 SORP.

Signed by one or two trustees/directors on behalf of all the trustees/directors

Print Name	Date of approval dd/mm/yyyy
Jonathan Pearce	
Nic Puntis	

Signature of director authenticating accounts being sent to Companies House

Signature	Date dd/mm/yyyy
Jonathan Pearce	
	<b>Print name</b>

# Section C

## Notes to the accounts

### NOTE 1: Basis of preparation

*This section should be completed by all charities.*

#### 1.1 Basis of accounting

These accounts have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant note(s) to these accounts.

The accounts have been prepared in accordance with:

- and with\* 

✓
---

 the Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued on 16 July 2014
- and with\* 

✓
---

 the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102)
- and with the Charities Act 2011.

The charity constitutes a public benefit entity as defined by FRS 102.\*

✓
---

\* -Tick as appropriate

#### 1.2 Going concern

*If there are material uncertainties related to events or conditions that cast significant doubt on the charity's ability to continue as a going concern, please provide the following details or state "Not applicable", if appropriate:*

An explanation as to those factors that support the conclusion that the charity is a going concern;

<b>Not applicable</b>
-----------------------

Disclosure of any uncertainties that make the going concern assumption doubtful;

<b>Not applicable</b>
-----------------------

Where accounts are not prepared on a going concern basis, please disclose this fact together with the basis on which the trustees prepared the accounts and the reason why the charity is not regarded as a going concern.

<b>Not applicable</b>
-----------------------

#### 1.3 Change of accounting policy

The accounts present a true and fair view and no changes have been made to the accounting policies adopted in note { }.

Yes\*

✓
---

\* -Tick as appropriate

No\*

--

Please disclose:

<i>(i) the nature of the change in accounting policy;</i>	<i>Not applicable</i>
<i>(ii) the reasons why applying the new accounting policy provides more reliable and more relevant information; and</i>	<i>Not applicable</i>
<i>(iii) the amount of the adjustment for each line affected in the current period, each prior period presented and the aggregate amount of the adjustment relating to periods before those presented, 3.44 FRS102 SORP.</i>	<i>Not applicable</i>

#### 1.4 Changes to accounting estimates

No changes to accounting estimates have occurred in the reporting period (3.46 FRS102 SORP).

Yes*	<input checked="" type="checkbox"/>	* -Tick as appropriate
No*	<input type="checkbox"/>	

Please disclose:

<i>(i) the nature of any changes;</i>	<i>Not applicable</i>
<i>(ii) the effect of the change on income and expense or assets and liabilities for the current period; and</i>	<i>Not applicable</i>
<i>(iii) where practicable, the effect of the change in one or more future periods.</i>	<i>Not applicable</i>

#### 1.5 Material prior year errors

No material prior year error have been identified in the reporting period (3.47 FRS102 SORP).

Yes*	<input checked="" type="checkbox"/>	* -Tick as appropriate
No*	<input type="checkbox"/>	

Please disclose:

<i>(i) the nature of the prior period error;</i>	<i>Not applicable</i>
<i>(ii) for each prior period presented in the accounts, the amount of the correction for each account line item affected; and</i>	<i>Not applicable</i>
<i>(iii) the amount of the correction at the beginning of the earliest prior period presented in the accounts.</i>	<i>Not applicable</i>

## NOTE 2: Accounting policies

### 2.1 INCOME

<b>Recognition of income</b>	<p>These are included in the Statement of Financial Activities (SoFA) when:</p> <ul style="list-style-type: none"> <li>the charity becomes entitled to the resources;</li> <li>it is more likely than not that the trustees will receive the resources;</li> <li>the monetary value can be measured with sufficient reliability.</li> </ul>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">✓</td> <td></td> <td></td> </tr> </tbody> </table>	Yes*	No*	N/a*	✓		
Yes*	No*	N/a*						
✓								
<b>Offsetting</b>	<p>There has been no offsetting of assets and liabilities, or income and expenses, unless required or permitted by the FRS 102 SORP or FRS 102.</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">✓</td> <td></td> <td></td> </tr> </tbody> </table>	Yes*	No*	N/a*	✓		
Yes*	No*	N/a*						
✓								
<b>Grants and donations</b>	<p>Grants and donations are only included in the SoFA when the general income recognition criteria are met (5.10 to 5.12 FRS102 SORP).</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">✓</td> <td></td> <td></td> </tr> </tbody> </table>	Yes*	No*	N/a*	✓		
Yes*	No*	N/a*						
✓								
	<p>In the case of performance related grants, income must only be recognised to the extent that the charity has provided the specified goods or services as entitlement to the grant only occurs when the performance related conditions are met (5.16 FRS 102 SORP).</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> <td style="text-align: center;">✓</td> </tr> </tbody> </table>	Yes*	No*	N/a*			✓
Yes*	No*	N/a*						
		✓						
<b>Legacies</b>	<p>Legacies are included in the SOFA when receipt is probable, that is, when there has been grant of probate, the executors have established that there are sufficient assets in the estate and any conditions attached to the legacy are either within the control of the charity or have been met.</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> <td style="text-align: center;">✓</td> </tr> </tbody> </table>	Yes*	No*	N/a*			✓
Yes*	No*	N/a*						
		✓						
<b>Government grants</b>	<p>The charity has received government grants in the reporting period</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td></td> <td style="text-align: center;">✓</td> <td></td> </tr> </tbody> </table>	Yes*	No*	N/a*		✓	
Yes*	No*	N/a*						
	✓							
<b>Tax reclaims on donations and gifts</b>	<p>Gift Aid receivable is included in income when there is a valid declaration from the donor. Any Gift Aid amount recovered on a donation is considered to be part of that gift and is treated as an addition to the same fund as the initial donation unless the donor or the terms of the appeal have specified otherwise.</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">✓</td> <td></td> <td></td> </tr> </tbody> </table>	Yes*	No*	N/a*	✓		
Yes*	No*	N/a*						
✓								
<b>Contractual income and performance related grants</b>	<p>This is only included in the SoFA once the charity has provided the related goods or services or met the performance related conditions.</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> <td style="text-align: center;">✓</td> </tr> </tbody> </table>	Yes*	No*	N/a*			✓
Yes*	No*	N/a*						
		✓						
<b>Donated goods</b>	<p>Donated goods are measured at fair value (the amount for which the asset could be exchanged) unless impractical to do so.</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> <td style="text-align: center;">✓</td> </tr> </tbody> </table>	Yes*	No*	N/a*			✓
Yes*	No*	N/a*						
		✓						
	<p>The cost of any stock of goods donated for distribution to beneficiaries is deemed to be the fair value of those gifts at the time of their receipt and they are recognised on receipt. In the reporting period in which the stocks are distributed, they are recognised as an expense at the carrying amount of the stocks at distribution.</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> <td style="text-align: center;">✓</td> </tr> </tbody> </table>	Yes*	No*	N/a*			✓
Yes*	No*	N/a*						
		✓						
	<p>Donated goods for resale are measured at fair value on initial recognition, which is the expected proceeds from sale less the expected costs of sale, and recognised in 'Income from other trading activities' with the corresponding stock recognised in the balance sheet. On its sale the value of stock is charged against 'Income from other trading activities' and the proceeds from sale are also recognised as 'Income from other trading activities'.</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> <td style="text-align: center;">✓</td> </tr> </tbody> </table>	Yes*	No*	N/a*			✓
Yes*	No*	N/a*						
		✓						
	<p>Goods donated for on-going use by the charity are recognised as tangible fixed assets and included in the SoFA as incoming resources when receivable.</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> <td style="text-align: center;">✓</td> </tr> </tbody> </table>	Yes*	No*	N/a*			✓
Yes*	No*	N/a*						
		✓						
	<p>Gifts in kind for use by the charity are included in the SoFA as income from donations when receivable.</p>	<table border="1"> <thead> <tr> <th>Yes*</th> <th>No*</th> <th>N/a*</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> <td style="text-align: center;">✓</td> </tr> </tbody> </table>	Yes*	No*	N/a*			✓
Yes*	No*	N/a*						
		✓						

<b>Donated services and facilities</b>	Donated services and facilities are included in the SoFA when received at the value of the gift to the charity provided the value of the gift can be measured reliably.	Yes*	No*	N/a*
				✓
	Donated services and facilities that are consumed immediately are recognised as income with an equivalent amount recognised as an expense under the appropriate heading in the SoFA.	Yes*	No*	N/a*
				✓
<b>Support costs</b>	The charity has incurred expenditure on support costs.	Yes*	No*	N/a*
			✓	
<b>Volunteer help</b>	The value of any voluntary help received is not included in the accounts but is described in the trustees' annual report.	Yes*	No*	N/a*
				✓
<b>Income from interest, royalties and dividends</b>	This is included in the accounts when receipt is probable and the amount receivable can be measured reliably.	Yes*	No*	N/a*
		✓		
<b>Income from membership subscriptions</b>	Membership subscriptions received in the nature of a gift are recognised in Donations and Legacies.	Yes*	No*	N/a*
		✓		
	Membership subscriptions which gives a member the right to buy services or other benefits are recognised as income earned from the provision of goods and services as income from charitable activities.	Yes*	No*	N/a*
				✓
<b>Settlement of insurance claims</b>	Insurance claims are only included in the SoFA when the general income recognition criteria are met (5.10 to 5.12 FRS102 SORP) and are included as an item of other income in the SoFA.	Yes*	No*	N/a*
				✓
<b>Investment gains and losses</b>	This includes any realised or unrealised gains or losses on the sale of investments and any gain or loss resulting from revaluing investments to market value at the end of the year.	Yes*	No*	N/a*
				✓
<b>2.2 EXPENDITURE AND LIABILITIES</b>				
<b>Liability recognition</b>	Liabilities are recognised where it is more likely than not that there is a legal or constructive obligation committing the charity to pay out resources and the amount of the obligation can be measured with reasonable certainty.	Yes*	No*	N/a*
		✓	✓	✓
<b>Governance and support costs</b>	Support costs have been allocated between governance costs and other support. Governance costs comprise all costs involving public accountability of the charity and its compliance with regulation and good practice.	Yes*	No*	N/a*
				✓
	Support costs include central functions and have been allocated to activity cost categories on a basis consistent with the use of resources, eg allocating property costs by floor areas, or per capita, staff costs by the time spent and other costs by their usage.	Yes*	No*	N/a*
				✓
<b>Grants with performance conditions</b>	Where the charity gives a grant with conditions for its payment being a specific level of service or output to be provided, such grants are only recognised in the SoFA once the recipient of the grant has provided the specified service or output.	Yes*	No*	N/a*
				✓
<b>Grants payable without performance conditions</b>	Where there are no conditions attaching to the grant that enables the donor charity to realistically avoid the commitment, a liability for the full funding obligation must be recognised.	Yes*	No*	N/a*
				✓
<b>Redundancy cost</b>	The charity made no redundancy payments during the reporting period.	Yes*	No*	N/a*
				✓
<b>Deferred income</b>	No material item of deferred income has been included in the accounts.	Yes*	No*	N/a*
				✓
<b>Creditors</b>	The charity has creditors which are measured at settlement amounts less any trade discounts	Yes*	No*	N/a*
			✓	
<b>Provisions for liabilities</b>	A liability is measured on recognition at its historical cost and then subsequently measured at the best estimate of the amount required to settle the obligation at the reporting date	Yes*	No*	N/a*
				✓
<b>Basic financial instruments</b>	The charity accounts for basic financial instruments on initial recognition as per paragraph 10.7 FRS102 SORP. Subsequent measurement is as per paragraphs 11.17 to 11.19, FRS102 SORP.	Yes*	No*	N/a*
				✓

## 2.3 ASSETS

<b>Tangible fixed assets for use by charity</b>	These are capitalised if they can be used for more than one year, and cost at least	£2,500		
	They are valued at cost.	Yes*	No*	N/a*
				✓
<b>Intangible fixed assets</b>	The depreciation rates and methods used are disclosed in note 14.			
	The charity has intangible fixed assets, that is, non-monetary assets that do not have physical substance but are identifiable and are controlled by the charity through custody or legal rights. The amortisation rates and methods used are disclosed in note 15.	Yes*	No*	N/a*
				✓
<b>Heritage assets</b>	They are valued at cost.			
	The charity has heritage assets, that is, non-monetary assets with historic, artistic, scientific, technological, geophysical or environmental qualities that are held and maintained principally for their contribution to knowledge and culture. The depreciation rates and methods used as disclosed in note 16.	Yes*	No*	N/a*
				✓
<b>Investments</b>	They are valued at cost.			
	Fixed asset investments in quoted shares, traded bonds and similar investments are valued at initially at cost and subsequently at fair value (their market value) at the year end. The same treatment is applied to unlisted investments unless fair value cannot be measured reliably in which case it is measured at cost less impairment.	Yes*	No*	N/a*
				✓
<b>Stocks and work in progress</b>	Investments held for resale or pending their sale and cash and cash equivalents with a maturity date of less than 1 year are treated as current asset investments	Yes*	No*	N/a*
				✓
	Stocks held for sale as part of non-charitable trade are measured at the lower or cost or net realisable value.	Yes*	No*	N/a*
<b>Debtors</b>	Goods or services provided as part of a charitable activity are measured at net realisable value based on the service potential provided by items of stock.	Yes*	No*	N/a*
				✓
	Work in progress is valued at cost less any foreseeable loss that is likely to occur on the contract.	Yes*	No*	N/a*
<b>Current asset investments</b>				✓
	Debtors (including trade debtors and loans receivable) are measured on initial recognition at settlement amount after any trade discounts or amount advanced by the charity. Subsequently, they are measured at the cash or other consideration expected to be received.	Yes*	No*	N/a*
				✓
<b>POLICIES ADOPTED ADDITIONAL TO OR DIFFERENT FROM THOSE ABOVE</b>	The charity has investments which it holds for resale or pending their sale and cash and cash equivalents with a maturity date less than one year. These include cash on deposit and cash equivalents with a maturity of less than one year held for investment purposes rather than to meet short-term cash commitments as they fall due.	Yes*	No*	N/a*
				✓
	They are valued at fair value except where they qualify as basic financial instruments.	Yes*	No*	N/a*
				✓

## NOTE 3: Income

Analysis of income		Unrestricted funds	Restricted income funds	Endowment funds	Total funds £	Prior year £
<b>Donations</b>	Donations and gifts	114,755	-	-	114,755	150,409
	Membership subscriptions and sponsorships which are in substance donations	29,954	-	-	29,954	25,286
	<b>Total</b>	<b>144,709</b>	<b>-</b>	<b>-</b>	<b>144,709</b>	<b>175,695</b>
<b>TOTAL INCOME</b>		<b>144,709</b>	<b>-</b>	<b>-</b>	<b>144,709</b>	<b>175,695</b>

## NOTE 4: Expenditure

Analysis	This year				Last year			
	Unrestricted funds	Restricted income funds	Endowment funds	Total funds	Unrestricted funds	Restricted income funds	Endowment funds	Total funds
<b>Expenditure on raising funds</b>				£				£
Fundraising consultants	-	-	-	-	1,125	-	-	1,125
<b>Total expenditure on raising funds</b>	-	-	-	-	1,125	-	-	1,125
<b>Expenditure on charitable activities:</b>								
All Member Meetings, Steering Group Meetings, Room Hire, Venue Costs	600	-	-	600	-	-	-	-
Patient Voice Film	-	-	-	-	-	1,483	-	1,483
Covid Impact Report	-	-	-	-	-	800	-	800
Shared Cancer Planning Project	-	-	-	-	-	600	-	600
Patient Survey Project	7,326	-	-	7,326	-	9,600	-	9,600
Pfizer Project Support	10,020	-	-	10,020	-	6,520	-	6,520
Impact Reporting and Annual Review	1,505	-	-	1,505	-	5,520	-	5,520
Telephone	74	-	-	74	-	-	-	-
IT and Computer running expenses	443	-	-	443	-	96	-	96
Policy consultants - Policy Support	19,605	-	-	19,605	-	18,140	-	18,140
Policy Report	2,175	-	-	2,175	-	-	-	-
Subscriptions	1,384	-	-	1,384	-	933	-	933
Secretarial expenses	31,855	-	-	31,855	-	29,713	-	29,713
Insurance	556	-	-	556	533	-	-	533
Management and Administration	4,000	-	-	4,000	34,806	3,958	-	38,764
Salaries and Employers NI and Pensions	66,060	-	-	66,060	-	-	-	-
Communications and PR	2,000	-	-	2,000	9,691	-	-	9,691
Bank and credit fees	216	-	-	216	216	-	-	216
Trustees/Directors Travel	162	-	-	162	-	-	-	-
Trustee Recruitment costs and expenses	319	-	-	319	-	494	-	494
Non-Trustee Recruitment	450	-	-	450	-	-	-	-
<b>Total expenditure on charitable activities</b>	148,750	-	-	148,750	45,246	77,857	-	123,103
<b>Other</b>								
Independent Examiner	2,400	-	-	2,400	1,800	-	-	1,800
<b>Total other expenditure</b>	2,400	-	-	2,400	1,800	-	-	1,800
<b>TOTAL EXPENDITURE</b>	151,150	-	-	151,150	48,171	77,857	-	126,028

## NOTE 5: Details of certain types of expenditure

### Note 5.1 Fees for examination of the accounts

Please provide details of the amount paid for any statutory external scrutiny of accounts and other services provided by your independent examiner. If nothing was paid please enter '0' in the appropriate box(es).

#### Independent examiner's fees

This year £	Last year £
2,400	1,800

## NOTE 6: Paid Employees

Please complete this note if the charity has any employees (transactions with Trustees dealt with in Note 28)

### 6.1 Staff Costs

	This year £	Last year £
Salaries and wages	60,000	-
Social security costs	3,060	-
Pension costs (defined contribution scheme)	3,000	-
Other employee benefits	-	-
<b>Total staff costs</b>	<b>66,060</b>	<b>-</b>

Please give details of the number of employees whose total employee benefits (excluding employer pension costs)

No employees received employee benefits (excluding employer

Band	Number of employees	
	This year	Last year
£60,000 to £69,999	1	-

Please provide the total amount paid to key management personnel

This year £	Last year £
60,000	-

### 6.2 Average head count in the year

The parts of the charity in which the employees work

	This year Number	Last year Number
Fundraising	-	-
Charitable Activities	-	-
Governance	1	-
Other	-	-
<b>Total</b>	<b>1</b>	<b>-</b>

## NOTE 7: Creditors and accruals

Please complete this note if the charity has any creditors or accruals.

### 7.1 Analysis of creditors

	Amounts falling due within one year		Amounts falling due after more than one year	
	This year £	Last year £	This year £	Last year £
Accruals and deferred income	25,290	1,800	-	-
Other creditors	370	-	-	-
<b>Total</b>	<b>25,660</b>	<b>1,800</b>	<b>-</b>	<b>-</b>

## NOTE 8: Cash at bank and in hand

Cash at bank and on hand  
Total

This year £	Last year £
135,949	118,530
135,949	118,530

## NOTE 9: Fair value of assets and liabilities

	This year	Last year
<p>9.1 Please provide details of the charity's exposure to credit risk (the risk of incurring a loss due to a debtor not paying what is owed) , liquidity risk (the risk of not being able to meet short term financial demands) and market risk (the risk that the value of an investment will fall due to changes in the market) arising from financial instruments to which the charity is exposed at the end of the reporting period and explain how the charity manages those risks.</p>	<p>Credit risk is low due to income being in the form of donations. Cash is the only investment so market risk is low on investment values falling. Liquidity risk is low as costs are managed in relation to income received.</p>	<p>Credit risk is low due to income being in the form of donations. Cash is the only investment so market risk is low on investment values falling. Liquidity risk is low as costs are managed in relation to income received.</p>
<p>9.2 Please give details of the amount of change in the fair value of basic financial instruments (debtors, creditors, investments (see section 11, FRS 102 SORP)) measured at fair value through the SoFA that is attributable to changes in credit risk.</p>	<p>Not applicable</p>	<p>Not applicable</p>

## NOTE 10: Charity funds

### 10.1 Details of material funds held and movements during the CURRENT reporting period

Please give details of the movements of material individual funds in the reporting period together with a balancing figure for 'Other funds' (which should include revaluation reserve and fair value reserve, if applicable). The 'Total funds' figure below should reconcile to 'Total funds' in the balance sheet.

\* Key: PE - permanent endowment funds; EE - expendable endowment funds; R - restricted income funds, including special trusts, of the charity; and U - unrestricted funds

Fund names	Type PE, EE R or UR *	Purpose and Restrictions	Fund balances brought forward £	Income £	Expenditure £	Transfers £	Gains and losses £	Fund balances carried forward £
General Fund	UR	General all purpose no restrictions	116,730	144,709	(151,150)	-	-	110,289
<b>Total Funds as per balance sheet</b>			<b>116,730</b>	<b>144,709</b>	<b>(151,150)</b>	<b>-</b>	<b>-</b>	<b>110,289</b>

Yes\*

No\*

Fund balances carried forward include assets and liabilities denominated in a foreign currency

If yes, please state the basis on which the assets and/or liabilities have been translated into sterling (or the currency in which the accounts are drawn up).

**10.2 Details of material funds held and movements during the PREVIOUS reporting period**

Please give details of the movements of material individual funds in the reporting period together with a balancing figure for 'Other funds' (which should include revaluation reserve and fair value reserve, if applicable). The 'Total funds' figure below should reconcile to 'Total funds' in the balance sheet.

\* Key: PE - permanent endowment funds; EE - expendable endowment funds; R - restricted income funds, including special trusts, of the charity; and U - unrestricted funds

Fund names	Type PE, EE R or UR *	Purpose and Restrictions	Fund balances brought forward £	Income £	Expenditure £	Transfers £	Gains and losses £	Fund balances carried forward £
General Fund	UR	General all purpose no restrictions	67,063	97,838	(48,171)	-	-	116,730
Covid-19 Restricted Fund	R	Restricted to Core Charitable Expenditure	-	77,857	(77,857)	-	-	-
<b>Total Funds as per balance sheet</b>			<b>67,063</b>	<b>175,695</b>	<b>(126,028)</b>	<b>-</b>	<b>-</b>	<b>116,730</b>

Yes\*  No\*

Fund balances carried forward include assets and liabilities denominated in a foreign currency

## NOTE 11: Transactions with trustees and relates parties

If the charity has any transactions with related parties (other than the trustee expenses explained in guidance notes) details of such transactions should be provided in this note. If there are no transactions to report, please enter "True" in the box or "False" if there are transactions to report.

### 11.1 Trustee remuneration and benefits

This year

None of the trustees have been paid any remuneration or received any other benefits from an employment with their charity or a related entity (True or False)

TRUE

### 11.2 Trustees' expenses

If the charity has paid trustees expenses for fulfilling their duties, details of such transactions should be provided in this note. If there are no transactions to report, please enter "True" in the box below. If there are transactions to report, please enter "False".

No trustee expenses have been incurred (True or False)

TRUE

Type of expenses reimbursed	This year	Last year
	£	£
Travel	-	-
<b>TOTAL</b>	-	-

Please provide the number of trustees reimbursed for expenses or who had expenses paid by the charity

0

0

### 11.3 Transaction(s) with related parties

Please give details of any transaction undertaken by (or on behalf of) the charity in which a related party has a material interest, including where funds have been held as agent for related parties. If there are no such transactions, please enter 'true' in the box provided.

This year

There have been no related party transactions in the reporting period (True or False)

TRUE

Last year

There have been no related party transactions in the reporting period (True or False)

TRUE



# Administrative details

## TRUSTEES

Jonathan Pearce,      Chair  
Helen Morement  
Rebecca Porta  
Nic Puntis  
Christopher Walden  
Anna Evans  
Dr Max Brodermann  
Michael Draeger  
Sophie Davies

## EXECUTIVE OFFICERS

Baroness Morgan of Drefelin      President  
Jane Lyons      Chief executive  
Jonathan Pearce      Company secretary

## REGISTERED OFFICE

c/o Teenage Cancer Trust 3rd Floor,  
93 Newman Street, London W1T 3EZ

## WEBSITE

[www.cancer52.org.uk](http://www.cancer52.org.uk)

## BANKERS

Co-operative Bank



# References

- <sup>1</sup> National Cancer Registration and Analysis Service (NCRAS) by Public Health England figures. May 2019
- <sup>2</sup> Cancer Statistics for the UK. Cancer Research UK. Available: <https://www.cancerresearchuk.org/health-professional/cancer-statistics-for-the-uk#heading-Zero>.
- <sup>3</sup> Cancer52 membership research, conducted April 2019
- <sup>4</sup> Average email open rates for 2022. Smart Insights. Available: <https://www.smartinsights.com/email-marketing/email-communications-strategy/statistics-sources-for-email-marketing/#q4>
- <sup>5</sup> Long Term Plan. NHS. Available: [www.longtermplan.nhs.uk/areas-of-work/cancer](http://www.longtermplan.nhs.uk/areas-of-work/cancer)
- <sup>6</sup> Clearing the backlog caused by the pandemic - Health and Social Care Committee (parliament.uk). Available: <https://publications.parliament.uk/pa/cm5802/cmselect/cmhealth/599/report.html>
- <sup>7</sup> Health and Social Care Committee report on Cancer services. Cancer52 response. Available: <https://www.cancer52.org.uk/single-post/health-and-social-care-committee-report-on-cancer-services>
- <sup>8</sup> 10-Year Cancer Plan. One Cancer Voice (OCV) response to the Call for Evidence. Available: <https://www.cancer52.org.uk/single-post/10-year-cancer-plan-one-cancer-voice-consensus-statement>
- <sup>9</sup> The NICE methods of health technology evaluation: the case for change. Cancer52 response. Available: <https://www.cancer52.org.uk/single-post/nice-methods-review>
- <sup>10</sup> 10-Year Cancer Plan. Call for Evidence. Available: <https://www.gov.uk/government/consultations/10-year-cancer-plan-call-for-evidence>
- <sup>11</sup> 10-Year Cancer Plan. Cancer52 response to the Call for Evidence. Available: <https://www.cancer52.org.uk/single-post/10-year-cancer-plan-cancer52-response-to-the-call-for-evidence>
- <sup>12</sup> Do You C Us? website: <https://www.doyoucus.org.uk/>
- <sup>13</sup> Together for Antibiotics. ABPI. Available: <https://www.togetherforantibiotics.org.uk>
- <sup>14</sup> ABPI AMR: Resources (togetherforantibiotics.org.uk): [https://www.togetherforantibiotics.org.uk/resources/?3b293f58a0d649e6a204d1476bc6a631\\_cat=Cancer52&3b293f58a0d649e6a204d1476bc6a631\\_page=1](https://www.togetherforantibiotics.org.uk/resources/?3b293f58a0d649e6a204d1476bc6a631_cat=Cancer52&3b293f58a0d649e6a204d1476bc6a631_page=1)
- <sup>15</sup> Policy on Working with the Pharmaceutical & Healthcare Industry. Microsoft Word - Cancer52 Pharmaco Policy March 2020 Amended after March Board FINAL

# List of charity members 2021/22

ACLT (African Caribbean Leukaemia Trust)  
[www.aclt.org](http://www.aclt.org)

Act for Cancer  
[www.actforcancer.org.uk](http://www.actforcancer.org.uk)

Action Against Heartburn  
[www.actionagaintheartburn.org.uk](http://www.actionagaintheartburn.org.uk)

Action Bladder Cancer UK  
[www.actionbladdercanceruk.org](http://www.actionbladdercanceruk.org)

Action Kidney Cancer  
[www.kcsn.org.uk](http://www.kcsn.org.uk)

Action on Womb Cancer  
[www.actiononwombcancer.org.uk](http://www.actiononwombcancer.org.uk)

Alike  
[www.alike.org.uk](http://www.alike.org.uk)

ALK Positive Lung Cancer  
[www.alkpositive.org.uk](http://www.alkpositive.org.uk)

AMMF – The Cholangiocarcinoma Charity  
[www.ammf.org.uk](http://www.ammf.org.uk)

Anthony Nolan  
[www.anthonynolan.org](http://www.anthonynolan.org)

Association for Multiple Endocrine Neoplasia Disorders (AMEND)  
[www.amend.org.uk](http://www.amend.org.uk)

Baggy Trousers UK  
[www.baggytrousersuk.org](http://www.baggytrousersuk.org)

Balls to Cancer  
[www.ballstocancer.co.uk](http://www.ballstocancer.co.uk)

Barrett's Oesophagus UK  
[www.barrettscampaign.org.uk](http://www.barrettscampaign.org.uk)

Blood Cancer UK  
[www.bloodcancer.org.uk](http://www.bloodcancer.org.uk)

Bone Cancer Research Trust  
[www.bcrct.org.uk](http://www.bcrct.org.uk)

Bowel Research UK  
[www.bowelresearchuk.org](http://www.bowelresearchuk.org)

Brain Tumour Research  
[www.braintumourresearch.org](http://www.braintumourresearch.org)

Brain Tumour Research Campaign (Wayahead)  
[www.btrc-charity.org](http://www.btrc-charity.org)

Brainstrust  
[www.brainstrust.org.uk](http://www.brainstrust.org.uk)

British Lymphology Society (BLS)  
[www.thebls.com](http://www.thebls.com)

British Thyroid Foundation (BTF-thyroid)  
[www.btf-thyroid.org](http://www.btf-thyroid.org)

Butterfly Thyroid Cancer Trust (BTCT)  
[www.butterfly.org.uk](http://www.butterfly.org.uk)

Cancer Laryngectomy Trust  
[www.cancerlt.org](http://www.cancerlt.org)

Cancer of Unknown Primary (CUP)  
Foundation – Jo's friends  
[www.cupfoundjo.org](http://www.cupfoundjo.org)

Childhood Eye Cancer Trust (CHECT)  
[www.checht.org.uk](http://www.checht.org.uk)

Children's Cancer and Leukaemia Group (CCLG)  
[www.cclg.org.uk](http://www.cclg.org.uk)

Chordoma UK  
[www.chordoma-uk.org](http://www.chordoma-uk.org)

Chris Lucas Trust  
[www.chrislucustrust.com](http://www.chrislucustrust.com)

Chronic Myeloid Leukaemia (CML) Support Group UK  
[www.cmlsupport.org.uk](http://www.cmlsupport.org.uk)

CLL Support Association  
[www.clisupport.org.uk](http://www.clisupport.org.uk)

Debbie Fund  
[www.debbiefund.org](http://www.debbiefund.org)

DKMS  
[www.dkms.org.uk](http://www.dkms.org.uk)

EHE Rare Cancer Charity (UK)  
[www.ehercc.org.uk](http://www.ehercc.org.uk)

Ellen MacArthur Cancer Trust  
[www.ellenmacarthurcancertrust.org](http://www.ellenmacarthurcancertrust.org)

Fight Bladder Cancer  
[www.fightbladdercancer.co.uk](http://www.fightbladdercancer.co.uk)

GIST Cancer UK  
[www.gistcancer.org.uk](http://www.gistcancer.org.uk)

Grace Kelly Childhood Cancer Trust  
[www.gkcct.org](http://www.gkcct.org)

GUTS Charity  
[www.gutscharity.org.uk](http://www.gutscharity.org.uk)

Heartburn Cancer UK  
[www.heartburncanceruk.org](http://www.heartburncanceruk.org)

HLRCC Family Alliance  
[www.hlrccinfo.org](http://www.hlrccinfo.org)

ICPV Independent Cancer Patients' Voice  
[www.icpv.org.uk](http://www.icpv.org.uk)

International Brain Tumour Alliance (IBTA)  
[www.theibta.org](http://www.theibta.org)

It's In The Bag Cancer Support Ltd  
[www.itsinthebag.org.uk](http://www.itsinthebag.org.uk)

It's on the Ball  
[www.itsontheball.org](http://www.itsontheball.org)

Jo's Cervical Cancer Trust  
[www.jostrust.org.uk](http://www.jostrust.org.uk)

Kidney Cancer UK  
[www.kcuk.org.uk](http://www.kcuk.org.uk)

Live Through This  
[www.livethroughthis.co.uk](http://www.livethroughthis.co.uk)

Leukaemia CARE  
[www.leukaemiacare.org.uk](http://www.leukaemiacare.org.uk)

Leukaemia UK  
[www.leukaemiauk.org.uk](http://www.leukaemiauk.org.uk)

Lymphoedema Support Network  
[www.lymphoedema.org](http://www.lymphoedema.org)

Lymphoma Action  
[www.lymphoma-action.org.uk](http://www.lymphoma-action.org.uk)

Maggie's Cancer Caring Centres  
[www.maggies.org](http://www.maggies.org)

MDS (Myelodysplastic Syndromes) UK Patient Support Group  
[www.mdspatientsupport.org.uk](http://www.mdspatientsupport.org.uk)

Melanoma Focus  
[www.melanomafocus.com](http://www.melanomafocus.com)

Melanoma UK  
[www.melanomauk.org.uk](http://www.melanomauk.org.uk)

Mesothelioma UK  
[www.mesothelioma.uk.com](http://www.mesothelioma.uk.com)

MPN Voice  
[www.mpnvoice.org.uk](http://www.mpnvoice.org.uk)

Mummy's Star  
[www.mummystar.org](http://www.mummystar.org)

Myeloma UK  
[www.myeloma.org.uk](http://www.myeloma.org.uk)

Neuroblastoma UK  
[www.neuroblastoma.org.uk](http://www.neuroblastoma.org.uk)

Neuroendocrine Cancer UK (NCUK)  
[www.neuroendocrinecancer.org.uk](http://www.neuroendocrinecancer.org.uk)

North West Cancer Research  
[www.nwcr.org](http://www.nwcr.org)

OcuMel UK  
[www.ocumeluk.org](http://www.ocumeluk.org)

Oracle Cancer Trust  
[www.oraclecancertrust.org](http://www.oraclecancertrust.org)

Orchid Cancer Appeal  
[www.orchid-cancer.org.uk](http://www.orchid-cancer.org.uk)

Ovacome, The Ovarian Cancer Support Network  
[www.ovacome.org.uk](http://www.ovacome.org.uk)

Ovarian Cancer Action  
[www.ovarian.org.uk](http://www.ovarian.org.uk)

Pancreatic Cancer Action  
[www.pancreaticcanceraction.org](http://www.pancreaticcanceraction.org)

Pancreatic Cancer UK (PCUK)  
[www.pancreaticcancer.org.uk](http://www.pancreaticcancer.org.uk)

Paul's Cancer Support Centre  
[www.pauls.org.uk](http://www.pauls.org.uk)

Pelvic Radiation Disease Association (PRDA)  
[www.prda.org.uk](http://www.prda.org.uk)

Penny Brohn UK  
[www.pennybrohn.org.uk](http://www.pennybrohn.org.uk)

PLANETS  
[www.planetscharity.org](http://www.planetscharity.org)

Pseudomyxoma Survivor  
[www.pseudomyxomasurvivor.org](http://www.pseudomyxomasurvivor.org)

Salivary Gland Cancer UK  
[www.salivaryglandcancer.uk](http://www.salivaryglandcancer.uk)

Sarcoma UK  
[www.sarcoma.org.uk](http://www.sarcoma.org.uk)

Shine Cancer Support  
[www.shinecancersupport.org](http://www.shinecancersupport.org)

Solving Kids' Cancer  
[www.solvingkidscancer.org.uk](http://www.solvingkidscancer.org.uk)

Target Ovarian Cancer  
[www.targetovariancancer.org.uk](http://www.targetovariancancer.org.uk)

Team Margot Foundation  
[www.teammargot.com](http://www.teammargot.com)

Teenage Cancer Trust (TCT)  
[www.teenagecancertrust.org](http://www.teenagecancertrust.org)

The Brain Tumour Charity  
[www.thebraintumourcharity.org](http://www.thebraintumourcharity.org)

The Charley Ashton Foundation  
[www.thecharleyashtonfoundation](http://www.thecharleyashtonfoundation)

The Eve Appeal  
[www.eveappeal.org.uk](http://www.eveappeal.org.uk)

The Mavis Nye Foundation  
[www.mavisnyefoundation.com](http://www.mavisnyefoundation.com)

The Myrovlytis Trust  
[www.myrovlytistrust.org](http://www.myrovlytistrust.org)

The Northern Ireland Rare Disease Partnership  
[www.nirdp.org.uk](http://www.nirdp.org.uk)

The Robin Cancer Trust  
[www.therobincancertrust.org](http://www.therobincancertrust.org)

The Urology Foundation  
[www.theurologyfoundation.org](http://www.theurologyfoundation.org)

ThymicUK  
[www.thymicuk.org](http://www.thymicuk.org)

Thyroid Cancer Support Group Wales  
[www.thyroidsupportwales.co.uk](http://www.thyroidsupportwales.co.uk)

Tom Bowdidge Youth Cancer Foundation  
[www.tombowdidgefoundation.org](http://www.tombowdidgefoundation.org)

Trekstock  
[www.trekstock.com](http://www.trekstock.com)

UCARE  
[www.ucare-cancer.org.uk](http://www.ucare-cancer.org.uk)

UK Masto  
[www.ukmasto.org](http://www.ukmasto.org)

Urostomy Association  
[www.urostomyassociation.org.uk](http://www.urostomyassociation.org.uk)

VHL UK/Ireland  
[www.vhl-uk-ireland.org](http://www.vhl-uk-ireland.org)

Wellbeing of Women  
[www.wellbeingofwomen.org.uk](http://www.wellbeingofwomen.org.uk)

Wendy Gough Cancer Awareness Foundation  
[www.wgcaf.com](http://www.wgcaf.com)

WMUK  
[www.wmuk.org.uk](http://www.wmuk.org.uk)

Womb Cancer Info  
[www.wombcancerinfo.wixsite.com/home](http://www.wombcancerinfo.wixsite.com/home)

Womb Cancer Support UK  
[www.wombcancersupportuk.weebly.com](http://www.wombcancersupportuk.weebly.com)

Yorkshire Cancer Community  
[www.yorkshirecancercommunity.co.uk](http://www.yorkshirecancercommunity.co.uk)

Young Lives Vs. Cancer  
[www.younglivesvscancer.org.uk](http://www.younglivesvscancer.org.uk)



**Cancer52** is registered as a charity in England and Wales, **Charity No. 1174569** and as a company limited by guarantee in England and Wales, **Company No. 07994413**

If we **work together**  
we can make as much noise as the big four

